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Abstract 
Background: A new contract for general practitioners in the United Kingdom represents the 
most radical shift towards pay for performance seen in any health care system. The contract 
provides an important opportunity to address inequalities in chronic disease management. 
This thesis examines the impact of this pay for performance incentive on inequalities in the 
management of diabetes between ethnic groups. 
Methods: (1) Population based longitudinal survey using electronic general practice records 
carried out in Wandsworth, south London before and after the introduction of pay for 
performance (2) Secondary analysis of data from the Health Survey for England (1998-2004). 
Results: The proportion of patients achieving treatment targets for diabetes increased 
significantly after the implementation of pay for performance. The extents of these increases 
were broadly uniform across ethnic groups, with the exception of the black Caribbean group, 
which had significantly lower improvement in HbAlc and blood pressure control relative to 
the white British group. Variations in prescribing and achievement of treatment targets 
between ethnic groups evident in 2003 were not attenuated in 2005. Processes of care for 
diabetes were generally equitable before the introduction of pay for performance. 
Conclusions: Pay for performance has not addressed inequalities in the management of 
diabetes between ethnic groups. Quality improvement initiatives must place greater 
emphasis on minority communities to avoid continued inequalities in morbidity and 
mortality from the major complications of diabetes. 
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1.0 Introduction 
Diabetes Mellitus 
1.1.1 Definition. 
Diabetes mellitus is a progressive, chronic disease characterised by elevated blood glucose 
levels commonly known as hyperglycaemia. The current World Health Organisation (2006) 
diagnostic criteria for diabetes is: - fasting plasma glucose ý! 7. Ommol/I (126mg/dl) or 2-h 
plasma glucose -eýý 11.1mmol/I (200mg/dl) (1). This threshold for defining diabetes was 
lowered in 1999, when the fasting plasma glucose concentration was reduced from the former 
level of > 7.8 mmol 1-1 (140 mg dl-1). 
There are three main types of diabetes, as defined by the World Health Organisation. Type 1 
diabetes - also known as insulin-dependent diabetes - is characterized by the process of beta- 
cell destruction that may ultimately lead to diabetes mellitus in which "'insulin is required for 
survival" to prevent the development of ketoacidosis, coma and death. Type 2 diabetes is a 
term used for individuals who have relative (rather than absolute) insulin deficiency. This 
term previously encompassed non-insuhn-dependent diabetes, or adult-onset diabetes. It 
usually occurs in people who are over the age of 45 and overweight. Gestational diabetes is 
carbohydrate intolerance resulting in hyperglycaemia of variable severity with onset or first 
recognition during pregnancy. Type 2 diabetes accounts for approximately 85% to 95% of all 
cases of diabetes in developed countries (1). 
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1.1.2 Incidence and Prevalence 
There is now a well recognised global epidemic of type 2 diabetes characterised by marked 
increases in incidence and prevalence over the past decade. The'upward trend in incidence is 
being driven by several factors, including decreasing levels of physical activity, dietary 
changes, consequent increases in obesity and, in many industrialised countries, an ageing 
population. Increases in prevalence rates are also been driven by better survival through 
improved secondary prevention, including improved management of risk factors and earlier 
detection and management of complications (2). These increases in incidence and prevalence 
are projected to continue over the next twenty years. Using national age- and sex-specific 
estimates of diabetes prevalence, King et al (3) estimated that the global prevalence of 
diabetes in adult populations (aged > 20 years) would increase from 4.0% in 1995 to 5.4% by 
the year 2025. These estimates were recently updated by Wild et al (4), whom employed a 
similar methodology, but used enhanced country specific prevalence estimates. They estimate 
that the global prevalence of diabetes will increase from 2.8% in 2000 to 4.4% in 2030 all age- 
groups; from 171 million in 2000 to 366 million in 2030. The International Diabetes Federation 
(IDF) has estimated that the global prevalence of diabetes in adults will increase from current 
levels of 5.1 % to 6.3 % in 2025, affecting some 333 million people. Figure 1 provides country 
specific estimates of diabetes prevalence in 2025. 
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Figure 1: Projected prevalence of diabetes in 2025 by country 
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Trends in incidence and prevalence of diabetes in the UK 
The population in the UK, as in most other European countries, has experienced a marked 
increase in incidence and prevalence of diabetes over the past decade. An analysis of 
electronic patient records from the General Practice Research Database (GPRD), based on 208 
general practices in England and Wales, found that the national rate of diagnosis of new cases 
of diabetes increased from 17.5 per 10,000 person-years in 1994 to 22.1 per 10,000 person-years 
in 1998 (5). These findings are consistent with a more current estimate derived from 
13 
QResearch, a comparable primary care database to GPRD, which found that the incidence of 
diabetes doubled between 1994 and 2003, from 1.8 to 3.3 per 1,000 (www. qresearch. org). 
Data from the Health Survey for England indicate that the prevalence of self-reported, doctor 
diagnosed diabetes in men increased from 2.9% in 1994 to 5.6% in 2004 (6). The prevalence of 
diabetes in women increased from 1.9% to 4.2% over the same period (Figure 2). 
Figure 2: Trends in prevalence of diabetes in England in men and women, 1994-2006 
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These figures are in keeping with those derived from epidemiological models. For example, 
the PBS (Public Health Observatory, Brent PCT, ScHARR) Prevalence Model (7), constructed 
by applying age-sex-ethnic-specific reference prevalence rates from epidemiological studies 
to resident populations, estimates the prevalence of total diabetes for all persons in England 
14 
1994 1998 2003 2006 
was 4.41 % in 2001, equating to 2 168 000 persons. Type 2 diabetes was estimated to affect 2 
002 000 persons (92.3%) and Type 1 diabetes 166 000 persons (7.7%). These figures are 
consistent, albeit slightly higher, than those derived from routine health care data. Data from 
the Quality and Outcomes Framework, which has near universal participation in GP practices 
in the UK, identified a prevalence of diabetes in England of 3.3 %, 3.6 %, 3.7 % in 2004,2005 and 
2006 respectively. The difference in prevalence rates may, in part, reflect inconsistent coding 
of diabetes diagnoses within general practice computer systems (8) 
1.1.3 The consequences of diabetes ,- 
Mortality and life expectancy 
Diabetes is expected to account for approximately 6% of total global mortality or 3.8 million 
deaths in 2007 (IDF 2007). This translates into more than 25 million years of life lost each year 
and represents a similar mortality burden to that of HIV / AIDS worldwide. Higher mortality 
rates and a reduced life expectancy in diabetes have been confirmed in UK and North 
American studies. A cohort study carried out in 2006 using the General Practice Research 
Database found a hazard ratio for all-cause mortality of 1.77 (1.72-1.83) in men and 2.13 (2.06- 
2.20) in women aged 35-89 years in patients with Type 2 diabetes compared to those without 
(9). The relative risk of mortality was considerably higher in younger people with diabetes; 
with a hazard ratio for men of 3.35 (95% Cl 2.86-3.93) and for women of 3.07 (95% Cl 2.37- 
3.97) in the 35-54 year old age group. Findings from a population-based diabetes registry in 
Ontario, Canada found that life expectancy in men and women with diabetes is 12.8 and 12.2 
years lower than those without diabetes (10). 
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Cardiovascular disease 
Whilst persistent hyperglycaemia associated with diabetes leads to a number of serious 
complications, it is the increased risk of cardiovascular disease which largely determines the 
considerable disease burden of this condition (11). Cardiovascular disease is responsible for 
two-thirds of all deaths in diabetes (11). This burden is further magnified in people with 
diabetes as they develop cardiovascular disease at a younger age than the general population. 
Moreover, women with diabetes are as susceptible to cardiovascular disease as men. A 
twenty year follow up study of the original Framingham cohort identified a twofold to 
threefold increased risk of clinical atherosclerotic disease in people with diabetes compared to 
those without (12). The study found that while the relative impact of diabetes on CHD and 
stroke incidence was similar for men and women, women had a worse CVD mortality profile 
These findings concur with of a major population health survey (1971-75 National Health and 
Nutrition Examination Survey) which identified an age-adjusted death rate from heart 
disease of 28.4 and 10.2 per 1,000 person-years in men aged 40-77 years with and without 
diabetes at 9-years, follow-up. The figures for women were 10.5 and 4.1 with and without 
diabetes respectively. In the Multiple Risk Factor Intervention Trial (MRFIT), men with 
diabetes were three times more likely to die from cardiovascular disease than those without 
(160 vs 53 cardiovascular deaths per 10 000 person-years) after controlling for additional risk 
factors 
The incidence of CVD and associated mortality in diabetes appears to be decreasing (2). 
However, some studies suggest that these reductions are considerably lower than the well 
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documented falls in CVD incidence and mortality in the general population. A nine year 
follow up study of participants in the National Health and Nutrition Examination Survey 
(NHANES 1) and the NHANES I Epidemiologic Follow-up Survey found a 36 % decline in 
age-adjusted cardiovascular mortality in men without diabetes compared with a 13 % decline 
for men with diabetes (14). Age-adjusted cardiovascular mortality declined by 23 % and 27 % 
in women with and without diabetes respectively. Similar patterns were also found for all- 
cause mortality and ischemic heart disease mortality. These findings contrast with recent 
study conducted in Sweden that suggests that this gap may be narrowing in some countries 
(15). Mortality rates and treatment in 1995-1998 and 1999-2002 were studied in 70 882 
patients (age <80 years), 14 873 of whom had diabetes, on the Swedish register of coronary 
care. One-year mortality rates decreased from 1995 to 2002 from 16.6 % to 12.1 % in patients 
without diabetes and from 29.7% to 19.7%, respectively, in those with diabetes. Patients with 
diabetes had an adjusted relative 1-year mortality risk of 1.44 (95 % Cl 1.36 to 1.52) in 1995- 
1998 and 1.31 (95 % CI 1.24 to 1.38) in 1999-2002. These findings are in keeping with an earlier 
study of diabetes incidence amongst the original participants (earlier cohort) of the 
Framingham study and their offspring (later cohort). Age- and sex-adjusted CVD incidence 
rate was 286.4 per 10 000 person-years in people with diabetes the earlier period and 146.9 per 
10 000 in the laterperiod, a 49.3% (95% confidence interval [CI], 16.7%-69.4%) decline (16). 
Among participants without diabetes, the age- and sex-adjusted incidence rate was 84.6 per 
10 000 person-years in the earlier period and 54.3 per 10 000 person-years in the later period, a 
35.4% (95% Cl, 25.3%-45.4%) decline. 
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Despite these reductions in incidence and associated mortahty, the absolute burden of CVD 
in diabetes has increased, reflecting the growing prevalence of this condition (17). An analysis 
of trends in hospital admissions for cardiovascular disease using national activity data in 
England found that the percentage admissions in people with diabetes increased for 
myocardial infarction (7.2% to 13.9%), angina (6.7% to 15.3%) and stroke (6.2% to 11.3%) 
relative to all admissions for these conditions between 1997 and 2006 (18). 
Microvascular disease and complications 
Retinopathy 
Diabetic retinopathy is damage to the small blood vessels in the retina which can result in 
visual loss and blindness. Retinopathy is the commonest complication of diabetes, with 
studies indicating that virtually all patients with type 1 diabetes and approximately 60 per 
cent with type 2 diabetes will have some degree of retinopathy twenty years after diagnosis 
(19). Diabetic retinopathy is estimated to be the cause of approximately 5% of blindness 
worldwide (20) and is the biggest single cause of severe visual impairment in the UK 
amongst working age people (21). Moreover, the burden of diabetic retinopathy appears to 
be increasing in the UK. A recent analysis of certifications for blindness and partial sight sent 
to local authorities in England and Wales found that the rates of certification for severe visual 
impairment due to diabetes doubled between 1990-1 and 1999-2000 from 1.99 to 3.84 per 
100,000 population (22). 
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Neu 
Between 30-50 % of patients with diabetes will develop chronic peripheral neuropathy during 
their lifetime and 10-20 % will develop severe symptoms (20; 23). The commonest form of 
neuropathy in diabetes is distal symmetrical sensory polyneuropathy which has two main 
clinical manifestations: foot ulceration and painful neuropathy. Foot ulcers occur in 
approximately 15 % of patients with diabetes and are a common reason for hospitalisation 
(24). The importance of early identification and prompt management of foot ulcers is further 
highlighted by the fact that they are a precursor to lower-limb amputations in around 85 % of 
cases. Diabetic neuropathy is also a common cause of erectile dysfunction. This has a major 
impact on quality of life and occurs in about half of men with diabetes over 50 years, a rate 
three times higher than in men without diabetes (25). 
Renal disease 
Diabetes is an important risk factor for renal disease which is contributing to an increased 
need for renal replacement therapy in the USA and Europe (26). The Multiple Risk Factor 
Intervention Trial, which included a total of 332,544 men aged 35 to 57 years from 18 cities in 
the United States, found that the age-adjusted incidence of End Stage Renal Disease (ESRD) 
was 199.8 per 100,000 person-years in men with diabetes compared with 13.7 per 100,000 
person years in those without (RR, 12.7; 95 % confidence interval [CI], 10.5-15.4) (27). A recent 
study of renal disease registries in ten European countries found an 11.9% annual increase in 
the number of people with Type 2 diabetes requiring renal replacement therapy (28) 
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1.1.4 Health care costs of diabetes 
Diabetes accounts for a substantial and growing proportion of health care expenditure. The 
International Diabetes Federation estimates that the global cost of preventing and treating 
diabetes and its complications diabetes will be at least US$ 232 billion in 2007 (29). By 2025, 
this cost is estimated to exceed US$ 302.5 billion. In the USA, which accounts for 
approximately half of global health care expenditure on diabetes, the national cost of diabetes 
is expected to increase from US$ 132 billion to US$ 192 billion between 2002 and 2020 (29). 
Diabetes has been estimated to account for 5% of all National Health Service expenditure (30) 
and 9% of hospital costs in the UK (31). A more recent estimated was presented in the 2002 
Wanless report which stated that the total annual cost of diabetes to the NHS to be E1.3 
billion. However, the increasing prevalence of diabetes means that these figures will quickly 
become dated. Economic modelling studies suggest that the cost of health care for patients 
with Type 2 diabetes may increase by up to 25 % by 2060, although the relative economic 
burden may increase by as much as 40-50 % given projected reductions in the economically 
active age groups (32). However, these projected increases, which are low compared to US 
estimates, may be conservative given that the economic model used does not take into 
account rapid increases in the prevalence of obesity. 
More detailed health care cost estimates for diabetes have been estimated in a study of several 
European countries (33). An average annual health care cost of E1934 ($3585) was found in a 
study of 7000 patients in 8 European countries. Approximately 
half (55%) of the costs were 
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incurred through hospital admissions and only 7% on prescribing of hyperglycaemic agents. 
However, the cost of diabetes prescribing has increased considerably over the past decade 
such that it now accounts for a higher proportion of overall prescribing costs than any other 
disease area (34). In an analysis of on all drug prescriptions for diabetes in community 
settings in England, Patel et al found that the total number of diabetes prescriptions 
(medicines and monitoring) rose from 7,613,000 to 24,325,640 between 1991 and 2004; an 
increase of over 300% (35). The total cost of diabetes prescribing increased by 650% over the 
same period with insulins the biggest contributor to cost followed by monitoring equipment 
and then oral medications. 
1.1.5 Scope for health improvement in diabetes 
A combination of primary and secondary prevention programmes are required to reduce 
morbidity and mortality and improve health outcomes in diabetes (36-38). The following 
section wiR concentrate on secondary prevention as primary prevention measures are beyond 
the scope of my doctoral research. 
Secondary prevention measures 
The evidence base for secondary prevention measures to reduce complications of diabetes is 
stronger than for other chronic diseases (20). In summary, key interventions include timely 
management of raised blood pressure, blood glucose and lipids; and encouraging smoking 
cessation (39). Early identification and management of complications is also essential, which 
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involves regular screening for retinopathy, nephropathy, peripheral neuropathy and 
peripheral arterial disease (20). 
Blood glucose control 
Allocation to "intensive' treatment compared to usual care in United Kingdom Prospective 
Diabetes Study (UKPDS) resulted in an 11% reduction in mean HbAlc (7.0% v 7.9%) at ten 
years follow up (40). This improved control conferred significant reduction in microvascular 
endpoints - with a 25 % reduction (95 % Cl 7% to 40 %) in the intensive treatment group. 
Observational analyses in the UKPDS found a 37% reduction in microvascular complications 
for each 1% reduction in glycated haemoglobin (41). Overall, there was a 12% reduction for 
any diabetes-related endpoint (95% CI 1% to 21%). No threshold was observed for any 
diabetes complication. 
Few clinical trials have been designed to examine the effect of improved glycaemic control on 
cardiovascular outcomes. The UKPDS identified a small but not significant benefit of 
glycaemic control on risk for myocardial infarction [AOR 0.84 95% CI 0.71-1.00] but not for 
stroke [AOR 1.1195 % Cl 0.81-1.511 (40). A recent meta-analysis of observational studies found 
that chronic hyperglycemia is associated with an increased risk for cardiovascular disease in 
persons with diabetes (42). The study found that the pooled relative risk for cardiovascular 
disease (coronary heart disease and stroke) was 1.18 (95% Cl, 1.10 to 1.26) for each one 
percent increase in glycosylated haemoglobin in persons with type 2 diabetes. However, the 
authors conceded that these results required confirmation in large, prospective clinical trials. 
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Blood pressure control 
Allocation to "intensive' treatment compared with usual care in the UKPDS resulted in 
significantly improved blood pressure control (mean BP 144/82 mm Hg compared with 
154/ 87 mm Hg) (43). This improved control was associated with a 24 % reduction in diabetes- 
related endpoints, (95 % Cl 8% to 38 %), 32 % reduction in deaths related to diabetes (95 % CI 6% 
to 51 %), 44 % reduction in strokes (95 % CI 11 % to 65 %), 37 % reduction in all microvascular 
endpoints (95 % Cl 11 % to 56 %) and a non-significant reduction in myocardial infarction and 
all-cause mortality (43). Patients allocated to the "tight' blood pressure control group in the 
UKPDS were significantly less likely to develop retinopathy than "normal' treatment group; 
with significantly lower microaneurysm counts and rates of photocoagulation at 7.5 years 
follow up (44). Observational analyses in the UKPDS found a 13% reduction in microvascular 
complications and 11 % reduction in myocardial infarction for each 10 mm Hg reduction in 
systolic blood pressure. 
A recent analysis of UKPDS data found that the risk of complications in type 2 diabetes is 
associated independently and additively with hyperglycaemia and hypertension (45). The 
study found an incidence of the "any diabetes-related endpoint' of 15 and 82 per 1,000 person- 
years respectively in the lowest (HbAic <6.0%, SBP <130 mmHg) and highest (HbAic ý! 8%f 
SBP ý450 mmHg) category combinations which highlights the importance of intensively 
treating both these risk factors. 
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Lipid control 
The importance of tight control of cholesterol and widespread use of statins as a secondary 
prevention measure in diabetes has been demonstrated in several randomised controlled 
trials and a recent meta-analysis. The MRC/BHF Heart Protection Study found that 
cholesterol-lowering therapy was beneficial to all groups of people with diabetes, even if they 
did not have existing coronary disease (46). Allocation to simvastatin in the study was found 
to reduce the rate of first major vascular events by about 25% in a wide range of diabetic 
patients studied. Importantly, these benefits extended to those people without previously 
documented raised cholesterol levels i. e. pretreatment LDL cholesterol concentration below 
3.0 mmol/L. This finding was supported by the Collaborative Atorvastatin Diabetes Study 
(CARDS), a randomised controlled trial of 2,838 patients with diabetes aged 40 to 75 years 
without a documented history of cardiovascular disease and without elevated LDL- 
cholesterol (47). This trial found that treatment with atorvastatin reduced the risk of acute 
coronary heart disease events by 36%, coronary revascularisations by 31%, stroke by 48% and 
mortality by 27%. A recent meta-analysis of fourteen randomised controlled trials, which 
included 18 686 individuals with diabetes, found that statin therapy reduced the 5-year 
incidence of major vascular events by about one-fifth per mmol/L reduction in LDL 
cholesterol in this group (48). Similar proportional reductions were found for major coronary 
events, stroke and the need for coronary revascularisation. These reductions were similar to 
those found in patients without diabetes. 
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Smoking 
Smoking is an important modifiable risk factor for cardiovascular disease and microvasculax 
complications in people with diabetes. A ten year follow up of patients enrolled in the 
UKPDS found that smokers had a significantly higher risk of developing coronary heart 
disease [hazard ratio 1.41(1.06 to 1.88)] (39) but were not found to be at significantly increased 
risk for stroke (49). The latter finding may be due to study being underpowered, as the 
number of participants who suffered a stroke at ten years follow up was small (n=99,2.6%). 
Smoking is a risk factor that varies strongly by socio-economic status. This social patterning 
partly explains inequalities in diabetes outcomes and variations in mortality between 
socioeconomic groups (50). 
Multiple risk factor management 
The importance of simultaneously addressing several risk factors for cardiovascular disease 
in diabetes has been demonstrated in controlled settings. The Steno-2 study, a small 
randomised controlled trial of diabetes management, found that allocation to intensive 
treatment (involving a stepwise implementation of behaviour modification and 
pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and 
microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin) 
led to improvements in HbAlc, systolic and diastolic blood pressure, serum cholesterol and 
triglyceride levels compared to usual care (51). The intensive treatment group had a 
significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95% CI 0.24 to 0.73), 
nephropathy (hazard ratio, 0.39; 95% CI 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 
95% CI 
0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 % Cl 0.18 to 0.79) at 8 years 
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follow up. A recently published longer term follow up (13 years) of patients entered into the 
Steno-2 trial found that the benefits of intensive therapy extended to lower mortality rates 
from cardiovascular causes (hazard ratio, 0.43; 95% Cl, 0.19 to 0.94; P=0.04) (52). 
Cost-effectiveness of diabetes control 
Improved control of diabetes has been shown to reduce health care costs in economic 
modelling and routine care setting studies (53). In a retrospective study of Health 
Maintenance Organisation enrolees in Seattle between 1992 and 1997, at ten years follow up 
Wagner et al found that health care costs were $685-$950 lower in people with diabetes whose 
HbAlc improved during the first three years of the study when compared to those whose 
HbAlc did not improve (54). 
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1.2 Ethnicity and diabetes prevalence, management and health outcomes 
Eflu-dc minority groups in the UK generally have a higher prevalence of diabetes and a worse 
morbidity and mortality profile than the general population. This appears to be particularly 
evident in south Asians. Before summarising the literature on diabetes and ethnic minorities 
in the UK, it is important to define ethnicity, discuss how the term is used and describe the 
characteristics of the main ethnic minorities in the UK. However, the following section is 
necessarily brief as a detailed discussion about ethnicity is beyond the scope of this thesis. 
Possible explanations for ethnic variations in health are described in Chapter 2. 
1.2.1 Ethnic minorities in the UK 
Definition of ethnicity 
The concept of ethnicity is complex and contested and its description has changed 
significantly over time. Despite this, there is a degree of consistency in approaches used and, 
according to Bhopal, most definitions include one or more of the following dimensions (55): 
* Shared origins or social background 
* Shared culture and traditions which are distinctive, maintained between generations, 
and lead to a sense of group identity 
*A common language or religious tradition 
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The Office for National Statistics which conducts the decennial census in the United Kingdom 
and formulates the ethnic categories used in the census has suggested that people use a 
similar combination of categories to assign themselves to an ethnic group: 
e country of birth 
9 nationality 
* language spoken at home 
9 parents' country of birth in conjunction with country of birth 
e skin colour 
* national/ geograpl-dcal origin 
9 racial group 
9 religion 
Categorizing ethnicity 
Categorizing ethnicity in a way that captures these important dimensions whilst achieving 
the clarity and brevity required by large population surveys such as the census is a 
challenging task. The Office for National Statistics has indicated that it employed the 
following rules to formulate the census ethnicity question: 
1. Group the items using a conceptual basis. 
2. Provide categories that reflect and distinguish between the significant ethnic groups 
present in the United Kingdom. 
3. Ensure that the classification will be able to be used for a number of years. 
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4. Create a classification that you will be able to use in a variety of different types of 
collections, for example, telephone, Internet, interviewer-administered and self-administered 
surveys, and for administrative data. 
5. Construct a classification that will produce data comparable with data previously 
produced on the subject. 
6. Ensure that, no matter what the response to the question, it will fit into the classification. 
Despite these steps, the extent to which people identify themselves with ethnic categories 
used in the UK census and by public services is an area of ongoing debate (55; 56). Eflu-dc 
categories used for the 1991 and 2001 censuses are compared in Table 1. The main change 
between census years was the addition of a mixed ethnic category in 2001. In addition to 
having a question about edmicity, both the 1991 and 2001 censuses asked about country of 
birth and a question on religion was introduced in 2001 census. The UK government has 
encouraged the use of census categories by public bodies, such as the NHS, in order to ensure 
consistency in ethnic monitoring across public services. This requirement was strengthened in 
2001 with the introduction of the Race Relations (Amendment) Act which requires public 
bodies to monitor whether access to public services is equitable between ethnic groups in a 
consistent way. Despite this, levels of ethnicity recording within health services in the UK 
remain stubbornly low (57). 
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Table 1: Ethnic group categories used in the 1991 and 2001 censuses 
1991 census 2001 census 
White White 
A British 
B Irish 
C Any other White 
background 
Mixed 
D White and Black 
Caribbean 
E White and Black African 
F White and Asian 
G Any other mixed 
background 
Asian or Asian British 
Indian H Indian 
Pakistani j Pakistani 
Bangladeshi K Bangladeshi 
Other groups: Asian 
L Any other Asian 
background 
Black or Black British 
Black Caribbean M Caribbean 
Black African N African 
Black other 
P Any other Black 
background 
Other ethnic categories 
Chinese R Chinese 
Other 
S Any other ethnic 
category 
Not stated 
Z Not stated 
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Main ethnic minority groups in the UK 
In 2001,4.6 million in 2001 or 7.9 per cent of the total population of the United Kingdom 
belonged to ethnic minority groups. Indians were the largest minority group (1.8%), followed 
by Pakistanis (1.3%), those of mixed ethnic backgrounds (1.2%), Black Caribbeans (1.0%), 
Black Africans (0.8%) and Bangladeshis (0.5%). 
1.2.2 Prevalence of diabetes in ethnic minority groups 
Some of the earliest community-based studies to document the very high prevalence of 
diabetes in efluiic minority communities in Britain were undertaken in Coventry and Lmdon. 
The Coventry Diabetes Study, which involved house to house screening in the Foleshill ward 
of the city between 1986 and 1989, found that the age-adjusted prevalence of non-insulin- 
dependent diabetes was 3.2 per cent and 4.7 per cent in European males and females but 12.4 
per cent and 11.2 per cent in south Asian males and females (58). The study also found that 
the age of onset of diabetes was lower in south Asians compared to whites. Using a similar 
methodology, the Southall Diabetes Survey which was conducted in 1984 found similar 
differences in age-adjusted prevalence rates, with a four-fold difference between south Asians 
and Europeans (59). On of the first studies to examine the prevalence of diabetes in the UK's 
black population was undertaken in Wolverhampton in the late 1980s. The study found that 
diabetes prevalence was nearly twice as high in West Indians when compared to whites on a 
computerised database of attendees to local primary and secondary care diabetes clinics (60). 
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These findings have been confirmed in more recent, nationally representative surveys. The 
Fourth Survey of Ethnic Minorities found that the prevalence of non-insulin dependent 
diabetes was 5 %, 20 %, 13 % in European, south Asian and African Caribbean men aged 40-64 
years (61). This data also indicate that rates may additionally vary within ethnic groups by 
socio-economic status. Variations in prevalence were even more marked in women; with 
figures of 2%, 16% and 18% respectively. These figures are broadly consistent with more 
recent figures from the 2004 Health Survey for England presented in Figure 3 (62). 
Figure 3: Prevalence of doctor diagnosed diabetes within minority ethnic group 
General population 
Indian 
Black Caribbean 
Bangladeshi 
Pakistani 
Black African 
Chinese 
of population 
Estimates derived from the PBS Model, constructed by applying age, sex and eflu-dc 
prevalence figures from epidemiological studies to resident populations in England using 
2001 Census data, found somewhat lower prevalence rates in black and south Asians than the 
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Health Survey for England; with whites 4.3%, blacks 5.7%, south Asians 6.6% (7). However, 
these estimates have been generated from previously cited epidemiological studies which 
may not be nationally representative, as they only covered small geographical areas (Foleshill 
in Coventry, Brent in London), and are now fairly dated as they were conducted in the 1980s. 
1.2.3 Morbidity and mortality from diabetes in ethnic minority groups 
Morbidity 
Evidence from the US and UK indicates that people from ethnic minority groups are more 
likely to develop diabetes-related complications than whites. For example, the high 
prevalence of coronary heart disease in south Asian and stroke in black populations with 
diabetes living in the UK has been extensively documented (63). Moreover, this increased risk 
of coronary heart disease in south Asians may be present at the time of diagnosis. In a 
prospective study of newly-diagnosed patients with Type 2 diabetes attending hospital and 
primary care clinics in west London, south Asians were significantly more likely than whites 
to present with a history of macrovascular (15.7% v 9.4%) and microvascular disease (27.3% v 
16.5 %), including retinopathy (17.5 %v7.9 %) and nephropathy (18.1 %v7.8 %). However, 
these findings differ from those of the UKPDS which identified a similar prevalence 
myocardial infarction, stroke or intermittent claudication. in whites, blacks and south Asians 
at diagnosis (64). The prevalence of ischaemic electrocardiogram, microalbuminuria, 
retinopathy and neuropathy was also similar between ethnic groups. 
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The finding of a lower risk of coronary heart disease in blacks compared to whites was 
confirmed in the UKPDS which found a hazard ratio for myocardial infarction (fatal and non- 
fatal) of 0.3 (0.2-0-6) after adjusting for conventional risk factors. The study also found a small 
but non-significant increased risk of MI amongst south Asians 1.2 (0.9-1.7) compared to 
whites. However, the increased risk of MI in south Asians may not have attained statistical 
significance due to the small numbers in this group. 
Renal failure is commoner in black and south Asian people with diabetes than whites. An 
analysis of patients receiving renal replacement therapy in Leicestershire from 1979 to 1988 
found an incidence rate of end-stage renal failure in south Asians of 486.6 (95% Cl, 185.1 to 
788.1) cases per million person-years per year, compared to 35.6 (17 to 54.2) in whites (65). A 
study of 370 consecutive south Asian and 368 consecutive white patients attending a hospital 
diabetes clinic in Leicester found higher levels of proteinuria, a precursor to renal disease, in 
south Asians than whites (14 %v6%; p<0.001) (66). These findings concur with the results 
from separate studies conducted in London and England. A study of residents in the Thames 
regions who were accepted as new patients for renal replacement therapy in 1991/ 92 found 
an average annual acceptance rates per million of 61 for white people, 175 for black people, 
and 178 for south Asians (67). A study of all 5901 patients resident in England with end-stage 
renal failure who had been accepted for renal replacement therapy in renal units in England 
found a crude relative acceptance rates were 3.5 and 3.2 higher respectively for south Asians 
and blacks compared with wl-dtes (68). Differences in need were more pronounced when the 
analysis was restricted to individuals with diabetes; with relative rates of acceptance for 
diabetic end-stage renal failure of 5.8 and 6.5 respectively. 
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Studies conducted in the US have found higher amputation rates among black people with 
diabetes when compared to whites (69; 70). However, this increased risk does not appear to 
apply to black or south Asian people in the UK (71). Findings from a case-control study 
conducted in Southall, west London found no difference in amputations rates in black and 
white women with diabetes (72). The amputation risk in black men was one third that of 
white men although this difference was wholly accounted for by variations in smoking, 
neuropathy and peripheral vascular disease rates. The same authors found a similarly lower 
rate in south Asians in a case-control study conducted in north-west England (73), with an 
odds ratio of 0.26 (95% Cl 0.11-0.65). However, this difference was again accounted for by 
lower rates of peripheral vascular disease (9% v 24%; p=0.02), neuropathy (30% v 54%; 
p=0.03) and lower rates of smoking (ever smoked: 31 %v 57%; p=0.03). 
Mortality 
Cardiovascular disease mortality has been found to be higher in black and south Asians with 
diabetes than in whites (74). An 11-year follow-up of a population-based sample of south 
Asians and whites with diabetes in Southall, west London found marked ethnic group 
differences in cardiovascular disease, especially in younger people. The study identified a 
mortality rate ratio for circulatory deaths of 1.80 (95% CI 1.03-3.16, p<0.05); and for heart 
disease was 2.02 (95% Cl 1.04-3.92, p<0.05); in south Asians compared to whites who were 
aged 30-64 years at baseline. Moreover, 77% of South Asian deaths were caused by 
circulatory disease, compared with 46% of European deaths and south Asian survivors were 
3.8 times (95% Cl 1.8-8.0, p=0.001) more likely to report a history of myocardial infarction 
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than Europeans. In a study of UK death certificates during 1985-6, Chaturvedi and Fuller(75) 
found that the rate for coronary heart disease mortality was three times higher in people with 
diabetes born in south Asia than those born in England and Wales. Stroke mortality rates 
were four times higher in people born in Africans and the Caribbean than those born in 
England and Wales. 
Eflu-dc group differences in all-cause mortality between effinic groups in diabetes are evident 
in the US, but findings from UK studies appear more equivocal (76). Analysis of data from 
the London cohort of the WTHO's multinational study of vascular disease in diabetes found 
lower all-cause mortality rates in blacks compared with whites (OR 0.4195% Cl 0.23-0.73). 
However, this difference was attenuated after adjustment for potential confounding factors. 
Inequalities in diabetes-related mortality will increasingly contribute to the variations in all- 
cause mortality between efluiic groups (77). Inequalities in mortality in the UK by country of 
birth have been found in several published studies using death certification and 1971,1981, 
1991 and 2001 census data (78-81). In the most recent analyses (79), all-cause standardised 
mortality rates are significantly higher in men born in East Africa (aged 40-59 years), West 
Africa (60-69 years), Bangladesh (45-59 years, 60-69 years) and Pakistan (45-59 years). 
Additional analyses of cause specific mortality indicate that premature mortality in these 
groups is probably due to their elevated risk of cardiovascular disease. Both men and women 
born in India, Pakistan and Bangladesh have considerably higher mortality rates from CHD 
and stroke than those born in England and Wales. In contrast, men and women born in Africa 
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or in the Caribbean have lower or similar mortality rates from CHD, but much higher rates of 
stroke, than those born in England and Wales. 
1.3 Key points from Chapter 1 
1. Diabetes is an important global public health problem with a growing morbidity and 
mortality burden 
2. In developed countries, the burden of diabetes is unequally distributed across society. 
In particular, people from ethnic minority groups have a higher prevalence of diabetes 
and a worse morbidity and mortality profile than that in the general population 
3. Secondary prevention interventions in primary health care settings are both effective 
and cost-effective in improving health outcomes in diabetes 
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2.0 Addressing ethnic group inequalities in health 
The presence of health inequalities between ethnic groups have long been recognised and 
described. During the past two decades the emphasis of enquiry has gradually shifted from 
description to explanation and, more recently, to the identification of effective strategies to 
reduce inequalities (82). 
2.1 Explaining inequalities in health between ethnic groups 
The underlying causes of ethnic group differences in health have been subject to considerable 
epidemiological investigation but remain an area of ongoing enquiry and debate. Employing 
Blacks" framework for understanding socio-economic differentials in health, Davey Smith et 
al have defined seven broad explanatory categories for health inequalities between ethnic 
groups; artefact, migration, socio-economic factors, culture, racism, biology and health service 
access and use (83). Artefact explanations suggest that there may be an inherent bias in the 
way that data on the health status of ethnic groups is produced. For example, ethnic minority 
groups may be more likely to self-report poorer health than others in population surveys. 
Mortality studies may be subject to bias if, for example, recording of country of birth is more 
complete on death certificates (numerator) than it is when collected during the decennial 
census (denominator) (84). Nfigration explanations highlight the possible adverse effects of 
migration on health, such as raised stress levels. However, many of these effects are likely to 
be short term and do not explain health differentials which accrue many years after migration 
(85). 
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The worse health outcomes experienced by ethnic minority groups may be due to greater 
relative exposure to socio-economic hardship. Whilst socio-econornic status differs widely 
both within and between ethnic groups in the UK, people from ethnic minorities frequently 
have a lower socio-economic status than white British (86). One of the first studies to examine 
the contribution of socio-economic status to ethnic group variations in health was conducted 
by Marmot et al in using mortality data during the 1970s (87). The study found that variations 
in mortality rates between ethnic groups were not attenuated after controlling for differences 
in socio-economic status. However, Davey Smith et al have highlighted several shortcomings 
in the application of conventional measures of socio-economic status to ethnic minority 
communities. First, inflation of occupational status on death certificates may be more 
pertinent within ethnic minority groups as many will have belonged to a skilled occupational 
grouping before their migration but had to work in unskilled occupations after their arrival in 
the UK. Second, social class groupings are not homogenous and may mask important within 
group differences in income and standards of living. For example, the Fourth National 
Survey of Ethnic Minorities found that ethnic minorities had a lower income than whites 
within the same social class grouping (88). Third, there will be people from ethnic minority 
groups not captured in social class groupings, including illegal migrant workers and failed 
asylum seekers. 
Differing cultural beliefs and behaviours have frequently been cited as a possible explanation 
for effinic group variations in health. However, cultural explanations for health inequalities 
have been criticised for not recognising the impact of material factors on health beliefs and 
behaviours (89). Behaviours of interest include smoking, drinking and diet but extend to the 
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other areas, such as the nature of interaction with public services, including healthcare 
(although the focus for this is too often limited to language and communication issues). The 
most studied health behaviours, which vary considerably between ethnic groups, are 
smoking and alcohol consumption. The 2004 Health Survey for England found a high 
prevalence of smoking in effmic minority men; 40% in Bangladeshis, 30% in Irish and 29% in 
Pakistanis compared with 24% in the general population. However, the patterning of 
smoking between ethnic groups in the UK differs considerably by gender, with a much lower 
prevalence in south Asian when compared to white British women. The pattern of alcohol 
consumption is more uniform in men and women across ethnic groups, with generally lower 
consumption in minority groups, with the exception of the Irish, when compared to that in 
the general population. 
The experience of racism may influence health in a number of ways although evidence to 
support this relationship is limited and study findings are not consistent (83). For example, 
the direct experience of racism and discrimination has been associated with mental distress 
and the presentation of acute illness in some studies (90). However, findings from the Fourth 
National Survey of Ethnic Minorities did not identify a consistent relationship between the 
experience of overt racial discrimination and poor health. The impact of racism on health may 
be more diffuse, indirectly perpetuating underlying socio-economic disadvantage through 
reduced educational and employment opportunities. 
Inequalities in health outcomes between ethnic groups may reflect inequitable access to high 
quality healthcare. There is considerable evidence highlighting inequity in access to health 
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care between ethnic groups in the United States (91; 92). Relatively fewer studies have been 
conducted in the UK, particularly in primary care settings (93). This may be a consequence of 
low levels of ethnicity recording in routine health care information systems (94). Moreover, 
there is much less research on the quality and appropriateness of health care delivered to 
black African and Caribbean groups. However, the volume of research literature on ethnicity 
and health is likely to increase in the UK as ethnic coding improves in health care information 
systems. 
Early studies comparing utilisation of primary care services found higher GP consultation 
rates in Pakistani, Indian and Black Caribbean adults when compared to the general 
population (95; 96). These differences are attenuated but not abolished when consultation 
rates are adjusted for indicators of need, such as health status (84). However, some disease- 
specific studies have identified under-utilisation of primary care in ethnic minorities. For 
example, in a retrospective study of medical records from a single GP practice in Brent, 
Giflam et al, found that south Asians were no more likely to consult for circulatory conditions 
than the general population despite having a higher prevalence of this condition (97). 
National patient surveys provide a more up-to-date comparison of (perceived) access to 
primary care between ethnic groups. A recent national survey conducted by the Healthcare 
Commission found that all of the main three south Asian groups were less likely to self-report 
being satisfied with access to primary care services than the white British group. (98) These 
differences remained significant after adjustment for age, gender and educational status. 
Black African and Caribbean respondents to the survey were as likely to report being satisfied 
with access to primary care services as white British respondents. 
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Studies examining differences in access to secondary care in the UK suggest lower utilisation 
in some ethnic minority groups. For example, in a prospective cohort study of patients 
deemed appropriate for coronary artery bypass grafting at a tertiary cardiac centre in 
London, south Asian patients were found to be less likely than white patients to receive 
surgery (99). This finding is in keeping with an earlier study which found that south Asian 
patients with chest pain are less likely to be referred for an exercise electrocardiogram and 
wait longer to be referred to a cardiologist (100). In a recent analysis of Hospital Episode 
Statistics (HES) data for London residents, Bangladeshi patients were found to have only two- 
thirds [proportional ratio 66.8,95% confidence interval (CI) 60.7-73.3] and Black Caribbean 
and Black African patients four-fifths (proportional ratios 80.5,72.0-89.9 and 80.7,68.0-95.2, 
respectively) revascularization rate in comparison with apparent need as the general 
population (101). However, these findings contrast with those from a study of over ten 
thousand civil servants based in London (Whitehall II study), which found that south Asian 
etImicity was not associated with lower use of cardiac procedures or drugs, independently of 
clinical need (102). 
In summary, there appears to be some evidence to suggest that the provision of health care in 
Britain may not be equitable between ethnic groups. However, the contribution of this 
inequity to overall inequalities in health outcomes between ethnic groups remains uncertain. 
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2.2 Policy response to health inequalities 
In addition to a longstanding policy objective of improving overall population health, 
reducing health inequalities has become a key priority of social policy in the UK since the late 
1990s. The 1998 Acheson Inquiry report (103), commissioned by the incoming Labour 
government to guide policy action on addressing health inequalities in UK, made three key 
recommendations: - 
* all policies likely to have an impact on health should be evaluated in terms of their 
impact on health inequalities; 
*a high priority should be given to the health of families with children; 
9 further steps should be taken to reduce income inequalities and improve the living 
standards of poor households. 
The report made specific reference to health inequalities between different ethnic groups, 
indicating that these may reflect "'different causes of poor health; differential susceptibility to 
these causes; differential access to factors which ameliorate cause or susceptibility, for 
example, preventive health care services; or a combination of these". Recommendations were 
made for governmental action on ethnic group inequalities in health in two general areas. 
First, to address ethnic group inequalities in the socioeconomic determinants of health. 
Second, to consider the needs of ethnic minority groups in the provision of health services. 
Specifically, the report recommended: 
9 that the needs of minority ethnic groups are specificaRy considered in the 
development and implementation of policies aimed at reducing socioeconomic 
inequalities. 
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* the further development of services which are sensitive to the needs of minority ethnic 
people and which promote greater awareness of their health risks. 
9 that the needs of minority ethnic groups are specifically considered in needs 
assessment, resource allocation, health care planning and provision. 
The report highlighted limitations of data currently collected to assess inequalities in health 
across ethnic groups and recommended that the capacity to monitor inequalities in health 
and their determinants at a national and local level be strengthened. 
UK Government response to Acheson 
Many of the recommendations of the Acheson Inquiry report were incorporated into two key 
policy documents published shortly thereafter; the public health white paper Saving lives: 
Our Healthier Nation (July 1999) and Reducing Health Inequalities: An Action Report 
(January 1999). The white paper focused on four priority areas; cardiovascular disease, 
cancer, mental health and accidents, and set out a high level target in each area. For example, 
the target for cardiovascular disease was to reduce the death rate from coronary heart disease 
and stroke and related diseases in people under 75 years by at least two fifths by 2010. 
However, despite placing considerable emphasis on "'improving the health of the worst off', 
targets set within the white paper focused on reducing overall mortality rates rather than 
reducing variations in rates between socio-economic and ethnic groups. The Action Report 
set out a more detailed cross-government response to the 39 recommendations of the 
Acheson report. In relation to the NHS, the report recommended: - 1) that the needs of 
minority ethnic groups are specifically considered in needs assessment, resource allocation, 
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health care planning and provision; 2) that the provision of equitable access to effective care 
in relation to need should be a governing principle of all policies in the NHS; and 3) that 
priority should be given to the achievement of a more equitable allocation of NHS resources. 
The Governments' health inequalities strategy was updated in July 2003 with the publication 
of Tackling Iwalth inequalities: A Programme for Action. The stated aim of the strategy was for the 
Government's investment in public services and programmes to have a maximal impact on 
reducing health inequalities. The strategy highlighted several key themes, including illness 
prevention and providing effective treatment and care and identifies improving primary care 
as a priority. 
The NHS Plan was published in July 2000 and put prevention and inequalities firmly on the 
agenda both in terms of NHS service delivery and in terms of the NHS working with, and 
through other agencies. The Government gave a commitment in the NHS Plan that, for the 
first time ever, local targets for reducing health inequalities would be reinforced by the 
creation of two Public Service Agreement (PSA) targets. The number of PSA targets which 
relate to health inequalities has since increased (see Table 2). 
Following on from this the Government completed a cross cutting review on health X... 
11) 
inequalities (2002) which assessed the progress that had been made and identified future 
cross-government funding priorities. The review identified a need to level up access to 
prevention, screening, diagnostic and treatment services for CHD and cancer, countering the 
inverse care law by developing service provision, access and quality in areas and among 
populations that are least well served in relation to need (e. g. through improved primary 
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care, prevention and early intervention). It also identified a need to improve the quality of 
preventive and treatment services for CHD, stroke, diabetes and cancer through NSF 
implementation, and levelling up access for groups and areas which have been under-served. 
Table 2: Current Public Service Agreement (PSA) targets for health inequalities 
Current Public Service Agreement (PSA) targets for health inequalities 
Starting with children under one year, by 2010 to reduce by at least 10 per cent the gap in 
mortality between routine and manual groups and the population as a whole 
Starting with local authorities, by 2010 to reduce by at least 10 per cent the gap in life 
expectancy between the fifth of areas with the worst health and deprivation indicators (the 
Spearhead Group) and the population as a whole. 
To reduce the inequalities gap between the fifth of areas with the worst health and 
deprivation indicators and the population as a whole by at least 40 % for cardiovascular 
disease and by at least 6% for cancer 
To reduce adult smoking prevalence in routine and manual groups to 26% or less by 2010 
This policy objective has been supported by information for local commissioners of health 
care around interventions that are likely to be effective in addressing health inequalities. For 
example, the recently published "Key NHS interventions to support the achievement of the 
national health inequalities targef" states that commissioners should ensure: 
* prevention and treatment services for cancer and Coronary Heart Disease (CHD) reach 
those in greatest need or with poorest health outcomes, including disadvantaged 
groups and efimic groups with high prevalence. For CHD in particular reducing 
hypertension and increasing prescription of statins. 
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* improved access to, and quality of, services for currently under-served areas and 
groups, particularly primary care services. 
The importance of addressing ethnic group inequalities in access to health care was 
strengthened by statutory requirements set out in the Race Relations (Amendment) Act 2001. 
The Act places a duty on all public sector authorities to promote race equality and requires 
them to demonstrate that their activities are not carried out in such a way which will 
discriminate against any ethnic / racial group. An integral part of this is for authorities to 
monitor whether access to public services is equitable between ethnic groups. This 
requirement has been supported by a recent requirement from the Cabinet Office for 
stringent impact assessments of government policy and strategy, including the potential and 
consequent impacts on inequalities (104). An Equality Impact Assessment (EIA) toolkit has 
been developed to consider the possible impact of new strategies on people according to their 
age, disability, race, religion and beliefs, gender and sexual orientation. 
2.3 Improving quality in health care 
Improving quality in health care has been a key policy objective in many developed 
countries, including the United States (US) and United Kingdom (UK) (105-107) over the past 
decade. This is in response to numerous factors, including rising health care costs, increased 
public expectation of public services, and growing evidence of sub-optimal health care 
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care (91; 108; 109), including substantial variations in care delivered in different geographical 
areas and to different population groups. 
Variations in the quality of care are present in all health care systems (108; 110). The influential 
Institute of Medicine report "Crossing the quality chasm" stated that the US health care 
system harms patients too frequently and routinely fails to deliver its potential benefits(106). 
The report called for a major investment (US$1 billion over 3-5 years) in quality improvement 
programmes to begin to address these shortcomings. A systematic review of the quality of 
primary care in the United Kingdom, New Zealand and Australia found that HbAlc 
recording in diabetes ranged from 25 to 100% (109). The percentage of people with diabetes 
who had retinopathy screening during the previous two years ranged from 44-72 %. This 
variation all too commonly follows the ""inverse care law", where quality of health care is 
poorer in deprived and culturafly diverse areas where need is greatest (111). Hence, efforts to 
improve health care quality are likely to reduce health inequalities if they are able to reduce 
existing variations in care. Conversely, if quality improvement initiatives improve care for 
more affluent groups at a higher rate than for disadvantaged groups, they may increase 
inequalities. 
2.3.1 Defining and measuring quality in health care 
The science of quality measurement in health care has been described as, at best, "still in if s 
adolescence' (112). Definitions and measures of quality employed have varied and the 
evidence base for many approaches used has been described as weak (113; 114). However, 
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whilst definitions remain contested, the use of quality measures to assess health care system 
performance is growing internationally and is a legal requirement in some countries, 
including the UK (115). According to Leatherman and Sutherland (105), this trend can be 
ascribed to four factors; first, a growing demand to hold professionals, health care managers 
and governments accountable for health care performance. Second, increasing consensus on 
clinical standards and protocols between governments, managers, clinicians and other 
stakeholders which has resulted in greater agreement on quality measures used. Third, the 
validity of quality measures has been better established through research. Fourth, 'public 
reporting' of quality performance data has increased. Added to this is the increased 
penetration of electronic health records, particularly within the UK, which simplifies 
extraction and aggregation of quality performance data. 
Defining qualijy in health care 
Quality in health care has been defined in several different ways. Campbell et al (116) 
distinguish between generic or global approaches and what they describe as disaggregated 
approaches. A commonly cited global definition of quality is that used by the Institute of 
Medicine; which is ""the degree to which health services for individuals and populations 
increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge, " (106). Disaggregated definitions involve a deconstruction of quality 
into individual dimensions or components, which are more amenable to measurement. The 
most recognised disaggregated definitions of quality have been developed by Maxwell and 
Donabedian. Maxwell defined quality in health care along six dimensions; accessibility, 
effectiveness, efficiency, acceptability, equity and relevance (117; 118). Donabedians 
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definition covers many of the same dimensions; effectiveness, efficiency, efficacy, 
acceptability, equity and legitimacy (119). In a recent evaluation of the impact of quality 
initiatives on care in the National Health Service, Leatherman and Sutherland have defined 
quality along six domains; access; effectiveness and appropriateness, responsiveness, safety, 
equity and system capacity. 
Equitv 
Equity has been defined as the "availability of care and quality of services .... based on 
individuals' particular needs and not on personal characteristics unrelated to the patient's 
conditions .... The quality of care should not differ because of such characteristics as gender, 
race, age, ethnicity, income, education, disability, sexual orientation or location of residence"' 
(91). In defining equity it is useful to distinguish it from the term equality, or the more 
commonly used antonyms inequity and inequality. Health inequality can be defined as 
differences in health status or in the distribution of health determinants between different 
population groups; for example, differences in mortality rates between people from different 
social classes. A health inequity is an inequality in health that is deemed to be unfair, 
unacceptable or stemming from some form of injustice. These terms are often used 
interchangeably, which has led to criticisms that inequalities in health are often assumed to be 
inequitable and should be addressed or in common NHS parlance "'tackled"" (120). The 
distinction between the terms inequity and inequality is less contentious within the context of 
access to health care, as unequal access between different population groups is generally 
considered to be inequitable. 
50 
In practice, equity is most commonly defined as equal access to care for equal need which has 
been described as horizontal equity. However, Dixon et al identify two problems with this 
definition (121). The first relates to the distinction that can be drawn between access and 
utilisation. They argue that achieving equality of access requires that individuals have the 
same opportunity to use the health service whereas achieving equality of utilisation requires 
equal use of health services for equal need. In practice, most researchers have used the latter 
approach. The second problem relates to the fact that the definition of health care need is 
contested. 
Measuring qualifýý in health care 
Disaggregated definitions of quality have been operationalised into large quality indicators 
sets, with each indicator measuring a discrete element of practice. Quality indicators are 
generally divided according to the three main components of health care; structure, process 
and outcomes (119). Structural measures assess the characteristics of health care 
organisations, such as the number of operating theatres and staffing levels. Process measures 
focus on the appropriateness of the interaction between provider and patient in health care 
settings. For example, is blood pressure regularly checked in people with hypertension?; are 
patients with coronary heart disease being prescribed a statin?; are children receiving 
appropriate immunisations? Outcome measures seek to examine the impact of health care on 
health status, through measurement of mortality, morbidity and quality of life but also 
incorporate patient perspectives, including measures of patient satisfaction. However, the use 
of outcome measures in assessing quality in health care systems is problematic for several 
reasons. Firstly, there will be a considerable time lag between unproved health care quality 
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and outcome measures such as reduced complication rates, hospital admissions and 
mortality. Secondly, health outcomes are influenced by factors outside of the scope of health 
care systems, such as poverty. Thirdly, there may be too few events e. g. myocardial 
infarction, stroke, deaths to draw meaningful conclusions about changes in quality within 
small areas. Finally, use of hospital admissions or mortality as outcome measures and relating 
this to information from primary care requires data linkage in many countries, which can 
present logistical and ethical difficulties. Intermediate clinical outcome indicators, such as 
attainment of established treatment targets for blood pressure or cholesterol in diabetes, have 
been more widely used as they will better reflect short term quality improvements (122). 
The importance of distinguishing between quality indicators and quality standards has been 
highlighted by several commentators. Quality indicators have been described as "explicitly 
defined and measurable items which act as building blocks in the assessment of care"(123). 
For example, in diabetes care, an indicator might be the proportion of patients who have had 
fundoscopy in the previous year. A quality standard ""examines the level of compliance with 
a criterion or indicator". Quality standards are defined prospectively and set a level of care 
that practitioners must meet. For example, that 90 % of individuals with diabetes should have 
had fundoscopy in the previous year. 
Quality indicator sets have been developed by national e. g. National Performance 
Assessment Framework in the UK, Agency for Healthcare Research and Quality and National 
Committee for Quality Assurance in the USA and the Australian Council for Safety and 
Quality in Health Care and international bodies such as the Organisation for Economic Co- 
52 
operation and Development (OECD) (124). The nature of performance monitoring systems 
and quality indicator sets differs markedly between countries. This reflects a number of 
factors. For example, quality indicator sets in the USA place less emphasis on intermediate 
clinical outcomes measures than the UK as they are considered to reflect factors outside the 
influence of health care systems. Indeed, the introduction of quality and outcomes 
framework in the UK has led to some debate about the inclusion of outcome measures and 
their relative weighting against process of care measures (125). Differences in performance 
monitoring are also driven by what data is routinely collected within health care systems and 
their ability, through the penetration of electronic health records, to obtain and report 
performance data in a timely fashion. However, there have been recent attempts to develop 
standardised international quality measures, i. e. OECD, which will encourage further cross- 
national research in this area. Despite widespread acknowledgement that equity is a key 
component of quality, most performance monitoring systems and quality indicator sets do 
not include an assessment of equity. 
2.3.2 Quality improvement initiatives in the UK 
The current Labour Goverm-nent has sought to address the considerable under-investment in 
the National Health Service during the 1980s and 1990s over the past decade and has recently 
brought health care spending (as a percentage of Gross Domestic Product) in line with other 
European Union countries. This massive uplift in health care spending has been accompanied 
by the establishment of a major national quality improvement programme. This was 
prompted by high profile quality failings during the mid to late 1990s, such as the paediatric 
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heart surgery scandal at the Bristol Royal Infirmary, and growing evidence of unacceptable 
variations in care, including differential access to pharmaceutical treatments between 
geographical areas or 'postcode prescribing". The importance of reducing variations in health 
care quality in addressing wider inequalities in health outcomes has been explicitly 
recognised within government policy. Numerous initiatives to improve health care quality in 
the UK over the past decade have been described collectively as 'clinical governance'. Clinical 
governance has been defined as "'a framework through which NHS organisations are 
accountable for continually improving the quality of their services, safeguarding high 
standards by creating an environment in which excellence in clinical care will flourish"'. In 
1998, the UK government sought to operationalise clinical governance into three main 
elements: (i) arrangements for setting clear national quality standards, through National 
Service Frameworks and the National Institute for Clinical Excellence (ii) mechanisms for 
ensuring local delivery of high-quality clinical services, through clinical governance 
reinforced by a new statutory duty of quality and supported by programmes of lifelong 
learning and local delivery of professional self-regulation; and (iii) effective systems for 
monitoring delivery of quality standards, in the form of a new statutory Commission for 
Health Improvement (now the Healthcare Commission) and an NHS Performance 
Assessment Framework, together with the first national survey of patient and user 
experience. Key elements of this national programme of quality improvement were recently 
set out by Campbell et al. and are described below (126). 
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9 National standards for the treatment of major chronic diseases, such as the 
National Service Frameworks for coronary heart disease (1999) and diabetes 
(2002) 
* Contractual requirement for practitioners to undertake clinical audit (initially a 
requirement in the 1990 contract) 
" Financial incentives for cervical cytology testing and immunisation (early 1990s) 
" Widespread use of audit and feedback by Primary Care Trusts 
" Release of comparative data for quality of care to practitioners (common) and the 
public (rare) by Primary Care Trusts 
e Annual appraisal of all primary care physicians (by the Primary Care Trusts 
including some discussion of the audit data) 
* National system of inspection and monitoring of performance (by the Healthcare 
Commission) 
As part of this investment, much effort has been made to improve the quality of primary care 
services for people with common, chronic conditions, such as coronary heart disease and 
diabetes. The main drivers for these initiatives has been the belief that services provided in 
primary care are more accessible to patients; more cost-effective than care provided in 
hospitals; and that higher quality and utilisation of primary care services will reduce the 
complication rates, demand for hospital services and thus overall healthcare spending 
(127; 128). 
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2.3.3 Quality improvement initiatives for diabetes (1997-2004) 
improving the quality of care for people with diabetes has been a longstanding policy 
concern in the UK. For example, the then Conservative government endorsed the 1989 St 
Vincent Declaration which set out key targets to improve the quality of care for people with 
diabetes throughout Europe. The publication of a Health Service Circular on diabetes in 1997 
(Key Features of a Good Diabetes Service) highlighted the importance of primary care in the 
management of diabetes and encouraged health authorities to benchmark local services 
against established standards of care (129). However, such benchmarking was not mandatory 
and the guidance was not supported with dedicated funding to address inadequacies in 
service provision where they existed. 
In 2000, a comprehensive Audit Commission report found that the quality of diabetes care in 
England and Wales remained highly variable (130). The report made numerous 
recommendations which include; better patient education and improved support for self- 
management, more systematic, structured care in both primary and secondary care settings; 
better strategic planning and monitoring of diabetes services at Health Authority (Primary 
Care Trust) level. The report highlighted the importance of clinical information systems 
providing up-to-date information on patients, surveillance and tests undertaken, and clinical 
outcomes. In addition, the report recommended that such systems should also have an 
automatic call/recall facility to prompt attendance at annual reviews. The report made a 
number of recommendations about the provision of diabetes services for ethnic minorities, 
including the importance of monitoring outcomes by ethnic group. A survey conducted as 
part of this review found that primary care staff provided routine care for about 75 per cent of 
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their patients with diabetes, further underlining the growing importance of primary care in 
diabetes management. This report was timely as it was produced before the publication of the 
National Service Framework for Diabetes, which acted on many of the recommendations 
made by the Audit Commission. 
Diabetes National Service Framework (NSF) 
The Diabetes NSF was published in 2001 with the stated aim of "maximising the quality of life 
of all people with diabetes and to reducing their risk of developing the long-term 
complications of diabetes' (131). Standard Four of the Diabetes NSF states that'all adults with 
diabetes will receive high-quality care throughout their lifetime, including support to 
optimise the control of their blood glucose, blood pressure and other risk factors for 
developing the complications of diabetes. Key interventions necessary to attain Standard 
Four are described in the box below. In addition twelve care standards in the NSF, two 
targets were set for the establishment of a national retinopathy screening programme and 
improvement of practice based disease registers in primary care. 
Diabetes NSF targets 
1. By 2006, a minimum of 80% of people with diabetes to be offered screening for the early 
detection (and treatment if needed) of diabetic retinopathy as part of a systematic 
programme that meets national standards, rising to 100% coverage of those at risk of 
retinopathy by end 2007 
2. In primary care, update practice-based registers so that patients with CHD and diabetes 
continue to receive appropriate advice and treatment in line with NSF standards and by 
March 2006, ensure practice-based registers and systematic treatment regimes, including 
appropriate advice on diet, physical activity and smoking, also cover the majority of 
patients at high risk of CHD, particularly those with hypertension, diabetes and a body 
mass index (BMI) greater than 30. 
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Key interventions to improve outcomes in diabetes 
* Improving blood glucose control reduces the risk of developing the microvascular 
complications of diabetes in people with both Type 1 and Type 2 diabetes. (Level 1) 
9 Improving blood glucose control may reduce the risk of people with diabetes 
developing cardiovascular disease. (Level 1) 
9 Controlling raised blood pressure in people with diabetes who have co-existing 
hypertension reduces their risk of developing both microvascular complications and 
cardiovascular disease. (Level 1) 
* Reducing cholesterol levels in people with diabetes who have raised cholesterol 
levels may reduce their risk of cardiovascular disease. (Level 2) 
e Smoking cessation in people with diabetes who smoke reduces their risk of both 
cardiovascular disease and microvascular complications. (Level 2) 
e Regular recall and review of people with diabetes can improve the quality of 
diabetes care and subsequent outcomes for people with diabetes. (Level 1) 
National Institute for Clinical Excellence guidance 
V- 
The role of the National Institute for Clinical Excellence (NICE) is promote clinical and cost- 
K 
effectiveness by producing clinical guidelines and audits, for dissemination throughout the 
NHS. Clinical guidelines are an important driver for standardising the quality of care in 
routine settings. NICE produced four sets of national guidance for Type 2 diabetes in 2002 
on: - 1. management of blood glucose; 
2. management of blood pressure and lipids; 3. 
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retinopathy; 4. renal disease. In 2004, it produced national guidance on foot care in diabetes. 
These sets of guidance are currently being updated and are due to be published in April 2008. 
The Scottish Intercollegiate Guidelines Network (SIGN) produced national guideline for 
diabetes in 2001. 
2.3.4 Impact of UK quality initiatives on diabetes care 
Findings from a small number of population-based longitudinal studies indicate that the 
major investment in quality initiatives in the UK has been associated with improvements in 
diabetes care. For example, Campbell et al examined trends in diabetes management in 42 
volunteer general practices in six geographdcal areas in England between 1998 and 2003 (132). 
They reported that the percentage of people with diabetes meeting a BP target of 140/85 mm 
Hg increased from 21.8 % to 35.8 % (an annual improvement of 2.3 %) over this period. 
Statistically significant improvements were found in 7/22 indicators used for diabetes (1998- 
2003). However, the small sample size in this study (504 patients with diabetes) meant that 
there may not have been adequate power to detect real changes across a number of the 
indicators used or to adequately assess predictors of quality care. In a separate study of 74 
general practices in England and Wales, de Lusignan et al found that the percentage of people 
with diabetes with a BP < 140/ 80 mm Hg increased from 13.6 % in 1994 to 21.8 % in 2001, an 
annual improvement of 1.2% per year (133). 
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2.3.5 Inequalities in diabetes care 
Despite overall improvements in diabetes care, variations in quality appear to have persisted. 
For example, quality indicators for diabetes have been shown to be less likely to be achieved 
in some parts of the country and within certain sectors of the population, including areas 
with high levels of deprivation and a diverse ethnic n-dx (134). McElduff and colleagues 
identified persistently higher HbAlc levels amongst south Asians compared to Europeans 
attending primary and secondary care settings in Blackburn, north-west England, from 1995- 
2001 (135). Whilst south Asians tended to have better blood pressure and cholesterol control 
than whites in 1995, these differences had been attenuated by the end of the study period. 
There were no significant differences in the measurement of process of care indictors between 
ethnic groups throughout the study period. Gender differences have also been identified, 
with women less likely to have quality indicators recorded and less likely to see their general 
practitioner for their diabetes than men (136). This is even though GP consultation rates are 
generally higher among women than men. Age inequalities in care have been identified in 
diabetes and the secondary prevention of CHD (137; 138). For example, in an analysis of the 
quality of diabetes care in 34 Wandsworth practices during 2003,1 identified a worse 
cholesterol and glycaemia profile in younger patients (18-44 years) (139). Conversely, older 
patients (75+ years) were less likely to achieve the treatment target for blood pressure control. 
Previous UK studies examining inequalities in diabetes care are cross-sectional, have often 
not been population based, had relatively small samples, used proxy measures for key 
variables such as ethnicity or only included people of European or south Asian origin. 
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There has been far less UK research on the quality of diabetes care and outcomes in black 
Africans and Caribbeans. Existing UK and US studies suggest poorer control of blood 
pressure amongst black groups with and without diabetes (140; 141). 
2.4 Key points from Chapter 2 
1. Inequalities in the delivery of diabetes care exist, with certain groups, including effmic 
minorities, less likely to receive high quality diabetes care than the general population 
2. These variations in care have persisted despite a major investment by the UK 
government over the past decade aimed at improving health care quality and 
reducing health inequalities 
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3.0 Pay for performance programmes 
in an effort to hasten improvements in health care quality and increase efficiency in 
healthcare systems, policymakers and purchasers of healthcare have increasingly aligned 
financial incentives to quality of care. The use of pay for performance schemes reward health 
care providers by paying them more if they succeed in meeting performance targets set by the 
government and other purchasers of healthcare. Pay for performance programmes are now 
an established part of the healthcare policy in the USA and UK but are under development in 
a number of other countries, including Germany, the Netherlands, New Zealand, Australia 
and Canada (142; 143). 
3.1 United States of America 
The influential Institute of Medicine (IOM) has argued that the effectiveness of efforts to 
improve the quality of health care in the USA has been limited by way in which health care is 
currently financed. Indeed, its recent report, Rewarding Provider Performance, states that the 
structure of the health care payment system in the USA does, at best, not encourage high 
quality care and, at worst, may actually produce disincentives for quality for certain clinical 
conditions (144). This is because fee-for-service payments, which can encourage clinically 
inappropriate care, remain the dominant approach to health care financing in the USA. For 
example, fee-for-service payments cover 88% of health care delivered to Medicare 
beneficiaries. The IOM report recommended a phased introduction of pay for performance 
incentives into Medicare programmes to address this. 
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Whilst pay for performance is a relatively new approach to improving health care quality in 
the US Medicare system, it has been widely implemented in both Medicaid (which provides 
healthcare for the poor and for people with disabilities) and in privately funded healthcare 
programmes. A survey conducted during 2006 found that some 26 US states had introduced 
pay for performance schemes into their Medicaid programmes with an additional 12 
planning to do so before 2008 (145). A study by Rosenthal et al conducted in 2006 found that 
more than half the health maintenance organizations (HMOs) in the private sector had pay for 
performance programmes and that these covered more than 80 % of the country's HMO 
enrolees (146). 
The nature of pay for performance programmes in the US differ markedly between states, 
between public and privately funded healthcare and between health plans. Differences are 
evident in the type of incentives being offered (bonuses, penalties, auto-assign-ment, public 
reporting), the type of achievement being rewarded (absolute or relative improvement) the 
performance measures used, the recipient of incentives (primary or secondary care, provider 
organisations or individual physicians) and their overall financial cost. At the same time, 
many commonalties exist and many "'second generation" programmes have incorporated 
performance measures for chronic disease management in their provider contracts in recent 
years. 
3.2 United Kingdom 
3.2.1 Use of financial incentives in primary health care 
Three main financial incentives have been applied in UK primary care since the inception of 
the NHS in 1948: linking GP pay to list size, efficiency gains and, most recently, the quality of 
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care provided. During most of the past sixty years, the majority of GP income was linked to 
the number of patients that have registered with their practice (their 'list size) through a 
capitation based funding system. It was assumed that'good' GPs would attract more 
patients, and hence receive more income. 
The 1990s saw the introduction of 'fundholding, in which around half of GP practices 
assumed responsibility for budgets covering prescribing and secondary care, with efficiency 
rewards for practices achieving an underspend on their budget. Financial incentives to 
improve health care quality first appeared in the 1990 GP contract when the achievement of 
cervical smear and vaccination targets attracted additional, albeit modest, payments. 
However, it was not until the introduction of the Quality and Outcomes Framework, as part 
of the 2004 General Practitioner contract, that quality achieved centre stage in the way 
primary care services were funded. The Quality and Outcomes Framework has been 
described by one US commentator as the boldest shift towards pay for performance seen 
anywhere in the world (147). 
3.2.2 The Quality and Outcomes Framework 
The new GP contract set outs that approximately one quarter of general practice income will 
be derived through the achievement of quality targets set out in the Quality and Outcomes 
Framework (QOF). This unique quality improvement initiative has been supported by; C1.8 
billion additional investment in primary care. In April 2004, QOF consisted of 146 
performance indicators (with one additional indicator for 'access'), grouped into five 
domains. 
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The components of the Quality and Outcomes Framework, 2004-6. 
Domain Number of Description of indicators 
indicators 
Chronic disease 76 Management of ten chronic diseases: 
management Coronary heart disease, stroke or transient ischaemic 
attacks, hypertension, diabetes mellitus, chronic 
obstructive pulmonary disease, epilepsy, 
hypothyroidism, cancer, mental health, asthma 
Practice 56 Records and information about patients, patient 
organisation communication, education and training, practice 
management and medicines management 
Patient experience 4 Length of consultation and patient surveys 
Additional 10 Cervical screening, child health surveillance, maternity 
services services and contraceptive services 
Access 1 Access to GPs and other health professionals 
Indicators cover the maintenance of a disease register, recording of risk factors, delivery of 
evidence-based treatments and achievement of established targets for intermediate outcomes, 
such as blood pressure control. Each indicator is assigned a certain number of points, which 
have been weighted according to perceived workload and importance (148). In 2004-05, a 
total of 76 indicators and 550 of the 1050 points relate to the management of 10 chronic 
diseases with each point worth E75 to an average practice. The lower threshold for payment 
was 25 % with an upper threshold of 90 % for most process measures and 50-70 % for most 
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intermediate outcome measures. Clinical points are weighted by the prevalence of each 
condition within practices, which encourages primary care teams to maintain accurate disease 
registers. A practice with a high prevalence of, say, diabetes, will attract a higher financial 
reward than practices with a lower prevalence. However, to attract double the funding, a 
practice would need to have four times the national prevalence of diabetes (the 'square root 
formula"). This "square root' policy limits the impact of prevalence on payments to practices 
and has been criticised because it means that the payments to practices may not fully reflect 
the workload for achieving targets in practices with high disease prevalence. 
The UK Department of Health had based their financial forecasts on the assumption that the 
average practice would score 750 points. By the end of the first year of the contract., it had 
become clear that GP performance had substantially exceeded expectations. Whilst partaking 
in QOF is voluntary, virtually all GP practices in England and other parts of the UK 
participated in this initiative. The mean score of general practices in England in 2004/5 was 
958.7 (91.3 % of the available points) (The Information Centre, 2007). In all, 222 out of 8576 
practices (2.2%) achieved the highest possible score of 1050 points. 
In the following year (2005/6), performance was Wgher still: the mean score was 1010.5 
(96.2% of the available points) and 813 out of 8409 (9.7%) of practices achieved the highest 
score (The Information Centre, 2007). 
In year three of QOF (2006/7), the indicators were revised (Box 2). Revisions were undertaken 
by an expert panel and new indicators were considered if there was a substantial evidence 
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base for their inclusion and if their achievement was feasible within primary care. The Access 
domain was removed from QOF, although similar achievements would still be rewarded 
through alternative means. As a result, the maximum QOF score was reduced to 1000 points. 
The original domains remained unchanged but nine new chronic diseases were added, with 
the clinical indicators now accounting for 655 QOF points. 
Changes introduced to the Quality and Outcomes Framework in 2006 
Domain Number of 
indicators 
Description of new indicators 
Chronic disease 80 Nineteen chronic diseases: the original ten chronic 
management diseases plus heart failure, palliative care, dementia, 
depression, chronic kidney disease, atrial fibrillation, 
obesity, learning disabilities and smoking. 
Not only were new diseases added to the list in 2006/ 07, but achievement of all minimum 
and some maximum payment thresholds have been raised. Hence, practices had to achieve a 
higher target to start scoring QOF points for many of the clinical indicators. The value of each 
point was increased to E125. The total number of indicators was reduced from 147 to 135, 
mainly by removing or merging previous versions of non-clinical indicators. 
Data on practice achievement in England, relating to the revised QOF indicators in 2006/ 
7, 
were released in September 2007. These showed that, with tougher targets, the mean practice 
score declined somewhat to 954.5 (95.15% of the available points); the maximum score was 
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achieved by 427 out of 8372 (5 .1 %) practices. A breakdown of the total scores reveals that the 
clinical domains with the lowest achievement were: depression, palliative care, mental health 
and epilepsy (The Information Centre, 2007). 
Targets for indicators within pay for performance schemes can either be relative or absolute. 
Relative targets reward practitioners for the extent to which their care has improved over 
baseline achievement. Absolute targets reward practitioners for achieving a set target, 
irrespective of baseline achievement. Each approach has strengths and weaknesses and both 
may impact upon existing variations in care between practices. Rewarding absolute 
achievement may discourage highly performing practices, who have already achieved 
performance targets, from improving further. At the same time, lower performing practices 
may not respond to targets if they are set too high and considered "'out of reach". Rewarding 
relative improvements may be administratively more burdensome and requires careful 
judgement about what constitutes comparable levels of improvement in high and low 
performing practices; i. e. the higher the baseline achievement, the more difficult 
improvement becomes. QOF rewards absolute achievement but does so in a way which aims 
to encourage improvement in low and average performing practices in two ways. Firstly, by 
setting a minimum and maximum threshold for which payment is released. And secondly, by 
setting two targets for difficult to meet treatment targets e. g. HbAlc < 7.5%, HbAlc < 10%. 
Diabetes 
In April 2004, diabetes accounted for 99 points available in the Clinical Domain of QOF (See 
Box 3). Half of these points are allocated to the achievement of treatment targets (Blood 
68 
pressure < 145/85 mm Hg [17 points], HbAlc < 7.4% [16 points], HbAlc < 10% [11 points], 
Cholesterol <5 mmol/L [6 points]) and the reminder to the recording of fourteen process 
measures of care, including ascertainment of smoking status [3 points], annual measurement 
of BMI [3 points] and retinopathy screening [5 points]. After revision of the contract in 2006, 
diabetes now accounts for 93 points in the clinical domain. This is largely due to the removal 
of smoking indicators from individual disease areas and the formation of a separate smoking 
cessation section within QQF. The evidence base supporting the selection and weighting of 
QOF indicators for diabetes has been published by the government (149). 
Quality and Outcomes Framework Indicators for Diabetes Care (April 2004) 
DM 2. The percentage of patients with diabetes whose notes record BMI in the previous 15 
months 
DM 3. The percentage of patients with diabetes in whom there is a record of smoking status in 
the previous 15 months except those who have never smoked where 
smoking status should be recorded once 
DM 4. The percentage of patients with diabetes who smoke and whose notes contain a record 
that smoking cessation advice has been offered in the last 15 months 
DM 5. The percentage of diabetic patients who have a record of HbAlc or equivalent in the 
previous 15 months 
DM 6. The percentage of patients with diabetes in whom the last HbAlC is 7.4 or less (or 
equivalent test / reference range depending on local laboratory) in last 15 months 
DM 7. The percentage of patients with diabetes in whom the last HbAlC is 10 or less (or 
equivalent test / reference range depending on local laboratory) in last 15 months 
DM 8. The percentage of patients with diabetes who have a record of retinal screening in the 
previous 15 months 
DM 9. The percentage of patients with diabetes with a record of presence or absence of 
peripheral pulses in the previous 15 months 
DM 10. The percentage of patients with diabetes with a record of neuropathy testing in the 
previous 15 months 
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DM 11. The percentage of patients with diabetes who have a record of the blood pressure in the 
past 15 months 
DM 12. The percentage of patients with diabetes in whom the last blood pressure is 145/85 or 
less 
DM 13. The percentage of patients with diabetes who have a record of micro-albuminuria testing 
in the previous 15 months (exception reporting for patients with proteinuria) 
DM 14. The percentage of patients with diabetes who have a record of serum creatinine testing 
in the previous 15 months 
DM 15. The percentage of patients with diabetes with proteinuria or micro-albuminuria who are 
treated with ACE inhibitors (or A2 antagonists) 
DM 16. The percentage of patients with diabetes who have a record of total cholesterol in the 
previous 15 months 
DM 17. The percentage of patients with diabetes whose last measured total cholesterol within 
previous 15 months is 5 or less 
DM 18. The percentage of patients with diabetes who have had influenza immunisation in the 
preceding 1 September to 31 March period 
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3.3 Impact of pay for performance on quality of health care 
Despite the widespread application of Pay for Performance in the USA and more recently the 
UK, there is little research examining the impact of these programmes on healthcare quality. 
A recent systematic review conducted by Petersen et al identified only seventeen studies 
studies which have examined the relationship between explicit financial incentives designed 
to improve health care quality which have used quantitative measures (150). In this review, 
the impact of pay for performance programmes were described as either positive, partial of 
negative. Positive studies were those for which all measures of quality demonstrated a 
statistically significant improvement with the financial incentive. Studies with partial effects 
showed improved performance on some measures of quality but not others. Negative studies 
were those for which all measures of quality demonstrated a statistically significant decrease 
in quality with the financial incentive. The final category was for studies demonstrating no 
effect 
Most studies (n=13) examined changes in process-of-care measures and mainly for preventive 
care services. Only five studies examined the impacts of pay for performance on quality of 
chronic disease management and effects seen were assessed as partial rather than positive. 
Five of six studies of physician-level financial incentives and seven of the nine studies of 
provider group-level financial incentives found partial or positive effects of financial 
incentives m measures of quality. Four studies identified unintended effects of incentives, 
including increased patient selection, also known as "cream skimming", and gaming. The 
authors stated that they were unable to draw conclusions about the cost-effectiveness of pay 
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for performance programmes as this was examined in only one study. The conclusion drawn 
by this study mirror those of three other reviews which have identified that there is a lack of 
empirical studies evaluating the impacts of pay for performance programmes (144; 151; 152). 
For example, the review conducted by the Institute of Medicine concluded that a "'robust 
literature demonstrating that pay for performance strategies lead to improved health 
outcomes did not exist". The report recommended that pay for performance programmes 
should be assessed for potential unintended consequences, including reduced access to care, 
increased disparities in care, impeded knowledge transfer and innovation, demoralised 
workforce, forestalled reform efforts and shifted costs. A review conducted by Rosenthal and 
Frank, using a tighter inclusion criteria than employed by Petersen, identified only seven 
studies evaluating the impact of pay for performance. Only two studies were found to have 
positive findings linked to pay-for-performance. Moreover, most of the gain in performance 
in one of these studies was achieved through better documentation of immunizations 
provided outside the physician's practice rather than improvements in actual immunization 
rates. 
The lack of US based research in this area may be due to a number of factors, including 
limited research funding within state health budgets, absence of a suitable control group, 
simultaneous introduction of other quality initiatives and insufficient 
data due to low 
penetrance of electronic health records. 
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3.4 Impact of the Quality and Outcomes Framework on quality of care 
Research into the impact of the introduction of pay for performance in UK primary care, 
through the Quality and Outcomes Framework (QOF), is also limited at present although the 
number of studies is growing. These can be divided into studies that have used: - 1) national 
QOF data derived from the Quality Management and Analysis System (QMAS) and 2) 
primary care datasets containing patient level information. 
3.4.1 Studies using national QMAS data 
Numerous ecological studies have been conducted which examine associations between 
quality of care and various patient, provider and organizational factors using national QOF 
data. These factors include summaries of NHS funding variables for the practice (exploring 
total practice funding receipts), practice based variables (practice characteristics such as list 
size per GP, number of GPs in the practice, postgraduate training practice status), prescribing 
variables (summaries of practice prescribing, particularly for the chronic diseases featuring in 
QOF) and national census based variables (providing sociodemographic information, 
particularly ethnicity and social deprivation). For example, Doran et al examined whether the 
socioeconomic, demographic, and health characteristics of practice populations and 
characteristics of the practices themselves affect the quality of clinical care provided in the 
first year of the contract (153). They found that achievement was lower in practices with a 
high proportion of patients who were living in single-parent or low-income 
households or 
were 65 years of age or older. Achievement was also lower in larger practices and 
in practices 
with a high proportion of family practitioners who received their medical education outside 
the United Kingdom or were 50 years of age or older. Achievement was higher in practices 
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with a high ratio of family practitioners to patients and lower in practices that were on the 
Primary Medical Services contract. However, the explanatory value of these variables was 
modest as only 20 percent of the variation between practices was accounted for in regression 
models. The study found that the factor with the greatest influence on QOF performance was 
exception reporting, with an increase of 1 percent in the estimated proportion of patients 
excluded being associated with an increase of 0.31 percent in reported achievement. Using a 
similar methodology, Ashworth et al. examined the relationship between social deprivation 
and quality of primary care in all English practices using national contract data in the first 
two years of the new contract (154). They found that the difference in the mean total QOF 
score between practices in the least and most deprived quintiles was small (64.5 points or 
6.1 % of the total points available) in 2004/ 05 and this difference was reduced further in 2005- 
06 (30.4 points or 2.9% of the total points available). This study confirms previous findings of 
McLean et al. (148) who identified small absolute differences for most process measures, such 
as recording of smoking status or blood pressure, between practices working in deprived and 
affluent parts of Scotland. However, the authors did find that inequalities were more marked 
when they compared achievement of selected intermediate outcome measures, such as 
glycaemic control in diabetes and influenza immunisation. An earlier Scottish study by the 
same author found that population characteristics, including levels of material deprivation, 
showed little association with the quality of primary medical care provided in the 
first year of 
the contract (155). A larger proportion (53 %) of the variation in quality scores 
between 
practices was explained by their multivariate model than in the Doran et al study, with the 
size and composition of the clinical team being the most important 
determinant. Similarly, a 
study of quality indicators for diabetes in 49 GP practices in Brighton and 
Hove found no 
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significant correlation between achievement for any of the 17 individual quality indicators 
and deprivation (156). This study did identify an association between levels of 'exception 
reporting' and deprivation. However, the direction of the relationship was not consistent 
across quality indicators e. g. patients in more affluent areas were more likely to be exception 
reported for outcome indicators (HbAlc < 7.4%, cholesterol <5 mmol/L) than those in 
deprived areas. In a study of patients with coronary heart disease registered with 38 practices 
in Rotherham, no significant correlation was found between deprivation and quality-of-care 
on ten of the eleven QOF indicators (157). Ashworth et al. examined statin prescribing in 
England during the first year of the contract. They found that general practices serving more 
deprived populations had significantly higher levels of statin prescribing than those in 
affluent areas, ' even after adjustment for other factors such as the increased prevalence of 
cardiovascular disease and diabetes in deprived areas (158). 1 examined associations between 
practice list size, deprivation and the quality of care of patients with diabetes using national 
QOF data from the first year of the contract (159). My findings suggest that practices located 
in deprived areas performed less well on quality measures than those based in affluent areas. 
Differences in achievement between small practices in deprived areas and large practices in 
affluent areas were considerable on some indicators. For example, the percentage of patients 
with a record of neuropathy testing differed by 15 %. The general trend of higher achievement 
with increasing practice size was less marked in affluent areas. For example, smaller practices 
were more likely to achieve the lower treatment targetfor HbAlc (<-7.4%) than larger practices 
in affluent areas. 
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Strengths and limitations of QMAS data 
The new contract represents a major innovation in the organization of primary care services 
and the first time that pay for performance has been used on this scale in any health care 
system. Performance data generated through the contract therefore provides comparative 
information on the quality of care in general practices nationally and unique data to measure 
the quality of primary care experienced by the entire national population. This is because 
coverage of the Quality and Outcomes Framework was extensive, with 98% all primary care 
practices covered nationally. The structure of primary care in England offers some unique 
opportunities to examine this association. Unlike in many other countries, almost the entire 
population (over 50 million people) is registered with a family practitioner, who is 
responsible for providing primary care services and arranging referrals for specialist care. In 
addition, individuals are only able to register with one family practice at a given time. This 
means that primary care has well-defined denominator populations, which in turn allows the 
calculation of accurate disease prevalence and treatment rates. 
As QOF was designed as a pay-for-performance system, rather than as a research tool, it 
perhaps not surprising that the data it generates has several limitations. First, the data is 
aggregated to practice level, lacking crucial patient level information about the age, sex and 
ethnicity of patients, and thus only permits ecological analyses. The scope for assessing the 
impact of this pay for performance initiative on known inequities in health care delivery is 
therefore very limited. Second, QOF data contains no continuous measures for quality 
indicators (for example, cholesterol measures are only available as the proportion of patients 
achieving the target level of 5 mmol/L rather than as a mean level; nor is variance data 
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available for each practice). Third, the system of "exception reporting, whereby certain 
patients are excluded from clinical targets for specified reasons, is open to gaming. Thus, true 
population achievement may therefore be considerably lower and variation in quality 
between practices may be much greater than the published national figures suggest. The 
proportions of excluded patients for key diabetes indicators in 2004/05 have been reported as 
follows: HbAlc:!! ý 7.4% median 9.4% (interquartile range 6.3-14.5%); blood pressure!! ý 145/85 
mmHg, 6.3% (4.0-9.4%); cholesterol:! ý- 5.0 mmol/l, 9.0% (6.3-12.7%). Fourth, the validity of 
other indicators has also been challenged, in particular the declared crude prevalence rates 
which depend entirely on detection and reporting by the practice with no independent 
assessment of community prevalence contributing to the values reported. Recording bias may 
therefore have distorted prevalence figures. Fifth, national QOF data is only available for the 
period after the general practitioner contract was introduced in April 2004, which makes it 
difficult to disentangle the impact of QOF from other quality initiatives. Substantial quality 
improvements occurred in the years immediately predating the introduction of QOF, and 
some of the improvement occurring since April 2004 is likely to be due to other, non-financial 
quality initiatives (126; 132). This limitation was partly overcome in a systematic review of 
published observational studies of quality of diabetes care in the UK that I was involved in 
(160). Our study compared achievement in published studies to that reported using national 
QOF data. Abstracts of 742 papers were identified, of which six papers fulfilled the final 
selection criteria. The total number of people included in the six published studies was 83 098 
(a range of 504 to 54 180 people) compared with the UK QOF data of 1.8 million people with 
diabetes. The quality indicators for assessment of care varied between different published 
studies, making comparisons more difficult. Overall, there was a trend towards improvement 
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in both process and outcome of care in the published studies. The quality of care achieved as 
a result of QOF was greater than that found in published studies suggesting that modest 
financial incentives in primary care are a successful method of improving care for people 
with diabetes. 
A final, and perhaps most important, limitation of QOF relates to the debate it has generated 
within the profession about how best to define and measure quality. Although individual 
QOF indicators were carefully selected with an evidence base to support their inclusion (161), 
large areas of primary care workload do not feature in QOF. What components of quality 
definitions does QOF cover? i. e. only clinical effectiveness, just one aspect of quality. The role 
of the GP as advocate, the quality of patient-doctor relationships, continuity of care, the skills 
of early diagnosis and palliative care are all omitted. Omission appears to be less a political 
decision and more a reflection of the lack of valid indicators in these areas and the difficulty 
in measuring quality for these dimensions of primary care. 
3.4.2 Studies using primary care datasets with patient level information 
A small'number of studies have examined trends in the quality of chronic disease 
management before and after the introduction of QOF using patient level data. Tahrani et al 
examined quality of diabetes care using GMS indicators before and after the implementation 
of the GP contract in 66 practices in Shropshire (162). They found statistically significant 
improvements on process and intermediate clinical outcomes between April 2004 and March 
2006, including improved control of blood pressure (< 145/85mm Hg; 47% to 65%), HbAlc (ý 
7.4 %; 41 % to 62 %) and total cholesterol (.: ý 5 mmol/ L; 47 % to 71 %). A retrospective 
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observational study of 1156 patients registered with 18 practices in Norfolk found significant 
improvements in quality of care after the implementation of the contract for conditions 
incentivised under QOF (asthma and hypertension) but no significant improvements for non- 
incentivised conditions (depression and osteoarthritis) (163). The study also found that non- 
incentivised quality indicators improved where they were related to incentivised conditions. 
However, the response rate for the study was low in patients with asthma (63 %) and 
depression (53 %), which increases the possibility of response bias. In addition, the use of a 
single measurement point before April 2004 in both of these studies precludes an assessment 
of whether these gains were part of an underlying trend of improvement. Other studies, 
which have used a greater number of measurement points, are better placed to assess 
whether QOF was associated with a "'step-change, " in quality. For example, Campbell et al 
examined the impact of QOF on quality of care in patients with coronary heart disease, 
diabetes and asthma in a representative sample of primary care practices in England over 
three time points (1998,2003,2005)(126). The study compared scores for observed quality in 
2005 with the scores predicted on the basis of the trend between 1998 and 2003 and found a 
significantly increased rate of improvement for asthma (P<0.001) and diabetes (P=0.002) 
between 2003 and 2005. Scores for coronary heart disease also increased, but the change in the 
rate of improvement was not significant (P=0.07). The authors suggest that the latter finding 
may be due to the fact that coronary heart disease has been a priority area for quality 
improvement for a number of years, thus leaving less scope for quality improvement. These 
findings concur with those of Gulliford et al who examined trends in the quality of diabetes 
care in 26 south London practices using extracted data from 2000 to 2003 and comparing this 
to 2005 national QOF data for those practices (164). They found that the median practice- 
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specific proportion of patients achieving HbAlc:! ý 7.4% each year increased: 2000,22%; 2001, 
32%; 2002,37%; 2003,38 % and 2005,57%. However, national QOF data used in 2005 are 
subject to exclusions and so may not be directly comparable to achievement in the preceding 
years 
3.5 Pay for performance programmes and ethnic group inequalities 
Pay for performance programmes aim to improve the quality of health care for all patients so 
11.1-t that it meets established standards, and therefore they provide an important opportunity to 
address disparities in chronic disease management between ethnic groups. The potential of 
the Quality and Outcomes framework to reduce inequalities in chronic disease management 
has been recognised by clinicians, policymakers and researchers (165; 166). Key to this is the 
considerable emphasis placed within QOF on improving the accuracy of chronic disease 
registers, which will in turn facilitate the provision of systematic, structured care, including 
regular surveillance and monitoring of risk factors in all patients. 
At the same time, concerns have also been raised, particularly in the US, about potential 
unintended consequences of pay for performance incentives, including their impact of health 
inequalities. Casalino & Elster have highlighted a number of ways in which pay for 
performance schemes in the United States could worsen health disparities, including through 
a reduction in the income of physicians treating underserved populations, through physicians 
avoiding patients perceived to lower quality scores and lower use of public quality reports in 
disadvantaged groups due to lower health literacy (167). Several of these concerns may be 
salient within the UK context. For example, concerns have been raised that lower QOF 
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performance, resulting in reduced funding, would perpetuate the inverse care law whereby 
the poorest communities with the highest health needs receive the lowest provision of health 
care. The system of 'exception reporting", whereby certain patients are excluded from clinical 
targets for specified reasons, is open to gaming. Early analysis suggests that levels of 
exception reporting were higher in practices working in deprived areas when compared to 
those working in affluent areas (156). Thus, true variation in quality being delivered to 
patients living in deprived and affluent areas may be much greater than the published 
national figures suggest. Further, it has been suggested the emphasis on disease specific 
quality indicators within QOF may lead to more fragmented care for patients with multiple 
conditions, who are disproportionately from effmic minority and lower socio-economic 
groups (168). 
Whilst the importance of evaluating the impact of pay for performance schemes on 
inequalities in access to health care and health outcomes has been recognised (144; 169), there 
has been very little empirical investigation of possible impacts. This has been demonstrated 
by the findings of a recent review of the literature on the impact of performance incentives 
(defined to include both pay for performance and public reporting programmes) on 
inequalities in care between ethnic groups identified only one study which examined this 
issue (170). This study found that the release of Coronary Artery Bypass Graft (CABG) report 
cards in New York was associated with a widening of the disparity in CABG use between 
white versus black and Hispanic patients (171). T his is reflected in the UK, where very 
few 
studies have examined the impact of QOF on health inequalities using patient level 
data and 
none have examined impacts on known variations in management 
between ethnic groups. 
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This is largely due to poor recording levels of patient based measures of ettu-dcity and of 
socio-economic status within primary care information systems in the UK. 
3.6 Key points from Chapter 3 
1. The use of pay for performance incentives in health care, such as the Quality and 
Outcomes Framework in the UK, is increasing internationally 
2. Such programmes have been introduced to expedite improvements in the quality and 
efficiency of healthcare 
Pay for performance programmes may produce unintended consequences, including 
widening inequalities in access to high quality diabetes care 
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4.0 Aims and objectives 
Summary of literature review findings 
1. Diabetes is an important global public health problem with growing incidence and 
prevalence in most countries 
2. In developed countries, the burden of diabetes is unequally distributed across society. 
In particular, people from ethnic minority groups have a higher prevalence of diabetes 
and a worse morbidity and mortality profile than that in the general population. 
3. Secondary prevention interventions in primary health care settings are both effective 
and cost-effective in improving health outcomes in diabetes. However, these 
interventions are not currently delivered in a systematic way in routine care settings 
4. Inequalities in the delivery of diabetes care exist, with certain groups, including ethnic 
minorities, less likely to receive high quality diabetes care than the general population 
5. These variations in care have persisted despite a major investment by the UK 
government over the past decade aimed at improving health care quality and reducing 
health inequalities 
6. Pay for performance programmes, such as the Quality and Outcomes Framework in 
the UK, have been introduced to expedite improvements in the quality and efficiency 
of healthcare. 
7. Pay for performance programmes may produce unintended consequences, including 
widening inequalities in access to high quality diabetes care. 
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Hypothesis 
The introduction of the Quality and Outcomes Framework will widen inequalities in access to 
high quality diabetes management between ethnic groups. 
Main research question 
What is the impact of the Quality and Outcomes Framework on inequalities in the 
management of diabetes between ethnic groups? 
Aim 
To examine the impact of the Quality and Outcomes Framework on inequalities in the 
management of diabetes between ethnic groups 
Objectives 
1. To establish the extent of inequalities in access to high quality diabetes care between 
ethnic groups prior to the introduction of the Quality and Outcomes Framework 
(Health Survey for England) 
2. To examine the impact of the Quality and Outcomes Framework on inequalities in 
process of care indicators for diabetes between ethnic groups (Wandsworth 
Prospective Diabetes Study) 
3. To examine the impact of the Quality and Outcomes Framework on inequalities in 
access to secondary prevention medications for diabetes between ethnic groups 
(Wandsworth Prospective Diabetes Study) 
84 
4. To examine the impact of the Quality and Outcomes Framework on inequalities in 
intermediate clinical outcomes in diabetes between ethnic groups (Wandsworth 
Prospective Diabetes Study) 
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5.0 Preliminary study 
Before seeking to answer my main research questions using the Wandsworth Prospective 
Diabetes Study, I sought to establish the extent of inequalities in diabetes care between socio- 
economic and ethnic groups in England prior to the introduction of the Quality and 
Outcomes Framework. 
5.1 Socio-economic status, ethnicity and diabetes management: an analysis of 
time trends using the health survey f or England 
Background 
The Health Survey for England is an annual survey of people living in private households 
and a primary mechanism for monitoring population health in England. The survey is 
conducted by the National Centre for Social Surveys and Research and University College 
London on behalf of the Department of Health. The 1998,1999,2003 and 2004 surveys 
examined cardiovascular disease and behavioural risk factors such as drinking, smoking and 
eating habits; within this, the 1999 and 2004 surveys focused on the main ethnic minority 
commuruties m England. 
Study aim 
To examine the impact of quality improvement initiatives (prior to the Quality and Outcomes 
Framework) on inequalities in diabetes management between efluiic and socio-economic 
groups. 
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Methods 
Sampling and data collection 
The sampling methodology for the Health Survey for England is described in detail 
elsewhere. In brief, interviewers obtained household, socioeconomic and personal details, 
information on health and health service use from respondents. A trained nurse took 
anthropometric measurements including height and weight at a follow up visit soon after the 
interview according to survey protocols. Blood pressure, HbAlc and total cholesterol were 
measured in all respondents aged 16 years and over. No HbAlc measurements were 
undertaken in 1998. 
The 1998 and 2003 surveys were conducted with a representative sample of the general 
population whilst the 1999 and 2004 surveys focused on ethnic minority communities, 
involving a three stage sampling process; a general population sample, an "ethnic boost" 
sample involving stratified multistage probability sampling and a follow up survey of 569 
Chinese households who took part in a Health Education Authority survey in 1998. 
Respondents to the 1998,1999,2003 and 2004 surveys aged forty years and above who 
answered yes to the question: "Were you told by a doctor that you had diabetes? " were 
selected for the study. Interviews with adults in the general population sample in 1999 and 
2004 did not include cardiovascular disease module questions. I used white British 
respondents to the 1998 and 2003 surveys with diabetes as a comparison group. 
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Studv variables 
Main outcome measures were control of HbAIc, blood pressure and cholesterol against 
national treatment targets [HbAlc < 7.0%, BP < 140/80 mm Hg, and total cholesterol < 5.0 
mmol/L] and prescribing for diabetes as they applied to our population in each of the four 
years. This was in keeping with the approach within QOF of setting treatment target 
thresholds. Independent study variables included ethnic origin, social class and household 
income. I collapsed ethnic origin into four categories (white British, black, south Asian, white 
Irish) and social class into two categories (manual, non-manual) for the analyses due to small 
numbers. Respondents were grouped into income quartiles, with those in quintile one having 
the lowest incomes and those in quintile four having the highest incomes. 
Data 
For each indicator, I describe percentage achievement of national treatment targets and 
change in achievement within each ethnic, social class and income group standardised by age 
and gender, with 95% confidence intervals. All analyses were weighted to the general 
population in England where indicated. I performed statistical analyses using Stata 9.1 
(Texas, USA: Stata Corporation). 
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Results 
The characteristics of the sample are described in Table 3. There were slightly more men than 
women with diabetes in each year except 2004. The age profile of the 1999 and 2004 surveys 
was younger than the 1998 and 2003 surveys which reflect the younger onset of diabetes in 
ethnic minority groups, particularly in the south Asian group. 
Table 3: Number and characteristics of HSE respondents with diabetes 
1998 1999 2003 2004 
Age 
40-54 
55-69 
70+ 
76 
160 
165 
19.0% 
39.9% 
41.1% 
100 
190 
67 
28.0% 
53.2% 
18.8% 
99 
232 
226 
17.8%12 
41.7%16 
40.6% 
4 
7 
81 
33.3% 
44.9% 
21.8% 
Gender 
Male 
Female 
209 
192 
1 
52.1% 
47.9% 
1 
203 
154 
1 
56.9% 
43.1% 
295 
262 
11 
53.0%18 
47.0%18 
1 
3 
9 
49.2% 
50.8% 
1 
L 401 1 1 357 1 557 11 372 11 
Presc 
Prescribing of oral hypoglycaemic agents (OHAs), insulin, lipid lowering and 
antihypertensive medications all increased significantly between over the study period. For 
example, the percentage of respondents taking lipid lowering drugs increased from 13.0% in 
1998 to 43.4% in 2003. The percentage of patients taking antihypertensive increased from 
38.9% to 50.6% over the same period. 
The extent of these increases differed between ethnic groups (Table 4). Increases in the use of 
lipid lowering and antihypertensive medications were significantly higher and insulin 
significantly lower in the south Asian and Irish groups when compared to the white British. 
South Asian and Black respondents were significantly more likely to be taking OHAs than 
white British respondents in both years (79.5%, 82.5%, 63.6% in 2004). 
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Increases in the use of lipid lowering medications and insulin were significantly higher and 
antihypertensive medications significantly lower in the manual when compared to the non- 
rnanual occupational group (Table 5). Increases in the use of insulin were significantly higher 
and the use of antihypertensive medications and OHAs significantly lower in the lowest 
income group when compared to the highest income group (Table 6). 
90 
rA 
cu 
(N CX? 00 CD 
C? 
r- CN (N 
(n 
I-- 0c) cy) 00 "4- C: ) S c) r- 04 Lo Cj 
c C) C") T- 
N -K- C14 04 (N 
0) o') 
CO LI) - 0) C") 
0) 00 r- 0 t- 0 
ce) C\j C14 
C? LO CY) 
(-9 (ý C9 1-9 
C14 LO r- CN CY) 
CF) (D LO (D 0) LO 
(D 
cr, ('4 
C LO C) '91- 
Wm (D 6 rl- C) (b 
< X- cli 
M: C) 
0 
(. C) Co CU LO LO 00 00 
CD C\J OC) o N (. 0 r- CO r-- r- 
ý . r) , (. C) t-- S.. 0) r-- (Y) Lr) 00 ,T LO LO (D 
co LO Q 
(Y) CF), 00 r- 
ý- 
= (ý C? T 
0 
0, 
III 
LO 00 (C) CD (Y) (D 
0) (14 00 r- (D (C) 
-T- CN 
cq lq- M (n C: C: co CO 0) 
CY) CY) 0) tl- 
o 
N LO 
0) CN r- C14 q Cyý 
CY) 
a) OD (C) 1- 00 LO (Y) (N IT ce) ce) 
0ý Lrý 
LO (6 
d) d) cy) cy) 
CY) CF) fl- (3) CY) 7-- 
(14 cy') CN (Y) CIO 
tm a) C) U') C) (C) (14 
a) CU CD 00 C: ) N 
CY) CY) C") 'IT (Y) 
Qc) t'- C) 4T CIS 
-j C: ) 'T I'- LX) LO cq LO CY) LO "T 
0) , r- `4ý C'ý 
83 I-T, ce) (C) 
V, Cl) 
CD 
-C n 
_cz 
. ý2 :D = (1) -, Ngý -0 
ry 
: t_- -5 co -r- 0 
U) 
(U 
Va -4 
(1) 4-0 
CY) el M rýj 
CL 
Z; 
(1) C: rs 
cjý 
LF 
U cg cý cý 
cý NA CD Lo C-) 
cm 
c (11) (0 (D 
LO n 
U) 
00 ce) (ýJ 
c: > 0c) n CD c", rli 
OD Lo r- (c) 
5 r-- (0 LO 
U. ) m op oý U-) LO LO 
cm 
cl) C, 4 
u) m (6 (0 (. 0 < 
0 
M Cj Co 
le to LO 
(N (0 (C) (0 
21 cý (P oý 
1 
(» ý- C» OD 
LO LO Lf) 
m CD 
o(0 (OC, 11 cö - 
d) Co 4 
> 
c: OD 
ci 
, C) Lr) (» (. 0 CD 
C: ) 
cq LO 't 
r, - CF) 
LO OD 
n 
uý 
oo ci 
Lc) 
F-- Lo CD 
r, - CD 
c2 (n CD le c: 
(10 Co (N CD 
C"J nn 
Z CD CD (D C*') 
C'4 e 't 't 
OD oý ý CD 
0 
Z 
CY) co 
.Q E 
a) 
0 CL 
0 
m- r- (. C) (Y) C5 't - cj - 
-0 
r- (N CY) IS) 
q, (6 r, ý C6 C? r-- ; I- 
(M C 0) 0 LO 0 
:6 LO 
in 
c C") Oo Lo Lo ED 
C) r- cy) 4N 
04 Ný (N N 
00 '1- 01) 'ý3 LI) (7) C'j 0) C6 LO 07) (. 0 r- 
LO 0') (C) CY) 
C6 , 
CN 
C? (y) (9 
LO Lo 
4. A 
0) " (N ý- 00 (D 
C: w C14 . C) (C) 
U) cu C14 cy') 60 
C) 
0 
c") Lo Lo 0) a) 
(C) LO ýT lql 04 (. 0 (D (D (. 0 (D 
c? 00 Cý Cl? 
0) 00 M LO 00 
(C) LO Lo Lo Lo 
LS) CD 
ý-) LO 00 -, 1- m (-0 
C'4 4,4"C? 
0) CY) 00 0 r- CY) 
> r- N 
cn c-0 (3) . (Y) c cu .. 00 (L) CF) o 
cl 
>- ce) 
_r_ C: ) oo cq ('ý Cý I--e CN, (-D QS -tl- W 
co cy) o cy) o Lo 
0. ) (. 0 (D 0. ) co 0 "t co "I- N "4- 
0-) r--ý C? ,: ý Lq 
CC1,04 
C-Y) 
0') rl- 'IT CY) LO 
(D 0 
Nm CY) (14 ce) 
cr (1) 
C rl- (14 LO CY) 
a) cu 00 (14 (N rl- 0 
N CO CY) 04 CY) 
0- 2ýý r-- (D 0') 
C) LO LO 04 
C%4 qT T ;T "T 
co N ý, - o) 9 
(. 0 C14 CY) C14 
T- 
N CY) 
0 
(D 
.S 0) Co 
CY) 
0 
-c-u 
0< 
m 
0 
r-ý 
crý 
Intermediate outcomes 
Significantly more patients met the treatment targets for blood glucose, blood pressure and 
total cholesterol over the study period. The percentage of respondents meeting treatment 
targets for blood glucose, blood pressure and total cholesterol increased by 23.6%, 16.8% and 
8.6% respectively between 1999 and 2004. 
The extent of these increases differed between ethnic groups (Table 7). Improvements in 
cholesterol control were significantly greater in the black and Irish groups and significantly 
lower in the south Asian group when compared to white British. Improvements in blood 
pressure control were significantly greater in the south Asian and Irish groups and 
significantly lower in the black group when compared to white British (18.6 %, 24.8 %, 13.9 
15.7% respectively). 
improvements in blood pressure and cholesterol control were significantly lower in manual 
occupation groups compared to non-manual groups (Table 8). Respondents in the lowest 
income group had a significantly lower improvement in cholesterol control but a significantly 
higher improvement in blood pressure control when compared to those in the highest income 
group (Table 9). 
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Comment 
This study identified significant improvements in intermediate clinical outcomes in 
individuals with diabetes participating in the HSE between 1998 and 2004. Improvements 
were not uniform between ethnic and socio-economic groups, and some trends may 
contribute to a widening of known inequalities in outcomes. One example is the significantly 
lower improvement in blood pressure control in the black group compared to white British 
and lower improvements in blood pressure and cholesterol control in manual compared to 
non-manual workers. These findings highlight the importance of assessing the impact of 
universally applied quality improvement initiatives on inequalities in chronic disease 
management. 
Strengths and weaknesses 
The HSE is national, representative survey and a primary mechanism for monitoring 
population health in England. Comparing outcomes across time using cross-sectional surveys 
may introduce bias, given that there may be systematic differences in the participants 
sampled between 1998 and 2004.1 combined Indians, Pakistanis and Bangladeshis into a 
single ethnic category of ""south Asians"" and black African and Caribbeans as ""blacks"', due to 
insufficient numbers. This may have masked differences in diabetes management and 
outcomes in what are known to be culturally and epidemiologically heterogeneous groups. 
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6.0 Wandsworth Prospective Diabetes Study 
6.1 Study Setting 
In England, the provision of primary care services is the responsibility of primary care trusts. 
There are approximately 150 primary care trusts in the country which typically cover a 
population of 300,000 to 400,000 people. Within each primary care trust, primary care services 
are largely delivered by general practitioners working in National Health Service (NHS) 
general practices. 
Wandsworth Primary Care Trust (PCT) is located in inner south-west London and is co- 
terminus with the local government borough of Wandsworth. The population of 
Wandsworth is younger than that of England in general, with 74% under 45 years (compared 
with a national average of 60%). 
Figure 4: Age breakdown of Wandsworth population by gender 
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According to data from the 2001 census, just over one in five Wandsworth residents (22%) 
belong to a non-white minority ethnic group. Of these, 4.9% are Black Caribbean, 3.9% Black 
African, 2.9% Indian, 2.1% Pakistani and 0.4% are Bangladeshi. The borough has 
considerably greater ethnic diversity than the United Kingdom as a whole, where 7.9% of the 
population belong to ethnic minority groups with 1.0% Black Caribbean, 0.8% Black African, 
1.8% Indian, 1.3% Pakistani and 0.5% Bangladeshi. Figures 5 and 6 provide a map of the 
distribution of south Asian (Indian, Pakistani, Bangladeshi) and Black populations (African 
and Caribbean) in Wandsworth. 
Figure 5: Percentage of people of south Asian origin in Wandsworth wards 
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Figure 6: Percentage of people of black African/ Caribbean origin in Wandsworth Wards 
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Figure 7: Deprivation levels in Wandsworth PCT 
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The borough has high levels of deprivation relative to elsewhere in England [Index of 
Multiple Deprivation 2004 (172) rankings: Overall 128/354, Income Scale 51/354, 
Employment Scale 60/354]. 
6.2 Study methods 
The Wandsworth Prospective Diabetes Study (WPDS) aims to examine the quality and 
outcomes of diabetes care in a diverse ethnic population. The WPDS emerged form the 
CONDUIT (Cutting Out Needless Deaths Using Information Technology) programme. 
CONDUIT began in 1998, being first piloted in the Battersea Primary Care Group in south- 
west London. The purpose of the programme was to establish comprehensive disease 
registers in Wandsworth to enable examination of the prevalence, management and outcomes 
of several national priority conditions in primary care. 
All computerised general practices in Wandsworth were invited to take part in the CONDUIT 
programme. However, data was only collected from practices within the two of three 
localities (Battersea and Wandsworth South) due to a change to different GP software 
provider in the third locality (Putriey) during 2002. Practices in the study area serve a more 
deprived, ethnically diverse population than those based in Putney. 
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Figure 8: Map of Wandsworth PCT showing locality borders 
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In 2005, the study area contained thirty six general practices with a registered population of 
243,519. The median list size of practices was 6349 patients and there was an even distribution 
of large, medium and small sized practices in the study area (13 practices had more than 8000 
patients, 13 practices had between 3000 and 8000 patients and 10 practices had fewer than 
3000 patients). 
Table 10 provides details about the timing of data collection, number of practices 
participating, percentage of the registered population covered by the survey and disease 
areas. 
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Table 10: Data collection period and coverage of the WPDS 
Collection 
round 
Period of data 
collection 
No. 
practices 
Population 
covered 
Disease areas 
CONDUIT 1 Sep 2000- May 2001 63/69 92.0% IHD, hypertension 
CONDUIT 2* Jun - Oct 03 34/40 85.6% IFID, hypertension, diabetes 
94.3% IHD, hypertension, diabetes, asthma 
Establishing a diabetes register 
The methodology used to develop a diabetes register in Wandsworth was extensively piloted 
in 2002, before I became involved in the project (8). The pilot study highlighted the 
importance of searching beyond diagnostic codes to identify all individuals with diabetes on 
general practice lists. At least nine separate Read code groupings and twenty five individual 
diabetes codes were in use in the 17 pilot study practices. Only one Read code (C10, diabetes 
mellitus) was being used in all 17 practices. However, the proportion of patients coded with 
this main diagnostic grouping was 63%, with variation of 14% to 98% between practices. The 
inclusion and exclusion criteria for the WPDS in described in Table 11. 
Table 11: Inclusion and exclusion criteria f or the WPDS 
Inclusion Exclusion 
A diagnostic Read code for diabetes (C10 or 
subcodes) 
< 18 years 
A diabetes care / monitoring Read code (66A) Gestational diabetes 
Repeat prescribing for diabetic medications Evidence of being treated for 
polycystic ovarian syndrom 
greater than 7.5% 
. All historical MAR and blood pressure readings and date of diagnosis was extracted from Battersea practices 
during a 
separate data extraction in 2003 
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Data extraction and cleaning 
Data was extracted from individual practices by members of the PCT staff after local ethics 
committee approval and consent had been provided by the practice. Data was downloaded 
onto a floppy disc from the practice computer system (Egton Medical Information Systems - 
EMIS) and then uploaded onto secure disease register files at the Wandsworth Research 
Centre offices. 
Table 12: Study variables 
Type of data extracted Examples 
Demographic Age, gender, ethnicity, postcode 
Risk factors Smoking, Body Mass Index 
Processes of care Blood pressure measured, retinopathy 
screening undertaken 
Prescribing Ace inhibitors prescribed 
Intermediate outcome HbAlc, cholesterol level 
Prospective longitudinal cohort (2003-2005) 
A unique patient identifier (NHS Number) was used to link patient records extracted in the 
CONDUIT 2 and 3 rounds to develop a longitudinal dataset. Linkage of the 2003 and 2005 
datasets was virtually complete as 99.2% of patients had an NHS number in 2003 and 99.4% 
had an NHS number in 2005. 
Recording of ethnicity and socio-economic status 
Wandsworth Primary Care Trust instituted an incentive scheme in 2005 to encourage general 
practices to improve levels of ethnicity coding in patients with chronic conditions such as 
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diabetes and coronary heart disease. Practices then approached patients to self-identify their 
ethnic origin from closed categories within the READ coding system which map to 
classifications used in the 2001 UK census (173). This occurred either during registration with 
the practice or during a consultation. Socio-economic status (SES) was assigned to individual 
patients based on their full residential postcode using the Index of Multiple Deprivation 
(IMD) 2004 (172). The Index of Multiple Deprivation is the most commonly used method of 
measuring area socio-economic status in the UK and is compiled from a variety of sources, 
including the 2001 UK census and unemployment and social security benefits records. 
Individual patient level indicators of socio-economic status such as educational attainment, 
employment status, income and social class are generally not routinely recorded in primary 
care information systems. 
Quality indicators 
Assessment of quality indicators was based on clinical information recorded on the practice 
computer in the previous 15 months. I examined selected process of care indicators from the 
General Medical Services (GMS) contract along with prescribing and intermediate clinical 
outcome indicators (174). Intermediate outcome indicators were assessed against national 
treatment standards (HbAlc < 7.0%, BP < 140/80 mm Hg, cholesterol <5 mmol/L) rather 
than those set in the GMS contract (HbAlc < 7.4% BP < 145/85 nun Hg, cholesterol <5 
mmol/L), in line with evidence-based guidance (175). 
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Statistical analyses 
All analyses relate to the longitudinal dataset. I calculated unadjusted mean values for 
systolic and diastolic blood pressure, HbAlc and cholesterol readings as all were 
approximately normally distributed. For all quality indicators, I describe percentage 
achievement in each group ethnic group. I used paired McNemar tests to compare mean 
differences in achievements between 2003 and 2005.1 undertook conditional logistic 
regression to determine the association of ethnicity (reference group: white British) with the 
indicator variables" odds ratios, with 95% confidence intervals, for both periods. I assessed 
changes in achievement between the two periods by conditioning 2005 achievements on 2003 
achievements. All standard errors are robust to account for the clustering of patients within 
general practices. Statistical analysis took into account that patients were clustered within 
practices and ethnic minority groups varied in their age and sex distributions (176). 1 
performed statistical analyses using Stata 9.1 (Texas, USA: Stata Corporation). 
Ethics approval 
Ethics approval for the studies was granted by the Wandsworth Local Research Ethics 
Committee. 
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6.3 Results 
6.3.1 Prospective longitudinal cohort (2003-2005) 
Sample characteristics 
The area covered by the study contained forty practices in 2003 with a total registered 
population of 245,872. Thirty four practices participated in the study, serving 85.6% of the 
registered population. In 2005, the total registered population in the study area was 243,519 in 
thirty six practices. Thirty two practices participated in the study serving 94.3% of the 
registered population. 
In 2003,6052 adults (> 18 years) were identified with diabetes in the 34 participating primary 
care practices. In 2005,7605 adults were identified with diabetes in the 32 participating 
primary care practices. The four practices that did not participate in the study in 2005 
accounted for less than 6% of the registered population in the study area. Non-participating 
practices were smaller (3 of 4 had fewer than 3000 patients) and located in more deprived 
areas than participating practices. 
The European age standardised prevalence of diabetes increased from 36.3 to 42.2 per 1000 
population in all age groups between 2003 and 2005. Ethnicity was recorded in 71 % and 93 % 
of the sample respectively in 2003 and 2005. The longitudinal dataset consisted of 4284 adults 
who were registered with participating practices in both 2003 and 2005. The characteristics of 
the sample are described in Table 13. 
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Table 13: Characteristics of WPDS sample (2003-2005) 
20 03 20 05 Longi udinal 
Age Number % Number % Number % 
18-44 1,010 16.7 1,142 15.0 557 13.0 
45-54 917 15.2 1,225 16.1 676 15.8 
55-64 1,494 24.7 1,785 23.5 1,165 27.2 
65-74 1,611 26.6 2,044 26.9 1,212 28.3 
75+ 1,020 16.9 1,409 18.5 674 15.7 
Gender 
Male 3,128 51.7 3,945 51.9 2,227 52.0 
Female 2,924 48.3 3,660 48.1 2,057 48.0 
Ethnicity 
White British 2,470 34.9 1,360 38.6 
Black Caribbean 1,192 16.8 813 23.1 
Black African 630 8.9 365 10.4 
Indian 801 11.3 464 13.2 
Pakistani 498 7.0 296 8.4 
Bangladeshi 106 1.5 60 1.7 
White Irish 214 3.0 166 4.7 
TOTAL 6052 7605 4284 
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1. Process of care 
Some variation in the quality of care delivered to different ethnic groups was evident in 2003, 
before the implementation of the Quality and Outcomes Framework (Tables 14 & 15). For 
example, BMI was less likely to be measured in the black African, Indian and Pakistani 
groups than in the white British group. HbAlc and cholesterol were less likely to be 
measured in the black African and Pakistani groups and blood pressure was less likely to be 
measured in the Indian group than in the white British group. 
In 2005, these variations had been largely attenuated. For example, there were no significant 
differences in recorded measurement of blood pressure, HbAlc, cholesterol, micro- 
albuminuria or retinopathy screening attendance between ethnic groups. Moreover, there 
was some evidence of better care being delivered to ethnic minorities, who were significantly 
more likely to have their BMI recorded that white British in 2005; except in the Pakistani and 
white Irish groups. 
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Smoking status, provision of cessation advice and prevalence 
Smoking status was significantly more likely to be ever recorded in 2005 than in 2003 (98.8 % 
v. 90.0%, McNemar test, p<0.001). The proportion of patients whose smoking status was 
recorded in the 15 months before the study period was also greater in 2005 than in 2003 
(86.7% v. 67.6%, McNemar test, p<0.001). The greatest improvements in the recording of 
smoking status were observed among nonwhite ethnic groups (except Bangladeshi) after 
adjustment for age, sex, ettmic background, deprivation status and practice-level clustering. 
The lower recording of smoking status in 2003 among the white British, white Irish and 
Bangladeshi groups was not attenuated in 2005 (Table 16). 
The proportion of patients with documented smoking cessation advice increased from 48.0% 
in 2003 to 83.5% in 2005 (McNemar test, p<0.001). This increase did not differ with ethnic 
background. The variation in the provision of smoking cessation advice evident between 
ethnic groups in 2003 was attenuated in 2005. 
The prevalence of smoking among patients with diabetes decreased significantly from 20.0% 
in 2003 and to 16.2% in 2005 (McNemar test, p<0.001). Reductions in smoking prevalence 
were lower in the black African and Bangladeshi groups than in the white British group. In 
2005, smoking rates differed significantly with ethnic background (4.9 % -24.9 %). The higher 
smoking rates observed in 2003 in both the white British and white Irish groups were not 
attenuated in 2005. 
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Prescribing and intermediate clinical outcomes 
Hypertension management and control 
The mean value for systolic blood pressure decreased significantly from 138.8 mm Hg (95% 
CI 138.1-139.5) to 135.1 mm Hg (95% Cl 134.5-135.8) between 2003 and 2005 (Figure 9). Mean 
systolic blood pressure levels were significantly higher in the black Caribbean group when 
compared with the white British group in 2003 and remained so after the implementation of 
QOF. The mean value for diastolic blood pressure decreased significantly from 79.6 mm Hg 
(95% CI 79.3-79.9) to 76.6 mm Hg (95% CI 76.3-76.9) between 2003 and 2005 (Figure 10). Mean 
diastolic blood pressure levels were significantly higher in the black Caribbean and African 
groups when compared with the white British group in 2003 and remained so after the 
implementation of QOF. 
Significantly more patients (McNemar test, p<0.001) met the treatment target for blood 
pressure control (ý 140/80 mm Hg) in 2005 (42.3%) than in 2003 (31.4%). These changes were 
uniform across ethnic groups, with the exception of the black Caribbean group, who had 
significantly lower improvement in blood pressure control relative to the white British group 
after adjusting for age, gender, deprivation and practice level clustering (Table 17). The worse 
blood pressure profile evident in the black Caribbean group in 2003 was not attenuated in 
2005. Significantly more patients (McNemar test, p<0.001) were treated with an Angiotensin. 
Converting Enzyme (ACE) inhibitor in 2005 (58.2%) than in 2003 (46.0%) and the increases 
were uniform across ethnic groups. 
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Hyperli idemia management and control 
The mean value for total cholesterol decreased significantly from 4.89 mm/ L (95 % Cl 4.83- 
4.94) to 4.51 mm/L (95% Cl 4.47-4.55) between 2003 and 2005 (Figure 11). Mean cholesterol 
levels were significantly lower in the Indian group when compared with the white British 
group in 2003 and remained so after the implementation of QOF. The mean blood pressure 
value in the Bangladeshi group became significantly lower than the white British group in 
2005. 
Significantly more patients (McNemar test, p<0.001) met the treatment target for total 
cholesterol (< 5 mmol/L) in 2005 (70.4%) than in 2003 (57.5%). These changes were uniform 
across ethnic groups, with the exception of the Bangladeshi group, who had significantly 
greater improvement in cholesterol control relative to the white British group after adjusting 
for age, gender, deprivation and practice level clustering (Table 18). A worse lipid profile 
evident within the white British group in 2003 was not attenuated in 2005. Significantly more 
patients (McNemar test, p, < 0.001) were treated with lipid lowering agents in 2005 (59.7%) 
than in 2003 (37.8 %). Lower prescribing of lipid lowering agents evident in the black African 
group in 2003 was not attenuated in 2005. 
114 
wo 
Ilz 
ro 
0 
a) 
1.0 
Lf) 
ON 
bt 
"0 
LL 
. ........................................ ................... 
(D 
co 
LO 
LO 
LO LO 
qsljl GI! qm 
! qsaPej5uee 
! Uelslýed 
uelpul 
ueoij; v ýOejg 
ueeqq! jeo ýoejEg 
qsll! jo GINAA 
.................... ................... 
qsljl ; 91! qm 
iqsepelbueg 
! uMsNed 
uelpul 
ueoljjv ýOejq 
ue, aqq! jeC) ýoeje 
qsll! jg al! q/\/\ 
LO 
(-i 
LO 
0 
C) 
N 
(Y) 
C) 
Lf) 
"IZ 
.Z 
(3) 
N 
C) 
LO 
00 
194- 
(3) 
qq- 
CF) 
11, 
00 
(Y) 
0 
c) 
C) 
C: ) 
00 
Cý 
OD 
d) 
r- r- 
C6 
LO 
(D 
_0 < 
C) C) C) CD CD 
U 
cn 
C14 
C) 
= 
T--- 
OD 
C) 
(Y) 
C) 
CY) 
CN 
C) 
M 
(D C) 
C/) (m =) 0) c " in 00 c) m C-) C-) , CF) . L- 
-0 
cu 
-C 
C) 
Cj 
CY) 
C14 
00 
C14 
C) 
C14 ci N cli CY) 6 - '1" 04 
c 
u) 
0 
cy) 
- 
N 
- 00 
cy) Lo 
. 
t- t-- 
0 
-0 
C) 
C'4 
CY) 
C-0 
M 
Lf) 00 ;: r 
C) 
(c) 
(Y) 
(D rl- 
CN 
(D 
0) 
Lr) 
CY) C) cu C) v--- (D CY) ', T 00 C) CN C") T Lf) or) C: ) N C) 'It N 'IT 00 cy) cy) "; r r- cr) 
C) 
Q- 
(D 
00 
NT 
Lo 
cle) 
r- 
0') 
OC) 
r- 
CD 
0 
C) 
C) 
C, 4 
00 
t- 
00 P- 
(3) 
CD 
CN 
C) 
Lc) 
(. 0 
< C: ) C: ) C: ) C) C) 
0 C) 
r-- 
CN 
Lo 
C) 
0) 
C) 
Ce) 
00 
c) 
C) 
E 
E I 
L(. ) 
V, 
(D 
00 00 C, 4 cy) (o r-- r, - 
.0 M 
75 (o CN 04 r-. 
ý (7) 
cn 
(D 
C) 
= 
Lo 
c) 
r- 
. T- 
(N (3) (N 0') Qc) q1t 
c) C5 C-4 CO rl- rl- r- LO I-- CY) OC) rl- Qc) C) I'- 
CY) 
o 
CD 0) m C) co (. 0 (D N . 
cu CY) LO 
0 
04 
1- 
Lf) 
00 
Lf) Cl) (D CY) (D Lf) It (. 0 Lo (o 
I_- 
(1) 
*z_- 
c 
Co 
(D 
-0 
C 
(D 
0 .- C: 
J-- 
(/) -F- (J) 
0 
0- 
D 
., z co 72 
("U- 
- ; - 4- 
< 
C CU M ý- 
Ln 
(L) -0 
g 
. C - 
(L) 
0 
w Q) C) -ý I -, cu - CY) C: 7L' -r- 
(D 
CLU) 
M (u co < 
00 
CO 
CY) a) 
(D 
(D 
L- 
0- 
,2-. 0 
a) C: 
o) C: .0 
D Q- 
(D 
> 
(D 
CY) 0- M 
0 
4- 
Z- E 
in :3 
CL LF (D cu 
a) _0 (D C: 
0 
c)) 
4- co 
C/) -F 
0 
C: ) 
C) 
C 
(=; 
4- S. - 
v 
2 
(L) 0- 
cn 
0 
a) E 
0) a) =3 Z : -F < 
Hyperglycaemia management and control 
The mean value for HbAlc decreased significantly from 7.93% (95% Cl 7.86-7.99) to 7.78% 
(95% Cl 7.73- 7.84) between 2003 and 2005 (Figure 12). Mean HbAlc levels were significantly 
higher in the black African and Pakistani groups when compared with the white British 
group in 2003 and remained so after the implementation of QOF. The mean blood pressure 
value in the black Caribbean group became significantly higher than the white British group 
in 2005. 
Significantly more patients (McNemar test, p=0.005) achieved recommended levels for 
HbAlc (< 7.0%) in 2005 (37.4%) than in 2003 (35.1%). These changes were uniform across 
ethnic groups, with the exception of the black Caribbean group, who had significantly lower 
improvement in glycaemic control relative to the white British group after adjusting for age, 
gender, deprivation and practice level clustering (Table 19). Worse HbAlc control in south 
Asian and black groups relative to the white British group persisted between 2003 and 2005. 
Significantly more patients (McNemar test, p<0.001) were treated with insulin in 2005 
(28.5%) than in 2003 (20.4%). However, increases in insulin prescribing were significantly 
lower within the black African and south Asian groups than the white British group resulting 
in a widening of existing variation evident before the new contract. Significantly more 
patients (McNemar test, p<0.001) were treated with oral hypoglycaernic agents (OHAs) in 
2005 (66.8%) than in 2003 (52.8%). These increases were significantly larger in all black and 
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south Asian groups relative to white British resulting in widening of existing variation 
between ethnic groups evident before the new contract was implemented. 
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6.3.2 Retrospective cohort study 
A key limitation of my main prospective study was that data was collected at only two time 
points, one before (2003) and one after (2005) the introduction of the QOF in April 2004. This 
absence of information on longer term trends in care meant that only limited conclusions 
could be drawn about the impact of QOF on inequalities given i. e. the underlying trend may 
have been one of widening inequalities in care. I sought to overcome this limitation by 
analysing an additional dataset extracted from 15 practices in the Battersea area during 2003 
data collection. This dataset contained each patienf s historical HbAlc and blood pressure 
readings and the date that they were diagnosed with diabetes. 
Methods 
Practices 
In 2005, the Battersea area contained sixteen general practices with a registered population of 
120,843. The median list size of practices was 8257 patients but there were fewer smaller sized 
practices than is typical nationally; six practices had more than 9000 patients, seven practices 
had between 3000 and 9000 patients and three practices had fewer than 3000 patients. 
Studv variables 
examined the percentage of patients with HbAlc and blood pressure measured and their 
mean values as they applied to the study population between 2000 and 2005. Patient level 
variables were age, gender, ethnicity, deprivation and duration of diabetes. Practice level 
variables were list size, number of full-time equivalent (FTE) general practitioners and 
deprivation. These were obtained from the Manchester Primary Care Research and 
Development Centre, University of Manchester. 
Statistical analysis 
I first fitted individual linear regressions for pre-QOF data (2000-2003) for each patient with a 
time indicator (2000= 1 to 2003= 4) and used the slope and intercept to predict the value at 
time point 6 (2005). This value represents the expected value of the outcome in 2005 if QOF 
had not been established. I adjusted this pre-QOF value and the outcome for 2005 (post-QOF) 
for age and deprivation (both after centering) and found out the mean values for the three 
ethnic groups separately for men and women using ordinary linear regression. An additional 
challenge in the statistical analyses was to accommodate the hierarchical nature of the data, 
which were years of measurement nested with in patients nested within practices. Ignoring 
this multi-level nature would have resulted in faulty estimation of standard errors. I, 
therefore, used a random effects model: 
Ylik :- 
180 yk 
+A 
yk 
XI +A 
jk 
X2 +Ak X3 
180 ijk =A+ 
VOk + UOjk+ eO ijk 
where the beta's were the coefficients; Xs the vector of explanatory variables; and v, u, and e 
the variance components for practice, patient and time respectively; the numerical subscripts 
represent the levels, the letter subscripts identify theithtime point for the jhpatient in the kth 
practice. The overall fit of the models were assessed using the change in the deviance score 
compared to an intercept only model with the degrees of freedom equal to number of 
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parameters in the model. Significances of the beta coefficients were assessed using the Wald 
test. The analyses were done using MlWin 2.02. 
Results 
1968 adults (> 18 years) with diabetes were identified who were: - (i) continuously registered 
with the 15 participating practices between 2003 and 2005 and (ii) had at least one previous 
blood pressure or HbAlc measurement. 996 were men and 972 were women. Ethnicity was 
recorded in 98.6% of the sample; 37.8% were white British (744), 33.4% were black (658), 
10.1% were south Asian (199) and 17.2% belonged to other ethnic groups (339). 
The south Asian group were less likely to have their blood pressure measured than the white 
group during 2000 and 2001 although these differences were not statistically significant. 
Disparities in blood pressure recording were not evident from 2002, before the introduction of 
pay for performance incentives in 2004. The south Asian and black groups were less likely to 
have their blood glucose measured than the white group during 2000-2002. However, these 
differences were not evident in 2003-2005 (Table 20). 
Mean systolic and diastolic blood pressure was significantly higher in the black group than in 
the white group before and after the introduction of QOF (Figures 13 & 14). Mean blood 
pressure values did not differ significantly between the south Asian and whites groups, 
except in 2000 and 2001 when mean systolic blood pressure was significantly lower in the 
south Asian group. This pay for performance incentive was associated with reductions in 
mean systolic and diastolic blood pressure which were significantly greater than that 
123 
predicted by the underlying trend in the white (5.8 mm Hg, 4.2 mm Hg), black (2.5 mm Hg, 
2.4 mm Hg) and south Asian (5.5 mm Hg, 3.3 mm Hg) groups. Mean HbAlc levels were 
significantly higher in the black group than in the white group before (2002-2003) and after 
the introduction of QOF (Figure 15). Mean Hbalc values did not differ significantly between 
the south Asian and whites groups before the introduction of QOF but were significantly 
higher in the south Asian group in 2005. Reductions in HbAlc levels were significantly 
greater than that predicted by the underlying trend in the white group (0.5 %) but not in black 
(0.3%) or south Asian groups (0.4%) (Table 21). 
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In my multi-level analyses, improvements in systolic and diastolic blood pressure and HbAic 
associated with pay for performance were significantly lower in the black group than in the 
white or south Asian groups. The impact of pay for performance on blood pressure and blood 
glucose levels was not found to vary significantly with the practice level variables examined 
or with deprivation, either at patient or practice level. Increasing age was associated with a 
significantly lower improvement in systolic blood pressure levels but a greater improvement 
in MAR levels. Pay for performance was associated with a significantly greater 
improvement in diastolic blood pressure in men than women but this pattern was reversed 
for HbAlc. 
Table 22: Impact of QQF on diabetes control (multi-level model) 
Systolic BP 
(mm Hg) 
Diastolic BP 
(mm Hg) 
HbAlc 
FIXED EFFECTS 
Age (year) 0.424 -0.083 -0.029 
Gender (women) -0.434 0.929 -0.023 
Time since diagnosis 0.014 -0.332 0.102 
QOF* -5.266 -4.376 -0.314 
Black 3.006 2.629 0.321 
South Asian -1.161 -0.876 0.138 
Patient level deprivation -0.012 -0.018 0.003 
Practice level 
deprivation 
0.018 0.009 0.003 
FTE Family Practitioners -0.130 -0.05 -0.038 
Intercept 140.733 82.138 7.438 
RANDOM EFFECTS" 
Practice 4.65 
(3.7%) 
1.21 
(25.6%) 
0.04 
(16.7%) 
Patient level 116.423 
(23.5%) 
35.58 
(7.2%) 
1.47 
(14.7%) 
Time level 4.65 
(3.7%) 
54.608 
(8.0%) 
1.541 
(-3.0%) 
MODEL FIT 
Deviance (DF, p value) 13508.02 
(91<0.0001) 
11,662.90 
(91<0.0001) 
4,362.95 
(9, <0.0001) 
Beta coefficients: bold numbers represent statistical significant values 
*This reports the effect of QOF on the white reference group. 
** Random effects are error variance apportioned between practices, patients and measurement years. 
Change from the intercept only model in parentheses. 
The intercept refers to the average outcome before QOF for a 64 years old White male. 
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7.0 Discussion 
7.1 Summary of key findings 
The proportion of patients reaching treatment targets for HbAic, blood pressure and 
cholesterol increased significantly after the implementation of a new contract for general 
practitioners in the UK that linked pay to performance. Improvements seen were significantly 
greater than that predicted by underlying trends and were suggestive of a step-change 
increase in quality. Improvements were broadly uniform across ethnic groups, except for the 
black Caribbean group, which had improvements in HbAjc and blood pressure control that 
were significantly lower than in the white British group. 
Variations in prescribing and achievement of treatment targets between ethnic groups 
evident in 2003 were not attenuated in 2005. The worse blood pressure profile evident in the 
black Caribbean group in 2003 was not attenuated in 2005. The worse cholesterol profile 
evident in the white British group in 2003 was not attenuated in 2005. Black Africans 
remained less likely to be prescribed a lipid-lowering drug and south Asians were less likely 
to be prescribed insulin after the introduction of pay for performance. Processes of care for 
diabetes, including blood pressure, cholesterol and H-bAlc measurement, retinal screening 
and provision of smoking cessation advice, were generally equitable between ethnic groups 
before the introduction of pay for performance in 2004. 
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7.2 Strengths and limitations of the Wandsworth studies 
The Wandsworth studies had several strengths and limitations. I was not able to demonstrate 
a definitive causal relationship between the introduction of QOF in April 2004 and the 
changes in diabetes management identified in the main prospective analysis. This is due to 
limitations of my study design; an observational study with two time points and no control 
group. Because the new contract for general practitioners in the UK was introduced 
nationally, evaluation of these incentives using a more rigorous study design, such as a 
randomised controlled trial, was not feasible. However, findings from my retrospective 
cohort study provide stronger evidence that QOF did result in a step-change improvement in 
quality of care. This was because I was able to demonstrate that quality achievement in 2005 
exceeded that predicted by the underlying trend (2000-2003). This finding is in keeping with 
those from a study by Campbell et al. who found that the magnitudes of improvement seen 
after the implementation of the QOF were considerably higher than those reported before, 
with significant differences between projected and actual achievement in 2005 (126). In an 
earlier analysis of data extracted from the same practices, they report that the percentage of 
people with diabetes meeting a BP target of 140/ 85 mm Hg (a less stringent target than the 
140/ 80 mm Hg we used) increased from 21.8 % to 35.8 % (an annual improvement of 2.3 %) 
over this period (132). In a separate study of 74 general practices in England and Wales, de 
Lusignan et al (133) found that the percentage of people with diabetes with a BP < 140/80 
mm Hg increased from 13.6% in 1994 to 21.8% in 2001, an annual improvement of 1.2% per 
year. This result contrasts with an annual improvement seen in my prospective study of 5.5% 
(from 31.4% to 42.3%). Similarly, improvements in HbAic control were more marked in my 
study than those observed in these previous studies. Improvements seen after the 
133 
introduction of QOF are even more impressive because early improvements in quality tend to 
be the easiest to achieve. Nonetheless, like Campbell et al, my estimates of improvements in 
blood pressure and HbAlc control associated with pay for performance may be conservative. 
As the contract was agreed in March 2003, general practitioners may have begun to improve 
the quality of care on incentivised indicators prior to it's introduction in April 2004 thereby 
inflating the quality of care measured during my final, pre-contract measurement point (June 
to October 2003). 
These studies represent some of the first population-based, longitudinal research in the UK to 
examine changes in diabetes management in a multiethnic population using individual 
patient level data. Most previous research examining quality of diabetes care has either not 
been population based e. g. carried out in hospital clinics, or compared outcomes using two or 
more cross-sectional surveys containing groups of patients that may differ systematically 
(135; 177). Use of routine clinical data means that there may have been some variability in the 
completeness and accuracy of the information collected (178). Further, use of routine data 
limits interpretation of some findings. For example, I was unable to determine the reasons for 
the differential prescribing patterns found. Such patterns may be due to a number of factors, 
including patient preferences, provider factors or wider organisational. factors given that 
patients from minority ethnic groups identify numerous barriers to quality diabetes care 
(179; 180). In addition, I was unable to examine adherence to medications or self-monitoring 
behaviour, which may systematically differ between the groups I studied (181). Similarly, I 
was unable to confirm smoking status using objective methods such as salivary cotinine 
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measurement, because these methods are not in routine use in clinical practice in the United 
Kingdom. 
I was also unable to adjust for certain patient factors, such as duration of diabetes 
(prospective analysis only), presence or severity of co-morbidities and complications, and 
diabetes type. These factors may have been confounders in the relationship between ethnicity 
and diabetes management. Some of the improvements identified, particularly in relation to 
process measures of care, may be due to improved recording rather than changes in actual 
care provided. Similarly, some of the variations in quality identified in my studies may be 
due to systematic differences in recording practice rather than actual differences in care. 
However, improved recording is unlikely to be a major explanatory factor for changes seen in 
intermediate clinical outcomes (HBAlc and cholesterol), as these measures are increasingly 
downloaded electronically from the laboratory directly into patient records. Some of the 
improvements seen after QOF may have been due to practices gaming the system, whereby 
achievement is inflated in order to meet performance targets and obtain related financial 
rewards. However, by employing lower treatment targets for blood pressure (< 140/80 mm 
Hg) and HbAlc control (< 7.0%), as advocated by NICE guidelines for Type 2 diabetes, rather 
higher targets set within QOF (145/ 85 mm Hg, < 7.5 %), some of the effects of gaming are 
likely to have been negated. 
Some of my findings may be influenced by recording bias. For example, improved recording 
may have resulted in better documentation of smoking status in patients known to be non- 
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smokers rather than an actual reduction in smoking prevalence. This is supported by findings 
from a longitudinal study of diabetes care by Gulliford et al which identified recording bias 
in HbAlc measurement (164). They found that an increasing proportion having tests being 
recorded was associated with greater achievement of targets and have suggested that the 
extension of testing may be to patients with better control of intermediate outcomes. This 
may have been a factor for my main outcome measures given that the percentage of patients 
with HbAlc, BP and cholesterol recorded at baseline in 2003 was 69.7%, 84.7% and 66.9% 
respectively. 
The list of measures I used to examine trends in quality of care was not exhaustive and was 
largely derived from the Clinical Domain of the Quality and Outcomes Framework. Whilst 
the selection of quality indicators for the Framework was in principle evidence-based, the 
actual strength of the evidence to support the inclusion of individual indicators was variable. 
For example, as outlined in my Introduction, the evidence base for including intermediate 
clinical indicators, such as blood glucose, blood pressure and cholesterol, is well established 
as good control of these indicators is associated with important health gains. In contrast, the 
clinical significance of certain process indicators such as annual recording BNH is less well 
established. I did examine trends in prescribing of antidiabetic, antihypertensive and lipid 
lowering medications. The omission of prescribing indicators within QOF has been criticised 
and may contribute to "'therapeutic inertia"', whereby treatment is not intensified in patients 
with longstanding inadequate control of cardiovascular disease risk factors (182). 1 was 
unable to examine quality using indicators which were not incentivised in QOF. 
However, 
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existing evidence suggests that QOF may have resulted in improvements in quality for both 
incentivised and non-incentivised indicators wifl-dn incentivised conditions (163). 
A major strength and unique aspect of my studies has been the high levels of ethnicity 
coding, which exceeded 90% in people with diabetes registered with practices. This meant 
that I had sufficient numbers within each ethnic group in the prospective analyses to avoid 
the known limitations of combining individuals from heterogeneous populations into a single 
ethnic category, such as "south Asians, " (183). However, I acknowledge that some of the 
comparisons made may not have reached statistical significance due to small numbers in 
certain groups, for example, in the Bangladeshi group. In addition, there were insufficient 
numbers in my study to examine quality of diabetes care in smaller eflu-dc minority groups, 
including long established communities such as the Chinese and communities who have 
migrated more recently, including those from Eastern Europe. I was unable to generate 
diabetes prevalence estimates for each ethnic group as levels of ethnicity recording in the 
general registered population was low. I did adjust for differences in deprivation between 
ethnic groups and clustering of patients in primary care practices. However, assigning 
patients an area-based deprivation score may have masked actual differences in affluence and 
educational attainment both within and between ethnic groups. I adjusted for the possibility 
of certain ethnic groups may have been clustered in a small number of GP practices within 
my analysis. This is important as earlier studies have found that up to 80% south Asian 
patients are registered with a south Asian GP (184). 
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My findings may represent a more complete picture of diabetes management than that 
derived from national contract data, which determine individual practice income and may 
exclude a considerable proportion of patients who have been exception reported by practices 
for poor treatment compliance (153). People with diabetes were identified from computerised 
records using algorithms based upon diagnostic and diabetes care codes. Previous research 
undertaken by my research group at Imperial College has shown that computer searches 
based on diagnostic Read codes for diabetes alone have a low sensitivity, as they may miss up 
to one-third of cases (8). 1 used a more comprehensive search strategy to compensate for this 
under-recording of diabetes, resulting in near complete ascertainment of cases. Moreover, my 
sample included details about the process and outcomes of care in patients that were 
exception reported in QOF. All but four general practices within the study area participated 
in the prospective study. Hence my findings provide a comprehensive and typical picture of 
the care provided in this diverse, inner city location. 
7.3 Previous research 
Few studies have examined the impact of pay for performance incentives on ethnic 
disparities in access to quality health care. As discussed in my Introduction, a recent review 
of the literature on the impact of performance incentives (defined to include both pay for 
performance and public reporting programmes) on ethnic disparities in care identified only 
one study which examined this issue (170). This study examined the impact of public 
reporting on ethnic disparities rather than pay for performance. it found that the release of 
Coronary Artery Bypass Graft (CABG) report cards in New York was associated with a 
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widening of the disparity in CABG use between white versus black and Hispanic patients 
(171) 
Whilst non-financial quality improvement initiatives have been associated with reductions in 
ethnic disparities in process measures in chronic disease management, variations in 
prescribing and intermediate clinical outcomes have generally not been attenuated in studies 
conducted in the United States (185). For example, Sequist et al examined the impact of a 
series of quality improvement initiatives for diabetes undertaken by Harvard Vanguard 
Medical Associates, including the use of information systems to facilitate focused patient 
outreach and to deliver clinical reminders to physicians within an electronic medical record 
system (186). They found that between 1997 and 2001 rates of annual cholesterol level testing 
increased from 39% to 64% and the white-black disparity decreased from 14% to 4%. There 
were no disparities in annual HblAc level testing (76%) at the beghu-dng or end of the study 
period. Whilst statin therapy rates increased from 20 %to, 37 % overall, black patients remained 
less likely than white patients to receive therapy. In addition, inequalities in HbAlc control 
between white and black patients remained constant at 10%. Trivedi et al examined the 
quality of care for elderly white and black beneficiaries enrolled in 183 Medicare managed- 
care plans from 1997 to 2003. Reductions in disparities between white and black groups were 
achieved for frequency of eye examination and testing of cholesterol and HbAlc- Whilst 
disparities were attenuated for LDL cholesterol control, these widened for HbAlc control 
from 4% in 1999 to 7% in 2002 (187). The findings from these studies concur with those from 
other US research which has examined general trends in inequalities in intermediate 
outcomes in diabetes using national health survey. Using the National Health and Nutrition 
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Examination Survey (NHANES), Saydah et al found that poorer glycaemic control evident in 
black and Mexican American participants relative to whites in the 1988-1994 survey had not 
been attenuated in 1999-2000, despite publication of national clinical guidance and other 
quality initiatives in the interim period (188). These differences were found to persist in a 
more recent analysis of NHANES data by the same research group (189). 
Few studies have examined the impact of quality improvement initiatives on inequalities in 
diabetes care between ethnic groups in the United Kingdom. My findings confirm those from 
other UK studies which suggest that many processes of care for diabetes were equitable 
between ethnic groups before the introduction of the family practitioner contract in 2004 
(135; 190). For example, SoIjak et al. found no significant differences in recording of blood 
pressure and HbAlc between white, black and south Asians registered with 173 general 
practices in north-west London in 2002. However, unlike in my studies, they found that 
cholesterol was recorded in significantly fewer south Asians patients. McElduff et al found 
only small differences in the provision of care on process of care measures in 820 South Asian 
and 2070 European people with Type 2 diabetes mellitus in Blackburn between 1995 and 
2001, after adjusting for age and sex. These findings probably reflect the impact of a 
considerable and sustained investment in quality improvement initiatives in the UK which 
predate the introduction of pay for performance, including national service frameworks and 
national clinical guidance as well as educational and clinical audit activities. 
I identified differential patterns of prescribing between ethnic groups which persisted after 
the introduction of QOF. In 2005, statin. prescribing was significantly lower in the black 
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group, prescribing of oral hyperglycaernic agents was significantly lower in the white group 
and prescribing of insulin was significantly lower in the south Asian group. These findings 
are consistent with findings from my preliminary study of effinicity and quality of care which 
used data from the Health Survey for England (Chapter 5). My findings have also been 
confirmed by SoIjak et al who identified lower prescribing of insulin in south Asian patients 
when compared to whites in GP practices in north-west London. McElduff et al found that 
south Asian patients in Blackburn were more likely to be prescribed oral hyperglycaemic 
agents than white patients but that these differences were not statistically significant. The 
study also found similar levels of insulin prescribing in south Asian and white patients, a 
finding which is consistent with those from a recent study conducted in Glasgow (177). 
However, these latter two studies contained large numbers of patients managed in secondary 
care settings which may explain the different pattern of insulin prescribing identified. 
Few UK studies have examined variations in access to lipid-lowering treatments by ethnic 
group. Existing studies have mainly been ecological and have identified lower prescribing of 
statins in geographical areas with high proportions of "non-white" or south Asian ethnic 
groups. However, these findings have not been confirmed by studies which have used 
individual patient data, including the Whitehall 11 and Health Survey for England, which did 
not identify variations in access to secondary prevention drugs between effinic groups 
(102; 191). Neither of these studies examined access to lipid-lowering treatments in black 
groups. My finding of lower levels of prescribing of statins in black groups confirms previous 
findings from US studies where financial barriers have been shown to have an impact on 
patient adherence to medications (192; 193). 
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7.4 Policy implications and future research 
The improvements in intermediate outcome control associated with pay for performance 
identified in my studies are likely to confer important clinical and public health benefits in all 
eflu-dc groups if they are sustained. However, given the differential impacts on intermediate 
outcomes seen, these benefits are unlikely to be evenly distributed between ethnic groups and 
may widen existing inequalities in health outcomes. For example, mean reductions in systolic 
and diastolic blood pressure associated with QOF were statistically lower in the black group 
(-2.5/ -2.4 mm Hg) when compared to the white (-5.8/ -4.2 mm Hg) and south Asian (-5.5/ -3.3 
mm Hg) groups. In the HOT study, a 4mmHg difference (85 mmHg vs 81 mmHg) in diastolic 
blood pressure was associated with a 50% decrease in risk of cardiovascular endpoints (194). 
Improvements in overall HbAlc control associated with QOF were much less marked at 0.3%, 
0.5% and 0.4% in the black, white and south Asian groups respectively. Nonetheless, these 
modest differential impacts may result in further widening of health outcomes between these 
groups as a1% reduction in glycated haemoglobin was associated with a 37% reduction in 
microvascular complications in the UKPDS (41). Improvements in cholesterol control and 
reductions in smoking prevalence associated with QOF were impressive and appear to have 
benefited all ethnic groups in a broadly uniform way. Additional studies should examine the 
impact of pay for performance on ethnic group inequalities using longer term clinical 
outcomes such as macrovascular and microvascular complications and mortality. However, 
the extent to which variations in outcomes reflect variations in quality of care has been subject 
to debate and findings from such studies would need to be interpreted with some caution 
(122). Nonetheless, this work would usefully extend some initial modelling studies which 
have examined likely population health impacts of QOF (195). 
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My findings demonstrate the importance of assessing the impact of quality improvement 
initiatives, such as QOF, on inequalities in access to high quality health care and outcomes. 
Such assessments should be set within a wider context of ongoing equity audit of health care 
in local settings. Indeed, monitoring access to local services in different ethnic groups is now 
integral to demonstrating organizational compliance with the Race Relations Amendment Act 
2001. However, in relation to QOF, this assessment has faced a number of impediments 
which are mostly due to the lack of routinely available, longitudinal patient-level data. First, 
annual extracts of QOF data undertaken by the national reporting system, the Quality 
Management and Analysis System (QMAS), do not include patient level data. The national 
reporting system should therefore be modified to allow patient level analyses of quality of 
care, in addition to the practice level measures of performance that are currently available, by 
extracting demographic variables such as age, gender and ethnicity. Second, the ability of 
practices to `e)ýception report' patients based on criteria agreed between the government and 
family practitioners means that the quality of care delivered in different areas and to different 
patient groups may be much more variable than this dataset indicates. Third, no baseline data 
is available to assess the extent of disparities in health care before the introduction of pay for 
performance. Finally, further efforts are required to improve levels of ethnicity coding in 
primary care, which remain very low. The inclusion of ethnicity coding as a quality indicator 
within QOF is a welcome step forward. However, this incentive is unlikely to stimulate 
marked improvements in recording levels given that it is restricted to newly registering 
patients and the associated financial incentive is low (1 QOF point) - Some of the main 
learning to come out of the Wandsworth studies is that high levels of ethnicity coding can be 
achieved in urban primary care settings serving mobile populations when the right incentives 
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are in place. The Primary Care Trust instituted a successful low cost incentive scheme in 2005 
to encourage practices to improve ethnicity coding which focused on registered patients with 
chronic conditions. This scheme resulted in over 90% coding of ethnicity in patients with 
diabetes, coronary heart disease and hypertension. 
More robust studies using longitudinal data with multiple measurement points and longer 
term follow up of patients are required to better evaluate the impact of pay for performance 
on inequity in access to care. Longer term follow-up is particularly important to permit 
examination of the "'inverse equity hypothesis"' which has been proposed by Victora et al to 
explain how inequities in access to health care and outcomes may get worse, remain the 
same, or improve over time after the introduction of major public health programmes (196). 
Using three epidemiological data sets for time trends in child-health inequities within Brazil, 
they have postulated that new public-health interventions and programmes initially reach 
those of higher socioeconomic status and only later affect the poor resulting in early increases 
in inequity ratios for coverage, morbidity, and mortality indicators. Inequities only improve 
later when the rich have achieved new minimum achievable levels for morbidity and 
mortality and the poor gain greater access to the interventions. The theoretical approach used 
by Victora et al illustrates the importance of taking a longer term approach when evaluating 
the impact of health policy on inequalities as results may vary at different time periods after 
implementation. Baker and Middleton found evidence to support this hypothesis when they 
examined the impact of the introduction of the national programme for cervical cancer 
screening in 1988 and financial incentives in the 1990 GP contract on inequalities in screening 
coverage (197). They found that initial variations in coverage of cervical cancer screening and 
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cervical cancer incidence between affluent and deprived health authority reduced gradually 
during the 1990s as achievement in deprived areas improved at a quicker rate than affluent 
areas because they quickly approached maximum levels. These findings contrast with an 
earlier study conducted by Reading et al which examined variations in uptake of childhood 
immunisations in four birth cohorts (1981-2,1985-6,1987-8, and 1990-1) in Northumberland 
(198). The study found that despite a substantial increase in immunisation uptake over the ten 
year period, inequalities in uptake between deprived and affluent areas persisted or actually 
increased for most immunisations. A recent study, which examined factors associated with 
not being immunised against measles, mumps and rubella (MMR) using data from the 
millennium cohort study, suggest that these inequalities have not been addressed (199). 
Pearce et al found that single parenthood, unemployment and lower educational attainment 
were all predictive factors for lower uptake of the MMR vaccine. 
My findings indicate that policy makers and health care planners should consider the 
potential negative impacts of pay for performance incentives on inequalities in access to high 
quality health care during the design of new and the evaluation of existing programmes. One 
option is for programmes to be explicitly designed to address health inequalities. For 
example, the Massachusetts Medicaid Program in the US has been established with an aim to 
reduce ethnic disparities in hospital care and represents a possible way forward (200). 
However, as is the case with other areas of public policy, the potential opportunity costs of 
directing greater resources to address health inequalities on overall health improvement 
needs to be carefully considered (120; 201). Future research should seek to identify the optimal 
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design features of pay for performance programs so that they, where possible, both promote 
overall improvements in health care quality and reduce inequalities in access and outcomes. 
The current configuration of incentives in QOF should be adjusted if inequities in chronic 
disease management identified in my studies are confirmed in other locations and found to 
persist over time. A number of changes could be considered. First, QOF could be adjusted to 
provide better rewards to those practices serving deprived and ethnically diverse 
populations. Currently practices with a high prevalence of diabetes attract a higher financial 
reward than practices with a lower prevalence. However, to attract double the funding, a 
practice would need to have four times the national prevalence of diabetes (the "square root 
formuld). This "square root' policy limits the impact of prevalence on payments to practices 
and has been criticised because it means that the payments to practices may not fully reflect 
the workload for achieving targets in practices working in ethnically diverse areas with high 
disease prevalence. Second, quality indicators could be developed and expanded in clinical 
areas where suboptimal and inequitable care has been identified. For example, there is a case 
for further shifting the emphasis of quality assessment from process of care measures, where 
achievement is high and generally equitable, to quality indicators for prescribing and 
intermediate outcomes, where inequity between ethnic groups remains apparent. Third, the 
inclusion of incentives which reward improvements in care rather than achievement of 
absolute targets may be more likely to result in equitable provision of care and outcomes, are 
they are likely to encourage relatively faster improvement amongst underachieving practices. 
Fourth, inequities in care are more likely to be attenuated where thresholds for quality 
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indicators are set high, hence these should continue to be increased over time. This is because 
low thresholds permit practices to earn maximum income without achieving adequate 
control of intermediate clinical outcomes in a large minority of their patients. For example, to 
achieve maximum QOF points for glycaemic control in diabetes, practices must ensure that 
50% of their patients achieve a HbAlc < 7.5%. Whilst the treatment targets within QOF have 
been criticised for being higher than those set out in national clinical guidelines, it is arguable 
that tighter targets may inadvertently result in widening inequities as thresholds would 
t\ 
necessarily be set at a lower level. Fifth, little is know- about the characteristics of patients 
who are being exception reported within QOF. One preliminary study conducted in Scotland 
has shown that younger patients with stroke and those living in more deprived areas were 
more likely to be exception reported using the codes: 'informed dissent' or 'no response to 
letters', than older patients and those residing in more affluent areas (202). The current 
agreement between general practices the government should be re-examined if higher rates of 
exception reporting are identified in socially excluded groups, including ethnic minorities. 
This is an important priority area for future research and policy evaluation. 
7.5 Conclusions 
My findings suggest that policy makers and health care planners should consider the 
potential negative impacts of pay for performance incentives on health inequalities during the 
design of new programmes. Pay for performance programmes should be subject to routine 
monitoring for possible negative impacts on inequalities and adjusted to minimize these 
effects if they are identified. Future research should seek to identify the design 
features of pay 
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for performance programs so that they both promote overall improvements in health care 
quality and reduce inequalities. 
Universal quality improvement initiatives, such as pay-for-performance, may need to be 
complemented with initiatives which specifically target ethnic minorities if inequalities in 
quality of care are to be addressed. This is because many longstanding variations in chronic 
disease management have persisted in countries such as the UK and US despite major 
investment in universal quality improvement programmes over the past decade (203). In the 
UK, this investment has involved a comprehensive ten year programme of quality 
improvement initiatives including the production of national clinical guidelines, education, 
audit, financial incentives and inspection. The variety of initiatives undertaken in this country 
is in keeping with an extensive research literature which suggests that multi-faceted rather 
than single focus interventions are required to improve clinical care. However, there has been 
relatively little investment over this period in programmes that are specifically tailored to 
improving the quality of care delivered to vulnerable groups, including effmic minorities. 
The optimal methods for addressing ethnic group inequalities in health remain unclear, and 
this is an area that would benefit from further high-quality interventional and observational 
studies (204-206). For example, in relation to the management of diabetes, a recent systematic 
review of the literature of health system interventions to improve control in ethnic minority 
groups identified only nine studies (206; 207). Whilst the review found that case management 
and use of linkworkers improved cardiovascular risk factor control, the impact of these 
interventions was modest. 
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Background 
Pay-for-performance rewards health-care providers by paying them more if they succeed in 
meeting performance targets. A new contract for general practitioners in the United Kingdom 
represents the most radical shift towards pay-for-performance seen in any health-care system. 
The contract provides an important opportunity to address disparities in chronic disease 
management between ethnic and socioeconomic groups. We examined disparities in 
management of people with diabetes and intermediate clinical outcomes within a multiethnic 
population in primary care before and after the introduction of the new contract in April 2004. 
Methods and Findings 
We conducted a population-based longitudinal survey, using electronic general practice 
records, in an ethnically diverse part of southwest London. Outcome measures were 
prescribing levels and achievement of national treatment targets (HbA, c :57.0%; blood 
pressure [BP] < 140/80 mm Hg; total cholesterol <5 mmol/l or 193 mg/c1l). The proportion of 
patients reaching treatment targets for HbAIc, BP, and total cholesterol increased significantly 
after the implementation of the new contract. The extents of these increases were broadly 
uniform across ethnic groups, with the exception of the black Caribbean patient group, which 
had a significantly lower improvement in HbAlc (adjusted odds ratio [AORI 0.75,95% 
confidence interval [CII 0.57-0.97) and BP control (AOR 0.65,95% CI 0.53-0.81) relative to the 
white British patient group. Variations in prescribing and achievement of treatment targets 
between ethnic groups present in 2003 were not attenuated in 2005. 
Conclusions 
Pay-for-performance incentives have not addressed disparities in the management and 
control of diabetes between ethnic groups. Quality improvement initiatives must place greater 
emphasis on minority communities to avoid continued disparities in mortality from 
cardiovascular disease and the other major complications of diabetes. 
The Editors'Summory of this article follows the references. 
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introduction 
Internationally, there has been a drive to reduce persistent 
health disparities among minority ethnic populations, partic- 
ularly in the United Kingdom and the United States [1]. In the 
UK, the government has recognised the importance of 
ensuring that new health policies are applied to all sectors 
of the population, including minority ethnic communities [2]. 
This consistent application is essential for policies directed at 
tackling the escalating diabetes epidemic in developed 
countries such as the UK and US, where diabetes is much 
more common in minority ethnic groups than in the general 
population [3,4]. Furthermore, these communities are likely 
to experience a disproportionate share of the future 
projected growth in the number of people with diabetes 
[3,41. This differential burden in prevalence is exacerbated by 
higher complication rates and a worse morbidity and 
mortality profile amongst minority ethnic groups when 
compared with white patients [5,6]. Because of these 
disparities, diabetes contributes substantially to the varia- 
tions in all-cause mortality between ethnic groups [7]. 
Quality improvement strategies have been shown to 
improve diabetes management and control [8,9]. A recent 
systematic review found that case management, patient 
reminders, patient and clinician education, audits, and 
electronic registers produced small to modest improvements 
in glycaemic control in individuals with type 2 diabetes [9]. 
However, these strategies appear to be less successful in 
addressing variations in care across socioeconomic and 
ethnic groups [10,111. In addition, available evidence suggests 
that the publication of several major clinical trials on 
optimum diabetes management during the 1990s and 
subsequent development of national diabetes guidelines have 
not reduced variations in hypertension and glycaemic control 
between ethnic groups [12,13]. 
The use of pay-for-performance incentive schemes as a 
quality improvement tool is increasing, particularly in the US 
and UK [14,15]. Such schemes aim to improve the quality of 
health care for all patients so that it meets established 
standards, and therefore they provide an important oppor- 
tunity to address disparities in chronic disease management 
between different ethnic and socioeconomic groups [16,171. 
Few previous evaluations of pay-for-performance schemes 
have focused on chronic disease management. Furthermore, 
most studies have been carried out in the US and thus 
international studies are lacking [14]. A new contract for 
general practitioners, introduced in the UK in April 2004, 
represents the most radical shift towards pay-for-perform- 
ance seen in any health-care system in the world [18]. This 
unique quality improvement initiative has been supported by 
91.8 billion additional investment in primary care and 
provides an opportunity to examine the impact of pay-for- 
performance on addressing current disparities in health care. 
In this paper, we examine diabetes management and 
outcomes using individual patient-level data in a multiethnic 
population before and after the introduction of a major 
performance incentive scheme. The findings are potentially 
important for other health-care systems, as pay-for-perform- 
ance is seen as one method of improving the quality of 
primary care services to disadvantaged groups and thus of 
reducing health disparities. 
Methods 
Pay-for-Performance in UK Primary Care 
Pay-for-performance was introduced in UK primary care as 
part of the new General Practitioner contract in April 2004 
[18]. About one-fourth of general practice income is now 
derived through the achievement of quality targets in 
managing chronic diseases such as diabetes, stroke, and 
coronary heart disease through the Quality and Outcomes 
Framework. The Framework consists of 1,050 points, which 
cover clinical care, practice organisation, and patient 
experience. 
Diabetes is one of ten disease areas within the clinical 
domain of the Quality and Outcomes Framework (although 
the number of indicators areas increased from ten to 
nineteen when the contract was revised in April 2006). Of 
the 99 points available for diabetes care, 50 are allocated for 
the achievement of treatment targets (blood pressure [BP] :5 
145/85 mm Hg, 17 points; HbAjc :57.4%, 16 points; HbA, c: 5 
10 %, II points; cholesterol <5 mmol/l or 193 mg/dI, 6 points) 
and the remainder to the recording of 14 process measures of 
care, including ascertainment of smoking status (3 points), 
annual measurement of body mass index (3 points), and 
retinopathy screening (5 points). 
Wandsworth Prospective Diabetes Study 
In England, the provision of primary care services is the 
responsibility of primary care trusts. There are approxi- 
mately 150 primary care trusts in England, each of which 
typically covers a population of 300,000 to 400,000 people. 
Within each primary care trust, primary care services are 
delivered by general practitioners working in National Health 
Service (NHS) general practices. Through the Wandsworth 
Prospective Diabetes Study (WPDS), the Wandsworth Primary 
Care Trust, located in southwest London, has established 
comprehensive primary care-based diabetes registers. Data 
for the present study were collected both before Uune- 
October 2003) and after (November 2005-january 2006) the 
introduction of the new general practitioner contract in the 
UK in April 2004. Ethical approval for the study was granted 
by the Wandsworth Local Research Ethics Committee. 
Setting and Participants 
The study area contained 36 general practices with a 
registered population of 243,519 patients, The median list 
size of practices was 6,349 patients and there was an even 
distribution of large, medium, and small practices in the 
study area (13 practices had more than 8,000 patients, 13 
practices had between 3,000 and 8,000 patients, and ten 
practices had fewer than 3,000 patients). 
The population of Wandsworth is younger than that of 
England as a whole, with 74% of people under age 45 y 
(compared with a national average of 60%). Approximately 
one in five Wandsworth residents (22%) belong to a nonwhite 
ethnic group. Of these, 4.9% are black Caribbean, 3.9% are 
black African, 2.9 % are Indian, 2.1 % are Pakistani, and 0.4 % 
are Bangladeshi. Wandsworth has high levels of disparities in 
income relative to elsewhere in England [19]. 
Identification of People with Diabetes 
The methods we used to develop our disease register for 
diabetes in Wandsworth have been described previously [20]. 
In brief, we approached all practices in the study area to 
.. 0. PLoS Medicine I www. plosmedicine. org 1088 June 2007 
1 Volume 41 Issue 61 e191 
Pay-for-Performance in Diabetes 
participate. All patients with type I and type 2 diabetes 
mellitus were identified from computerized general practice 
records in participating practices by searching for diagnoses 
of diabetes (CIO) or diabetes care (66A) Read codes. Patients 
with repeat prescribing for diabetic medications, or with an 
HbAic greater than 7.4%, were also included in our sample. 
Patients under 18 y of age, or women with gestational 
diabetes or receiving treatment for polycystic ovarian 
syndrome rather than diabetes, were excluded. A unique 
patient identifier (NHS Number) was used to link patient 
records extracted in both collection periods. 
Study Variables 
We examined prescribing levels and intermediate clinical 
outcome indicators for diabetes as they applied to our 
population in 2003 and 2005. Each indicator is based on 
clinical information recorded on the practice computer. 
Intermediate outcome indicators were included if they were 
recorded during the previous 15 mo. Patients self-identified 
their ethnic origin from closed categories based on the 
classifications that map to those used in the 2001 UK census 
[21], either at registration or during a consultation at the 
general practice. We assigned socioeconomic status to 
individual patients based on their postcode using the Index 
of Multiple Deprivation 2004 [19]. The Index of Multiple 
Deprivation is the most commonly used method of measuring 
neighbourhood socioeconomic status in the UK and is 
compiled from a range of sources, including the 2001 UK 
census, unemployment, and social security benefits records. 
Statistical Analyses 
Our analyses took into account that we have repeated 
measurements for each patient, patients were clustered 
within practices, and ethnic minority groups varied in their 
age distributions. For each indicator, we described percent- 
age achievement of quality indicators in each ethnic group. 
We used the McNemar test to examine overall differences in 
the frequency distributions of indicators between 2003 and 
2005. To determine the association between ethnicity and 
achievement of quality indicators we used conditional logistic 
regression specifying for the clustering of patients within 
practices. We studied the association of change in achieve- 
ment with ethnicity by conditioning the 2005 achievement on 
the 2003 achievement in a conditional logistic model. All 
standard errors are robust [22]. As we have measurements at 
two time points, our findings could be influenced by a 
regression to the mean effect [23]. To test for this effect we 
did a sensitivity analysis by repeating our analyses after 
stratifying the data according to the outcome for each 
indicator in the first time point. In doing this, we were 
looking for any substantive differences in results between the 
two strata. All analyses were undertaken using the Stata 9.1 
program (Stata Corporation, http: //www. stata. com). 
Results 
We identified 4,284 adults (aged > 18 y) with diabetes 
registered with the 32 participating practices in both 2003 
and 2005. Included were 2,227 men and 2,057 women. The 
European age-standardised prevalence of diabetes in 2005 
was 42.2 per 1,000 people in all age groups. Ethnicity was 
recorded in 95.1 % of the sample (Table S 1). Overall, the four 
practices that did not participate in the study accounted for 
less than 6% of the registered population in the study area. 
Nonparticipating practices were smaller (three of the four 
had fewer than 3,000 patients) and were located in more 
deprived areas than the participating practices. Our findings 
were substantially unchanged when we applied sensitivity 
analyses to test for the effect of measurement at two time 
points. 
Hyperglycaemia Management and Control 
Significantly more patients (McNemar test, P=0.005) 
achieved recommended levels for HbAI, in 2005 (37.4%) than 
in 2003 (35.1%). These changes were uniform across ethnic 
groups, except in members of the black Caribbean group, 
who had significantly less improvement in glycaemic control 
than did the white British group after adjusting for age, 
gender, deprivation, and practice-level clustering (Table 1). 
Worse HbAIc control in south Asian and black groups 
relative to the white British group persisted between 2003 
and 2005. 
Significantly more patients (McNemar test, p<0.001) were 
treated with insulin in 2005 (28.5%) than in 2003 (20.4%). 
However, increases in insulin prescribing were significantly 
lower within the black African and south Asian groups than 
in the white British group, resulting in a widening of the 
variation existing before the new contract. Significantly more 
patients (McNemar test, P<0.001) were treated with oral 
hypoglycaemic agents (OHAs) in 2005 (66.8%) than in 2003 
(52.8%). These increases were significantly larger in all black 
and south Asian patient groups relative to white British 
patients, resulting in widening of the existing variation 
between ethnic groups evident before the new contract was 
implemented. 
Hyperlipidemia Management and Control 
Significantly more patients (McNemar test, p<0.001) met 
the treatment target for total cholesterol in 2005 (70.4%) 
than in 2003 (57.5%). These changes were uniform across 
ethnic groups, with the exception of the Bangladeshi group, 
who had significantly greater improvement in cholesterol 
control relative to the white British group after adjusting for 
age, gender, deprivation, and practice-level clustering (Table 
2). A worse lipid profile evident within the white British 
group in 2003 was not attenuated in 2005. Significantly more 
patients (McNemar test, p<0.001) were treated with lipid- 
lowering agents in 2005 (59.7%) than in 2003 (37.8%). Lower 
prescribing of lipid-lowering agents evident in the black 
African group in 2003 was not attenuated in 2005. 
Hypertension Management and Control 
Significantly more patients (McNemar test, p<0.001) met 
the treatment target for BP control in 2005 (42.3%) than in 
2003 (31.4%). These changes were uniform across ethnic 
groups, with the exception of the black Caribbean group, who 
had significantly less improvement in BP control than did the 
white British group after adjusting for age, gender, depriva- 
tion, and practice-level clustering (Table 3). The worse BP 
profile evident in the black Caribbean group in 2003 was not 
attenuated in 2005. Significantly more patients (McNemar 
test, P<0.001) were treated with an angiotensin-converting 
enzyme (ACE) inhibitor in 2005 (58.2%) than in 2003 (46.0%) 
and the increases were uniform across ethnic groups. 
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Table 1. Ethnic Disparities in Glycaemic Management and Control 
Patient Group Percent Patients with HbAj, <7.0% Percent Patients Prescribed OHA Percent Patients Prescribed Insulin 
2003 2005 Change AOR' (95% CI) 2003 2005 Change AOR' (95% CI) 2003 2005 Change AORa (95% CI) 
White British 38.8 42.2 3.4 1.00 46.4 61.3 14.9 1.00 21.0 33.2 12.1 1.00 
Black Caribbean 35.1 b 36.7 
b 1.6 0.75 (0.57-0.97) 57.6 71 . 1b 13.5 1.43 (1.16-1.76) 23.7 31.0 7.3 1.05 (0.84-1.30) 
Black African 32.7 33.3 0.6 0.88 (0.62-1.26) 59.5 74.3 b 14.8 1.83 (1.37-2.46) 19.5 28.2 b 8.7 0.69 (0.51-0.93) 
Indian 32.5 32.2 -0.3 0.80 (0.56-1.14) 57.5 
b 76.7 b 19.2 2.06 (1.55-2,73) 15.1 b 20.5 b 5.4 0.51 (0.38-0.70) 
Pakistani 25.3 27.1 b 1.8 0.73 (0,47-1.13) 54.7 74.6 b 19.9 1.91 (1.37-2.65) 22.0 25 Ob 3.1 0.56 (0.40-0.78) 
Bangladeshi 33.1 34.0 0.9 1.32 (0.59-2,93) 51.7 68.3 16.6 1.61 (0.88-2.96) 20.0 21.7 b 1.7 0.49 (0.25-0.98) 
White Irish 44.1 39.0 -5.1 0.82 (0.54-1.27) 46.4 63.3 16.9 1.11 (0.78-1.58) 16.9 27.1 10.2 0.83 (0.56-1.23) 
All groups 35.1 37.4 2.3 52.8 66.8 14. Oc 20.4 28.5 8.1 c 
'AOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British) 
b Significantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering 
'McNemar test (p < 0.001) 
doi: 10.1371/journal. pmed. 0040191. tOO1 
Discussion 
Main Findings 
The proportion of patients reaching treatment targets for 
HbA,,, BP, and total cholesterol increased significantly after 
the implementation of a new contract for general practi- 
tioners in the UK that linked pay to performance. The 
increases were broadly uniform across ethnic groups, except 
for the black Caribbean group, which had improvements in 
HbAjc and BP control that were significantly lower than in 
the white British group. Variations in prescribing and 
achievement of treatment targets between ethnic groups 
evident in 2003 were not attenuated in 2005. 
Comparison with Previous Research 
Few studies have examined the impact of pay-for-perform- 
ance incentives on variations in chronic disease management 
and outcomes [14,15]. Complementary quality improvement 
strategies in diabetes management have shown small to 
modest improvements in glycaemic management in con- 
trolled trial settings [8]. However, the impact of such 
strategies in population settings appears mixed, with some 
evidence of overall improvement in care in countries such as 
the UK and Sweden [24,25], but more equivocal results in the 
US [26,27]. Most previous studies highlight persisting varia- 
tions in diabetes management and outcomes between ethnic 
groups. For example, findings from the National Health and 
Nutrition Examination Survey (NHANES) in the US suggest 
that poorer glycaemic control evident in black and Mexican 
American participants relative to whites in the 1988-1994 
survey had not been attenuated in 1999-2000, despite 
publication of national clinical guidance and other quality 
initiatives in the interim period [12]. Similarly, McElduff and 
colleagues [13] identified persistently higher HbAjc levels 
amongst south Asians compared with Europeans attending 
primary and secondary care settings in Blackburn, northwest 
England, throughout a comparable time period (1995-2001). 
Strengths and Limitations 
We are not able to demonstrate a definitive causal 
association between pay-for-performance incentives (intro- 
duced in April 2004) and the changes in diabetes manage- 
ment between 2003 and 2005. This is due to limitations of our 
study design; an observational study with two time points and 
no control group. Because the new contract for general 
practitioners in the UK was introduced nationally, evaluation 
of these incentives using a more rigorous study design, such 
as a randomised controlled trial, was not feasible. Recent 
observational studies indicate that the management of 
diabetes in primary care was improving in the UK before 
Table 2. Ethnic Disparities in Cholesterol Management and Control 
Patient Group Percent Patients with Cholesterol <5 mmol/I Percent Patients Prescribed Lipid-Lowering Drugs 
2003 2005 Change AORa (95% Cl) 2003 2005 Change AOR" (95% Cl) 
White British 54.9 67.7 12.8 1.00 43.7 63.9 20.2 
Black Caribbean 58.3 71.1 b 12.8 1.07 (0.82-1.40) 35.7 b 59.2 23.5 
Black African 63 Ob 74.2 b 11.2 1.27 (0.87-1.86) 20.0b 48.8 b 28.8 
Indian 63.6 b 74. gb 11.3 1.05 (0.71-1.54) 40.1 60.3 20.3 
Pakistani 57.6 75.2 b 17.6 1.09 (0.69-1.73) 42.6 63.5 20.9 
Bangladeshi 64.2 83 gb 19.7 2.83 (1.02-7.89) 38.3 71.7 
b 33.3 
White Irish 65 gb 67.6 1.7 1.00 (0.65-1.67) 43.4 62.7 19.3 
All groups 57.5 70.4 12.9c 37.8 59.7 21.9c 
&AOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British) bSignificantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering 'McNemar test (p < o. ooi) 
doi: 10.1371/journal. pmed. 0040191. tOO2 
1.00 
1.02 (0.80-1.29) 
1.11 (0.82-1.50) 
1.08 (0.79-1.48) 
1.03 (0.71-1.49) 
2.23 (1.11-4.49) 
0.90 (0.58-1.38) 
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Table 3. Ethnic Disparities in BP Management and Control 
patient Group Percent Patients with BP < 140/80 mm Hg 
2003 2005 Change AORa (95% CI) 
Percent Patients Prescribed ACE Inhibitors 
2003 2005 Change AOR' (95% C11) 
White British 33.5 46.1 12.7 1.00 47.3 59.9 12.7 1.00 
Black Caribbean 24.1 
b 34.6 10.5 0.65 (0.53-0.81) 51.3 61.4 10.1 0.88 (0.69-1,14) 
Black African 32.0 43.4 11.4 1.08 (0.81-1.44) 42.7 54.0 11.2 0.89 (0.64-1.25) 
Indian 33.9 44.6 10.8 1.14 (0.86-1.50) 48.3 62.5 14.2 1.30 (0.94-1.80) 
Pakistani 33.6 45.4 11.8 1.02 (0.73-1.42) 44.9 55.7 10.8 0.94 (0.64-1,38) 
Bangladeshi 40.1 43.2 3.1 1.23 (0.66-2,30) 41.0 56.7 15.7 1.35 (0.67-2,70) 
White Irish 27.9 39.5 11.7 0.80 (0,56-1.14) 48.2 60,8 12.7 0.99 (0.64-1.54) 
All groups 31.4 42.3 1 0.9c 46.0 58.2 1 2.2c 
OAOR adjusted for age, gender, deprivation and practice level clustering (reference group: white British) 
'Significantly different to white British group after adjustment for age, gender, deprivation, and practice level clustering 
cMcNemar test (p < 0.001) 
doi: 10.1371/journal. pmed. 0040191. tOO3 
the introduction of the contract. However, the magnitudes of 
improvement seen before the contract was introduced are 
considerably lower than those reported here. For example, 
Campbell et al. [24] examined trends in diabetes management 
in 42 volunteer general practices in six geographical areas in 
England between 1998 and 2003. They reported that the 
percentage of people with diabetes meeting a BP target of 
140185 mm Hg (a less stringent target than the 140/80 mm Hg 
we used) increased from 21.8% to 35.8% (an annual 
improvement of 2.3%) over this period. In a separate study 
of 74 general practices in England and Wales, de Lusignan et 
al [28] found that the percentage of people with diabetes with 
a BP < 140/80 mm Hg increased from 13.6 % in 1994 to 21.8 % 
in 200 1, an annual improvement of 1.2 % per year. This result 
contrasts with an annual improvement seen in our study of 
5.5% (from 31.4% to 42.3%). Similarly, improvements in 
HbAI, control were more marked in our study population 
than those observed in these previous studies. Improvements 
seen after the introduction of pay-for-performance incen- 
tives are even more impressive because early improvements 
in quality tend to be the easiest to achieve. 
To our knowledge this is the first population-based, 
longitudinal study in the UK to examine changes in diabetes 
management in a multiethnic population using individual 
patient level data. Most previous research examining quality 
of diabetes care has either not been population based [13,29], 
or compared outcomes using two or more cross-sectional 
surveys containing groups of patients that may differ 
systematically [25,26]. Use of routine clinical data means that 
there may have been some variability in the completeness and 
accuracy of the information collected [30]. We were also 
unable to adjust for certain patient factors, such as duration 
of diabetes, presence or severity of complications, and 
diabetes type, which may have been confounders in the 
relationship between ethnicity and diabetes management. We 
were able to adjust for differences in deprivation between 
ethnic groups and clustering of patients in primary care 
practices. However, adjusted findings were not substantially 
different from those based on unadjusted analyses (unpub- 
lished data). Assigning patients an area-based deprivation 
score may have masked actual differences in affluence and 
educational attainment both within and between ethnic 
groups. 
We had sufficient numbers within each ethnic group to 
avoid the known limitations of combining individuals from 
heterogeneous populations into a single ethnic category, such 
as "south Asians" [3 1 ]. However, we acknowledge that some of 
the comparisons made may not have reached statistical 
significance due to small numbers in certain groups, for 
example, Bangladeshis. Our findings may represent a more 
complete picture of diabetes management than that derived 
from national contract data, which determine individual 
practice income and may exclude a considerable proportion 
of patients who have been exception reported by practices 
for poor treatment compliance [32]. People with diabetes 
were identified from computerised records using algorithms 
based upon diagnostic and diabetes care codes. We have 
previously shown that computer searches based on diagnostic 
Read codes for diabetes alone have a low sensitivity, as they 
may miss up to one-third of cases [20]. We used a more 
comprehensive search strategy to compensate for this under- 
recording of diabetes. All but four general practices within 
the study area participated in our survey. Hence our findings 
provide a comprehensive and typical picture of the care 
provided in this diverse, inner city location. 
Policy Implications 
Our findings suggest that the implementation of a new 
contract for primary care physicians, which is one part of a 
comprehensive policy drive to improve the quality of chronic 
disease management within the National Health Service since 
1997 [33], may have failed to address known disparities in 
diabetes management and outcomes between ethnic groups. 
Should we thus conclude that the principal mechanisms for 
attenuating these differential outcomes lie outside the reach 
of health-care systems [11]? The definitive answer to this 
question lies beyond the scope of this study, but it is worth 
reflecting on the following points. First, we found evidence of 
differential management of hyperglycaemia across ethnic 
groups, with lower relative increases in insulin prescribing in 
minority ethnic patients when compared with white patients. 
This pattern may not be solely due to provider factors, given 
that patients from minority ethnic groups identify numerous 
barriers to quality diabetes care [34,35]. Whilst this finding was 
coupled with higher levels of OHA prescribing amongst 
minority ethnic groups when compared with white patients, 
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we were unable to examine adherence to medications or self- 
monitoring behaviour, which may systematically differ be- 
tween the groups we studied [35,36]. Second, the current 
configuration of incentives within the new contract may 
provide insufficient rewards for practices working to achieve 
the key treatment targets for diabetes in ethnically diverse 
areas. At present, only one-fourth of practice income is 
derived through the quality and outcomes framework, of 
which approximately 50% is dependent on the achievement 
of treatment targets. Third, our analysis is based on data 
extracted 18 mo after the implementation of the new contract, 
This may be too soon to assess the full impact of pay-for- 
performance incentives on disparities in diabetes outcomes. 
Finally, the UK Prospective Diabetes Study (UKPDS) found 
similar glycaemic control amongst white, black, and south 
Asian patients at baseline and 9y follow-up [37]. However, 
clinical trials include only a minority of patients with diabetes 
and may not be fully representative. Our findings highlight the 
importance of routinely recording ethnicity in health-care 
information systems and the ongoing need for local equity 
audits examining disparities in health-care access. 
Conclusions 
There remains considerable scope to improve the manage- 
ment of diabetes in minority ethnic communities if the 
patterns of care and outcomes identified in this study apply 
elsewhere. Although diabetes management improved in all 
ethnic groups after the introduction of pay-for-performance 
incentives in UK primary care, disparities in prescribing and 
intermediate clinical outcomes persisted. Hence, the main 
lesson from this study for health-care systems in other 
countries is that pay-for-performance by itself may not be 
sufficient to address ethnic disparities in the quality of care. 
Consequently, future quality improvement initiatives must 
place greater emphasis on minority communities. This effort 
may help prevent continued disparities in mortality from 
cardiovascular disease and the other major complications of 
diabetes. However, the optimal methods for addressing 
ethnic disparities in health remain unclear, and this is an 
area that would benefit from further high-quality interven- 
tional and observational studies. 
Supporting Information 
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Found at doi: 10.1371/journal. pmed. 0040191. stOOI (34 KB XLS) 
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Editors' Summary 
Background. When used in health care, the term "pay-for-performance" records ke 
means rewarding health-care providers by paying them more if they targets" s( 
succeed in meeting performance targets set by the government and and chole 
other commissioners of health care. It is an approach to health service defined IE 
management that is becoming common, particularly in the US and the (HbA, c), w 
UK. For example, the UK's general practitioners (family doctors) agreed which ap 
with the government in 2004 that they would receive increases to their the percer 
income that would depend on how well they were judged to be Overall, m, 
performing according to 146 quality indicators that cover clinical care for of pay-for 
ten chronic diseases, as well as "organization of care, " and "patient ethnic gro 
experience. " One of the chronic diseases is diabetes, a condition that has did not b 
reached epidemic proportions in the UK, as it has also in many other patients %% 
countries. and patier 
Ethnic minorities often suffer more from health problems than the 
same. 
majority population of the'country they live in. They are also likely to be What Do' 
served less well by the health services. Diabetes is a case in point; in the intro( 
many countries-including the US and UK-the condition is much more beneficial, 
common In minority groups, In addition, their diabetes is usually less well control of 
"managed "-I. e., it becomes more severe more rapidly and there are to improv, 
more complications. In the UK, the govemment recognizes the need to reduce su 
ensure that its health policies are applied to all sectors of the population, practice is 
Including minority ethnic communities. Nevertheless, the advances that countries i 
have been made in the management of diabetes have not benefited the the study 
UK's ethnic minorities to the same extent as they have the majority 
population, It is hoped that the use of pay-for-performance management Add . 
itiona 
by the UK National Health Service will lead to more efficient delivery of version o 
health care, and that one consequence will be that different commu- 0040191. 
nities will be more equally served, 0 Wikiped 
Why Was This Study Done? The researchers wanted to find out Wikiped 
whether the introduction of pay-for-performance management in 0 Informa 
general medical practice in the UK was leading to a reduction in the 0 Diabete 
gap in the quality of care provided to people with diabetes who with dia 
belonged to ethnic minorities and other people with diabetes. 0 The Lon 
up by tl- 
What Did the Researchers Do and Find? The research was carried out page dE 
in Wandsworth, an area of southwest London that Is considered to be 0 introdu( 
"ethnically diverse. " Over 4,200 people with diabetes are registered with be foun 
general practitioners in this area. The researchers used the electronic pages o 
pt by these doctors and they focused on diabetes "treatment 
?t by the government, according to which the blood pressure 
sterol levels of people with diabetes should be kept below 
vels. There is also a target level for glycated hemoglobin 
hich is a substance that can be used to measure the extent to 
atient's diabetes is under control. The researchers calculated 
itage of patients who were meeting these treatment targets, 
we patients met their treatment targets after the introduction 
-performance management than were doing so before. All 
ups seemed to have benefited, but the black Caribbean group 
enefit as much as the other groups; the number of these 
ho met the targets did improve, but the gap between them 
ts with diabetes from other ethnic groups remained about the 
rhese Findings Mean? The researchers concluded that, while 
Juction of pay-for-performance did seem to have been 
it had not addressed disparities In the management and 
diabetes between ethnic groups. They say that, in all initiatives 
a the quality of health care, special efforts must be made to 
ch gaps. The UK's use of pay-for-performance in general 
regarded internationally as a very bold step, but, as other 
ire also considering moving in this direction, the lessons from 
will be relevant in many other parts of 
-the 
world. 
I Information. Please access these Web sites via the online 
f this summary at http: //dx. doi. org/10.1371/Jýournal. pmed. 
ia has an entry on pay-for-performance in health care (note: 
ia is a free online encyclopedia that anyone can edit) 
tion about how the NHS works in England 
s UK is the largest organization in the UK working for people 
betes and its website includes a useful Guide to Diabetes 
don Health Observatory is one of nine health observatories set 
ie NHS to monitor health and health care in England. There is a 
voted to "ethnic health intelligence" 
. tory information about 
diabetes as a medical condition may 
d on the MedlinePlus website; there are several MedlinePlus 
n diabetes as well 
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impact of a pay-for-performance incentive on support for 
smoking cessation and on smoking prevalence among 
people with diabetes 
Christopher Millett, Jeremy Gray, Sonia Saxena, Gopalakrishnan Netuveli, Azeem Majeed 
00 See related article page 1717 
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Background: Many people with diabetes continue to 
smoke despite being at high risk of cardiovascular dis- 
ease. We examined the impact of a pay-for-performance 
incentive in the United Kingdom introduced in 2004 as 
part of the new general practitioner contract to improve 
support for smoking cessation and to reduce the preva- 
lence of smoking among people with chronic diseases 
such as diabetes. 
Methods: We performed a population-based longitudinal 
study of the recorded delivery of cessation advice and the 
prevalence of smoking using electronic records of patients 
with diabetes obtained from participating general practices. 
The survey was carried out in an ethnically diverse part of 
southwest London before Oune-October 2003) and after 
(November 2005-January 2oo6) the introduction of a pay-for- 
performance incentive. 
Results: Significantly more patients with diabetes had their 
smoking status ever recorded in 2005 than in 2003 (98-9010 v. 
go. o%, p <o. ool). The proportion of patients with d. ocu- 
mented smoking cessation advice also increased signifi- 
cantly overthis period, from 48-0%tO 83-5% (P < o. ooi). The 
prevalence of smoking decreased significantly from 20.0% 
to 16.2% (P < o. ool). The reduction over the study period 
was lower among women (adjusted odds ratio 0.71,95% 
confidence interval 0-53-0.95) but was not significantly dif- 
ferent in the most and least affluent groups. in 2005 ' smok- ing rates continued to differ significantly With age 
0 (10.6 /0-25-10/0), sex (women, 11.5%; men, 20.6%) and ethnic 
background (4.90/0-24.9%). 
Interpretation: The introduction of a pay-for-performance 
incentive in the United Kingdom increased the provision of 
support for smoking cessation and was associated with a re- 
LA duction in smoking prevalence among patients with dia- 
0 . -Z. 
I 
betes in primary health care settings. Health care planners EI 
I in other countries may wish to consider introducing similar 
0 incentive schemes for primary care physicians. 
0 
CMAf 2007; I76(u): 705-10 
iabetes is a growing public health concern world- 
wide, with prevalence rates increasing rapidly in 
Dmost 
reg* ions. ' People with diabetes experience con- 
siderably worse health outcomes and have a shorter life ex- 
pectancy than the general population. This is largely attribut- 
able to a 2-4 times greater risk of cardiovascular disease, 
which accounts for two-thirds of deaths among people with 
diabetes. " 
Smoking is an important modifiable risk factor for cardio- 
vascular disease and microvascular complications in people 
with diabetes. ' Smoking also contributes to inequalities in di- 
abetes outcomes and explains in part the variations in mortal- 
ity between socioeconomic groups. ' Despite being at an in- 
creased risk of cardiovascular disease, many people with 
diabetes smoke, with the rate of smoking among people with 
diabetes approaching the rate in the general population. ', ' 
Comprehensive tobacco control strategies have been an 
integral component of public health policy in the United 
Kingdom, North America and Australia for many years. "' 
These strategies aim to reduce overall tobacco use and expo 
sure and include interventions targeted at groups with high 
smoking rates, including young people, those of low socio- 
economic status and ethnic minorities. As part of these ef- 
forts, the UK government established a universal smoking 
cessation service (which combines psychological support 
and medication) for smokers who would like to quit. An im- 
portant component of this service is the delivery of brief ces- 
sation advice and referral to "stop smoking clinics" by pri- 
mary health care providers. However, despite evidence that 
cessation advice improves quit rates, "" studies have shown 
that primary health care providers are not routinely offering 
11,16 cessation advice during consultations. A systematic re 
view published in 2005 suggested that this may be partly due 
to negative views held by some practitioners about dis- 
cussing smoking with their patients. "' Vogt and colleagues" 
found that many general practitioners felt that such discus- 
sions were too time consuming (42%) or were not effective 
(38%), or that they lacked the required skills to provide 
smoking cessation advice (22%). 
Pay-for-performance incentives have been proposed as a 
method to improve the quality of care received by patients. ", " 
CMAJ - JUNE 5,2007 - 176(12) 1705 
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Quality targets to identify and counsel patients with chronic 
disease who smoke were introduced in the United Kingdom as 
20 
part of the new general practitioner contract in April 2004 
These targets form part of one of the most radical shifts to- 
ward pay-for-performance seen in any health care setting. 
About one-quarter of general practice income is currently de- 
rived through the achievement of quality targets in managing 
chronic diseases such as diabetes and coronary artery disease. 
Six of the io disease indicator areas in the contract have a 
smoking cessation component, accounting for 13% (74/550) 
of points available in the clinical quality indicators. 
In this article, we present the findings of a population- 
based longitudinal study that examined the impact of a pay- 
for-performance incentive on support for smoking cessation 
and on smoking prevalence among people with diabetes in a 
multiethnic population. 
Methods 
Diabetes was i of io disease indicator areas within the clini- 
cal domain of the Quality and Outcomes Framework in the 
United Kingdom's general practitioner contract of April 
2004 (the number of indicator areas was increased to ig 
when the contract was revised in April 2oo6). Of the 99 
points available for diabetes care, 5o are allocated for the 
achievement of treatment targets (blood pressure 
145/85 mm Hg 117 points], glycosylated hemoglobin 
7.4% [A points], glycosylated hemoglobin : -: ý io% [ii 
points], cholesterol !55 mmol/L [6 points]). The remaining 
points are awarded for the recording Of 14 process measures 
of care. These mea-sures of care include Diabetes Mellitus 
Indicator 3 (the proportion of patients with diabetes for 
whom there is a record of smoking status in the previous 
15 months, except those who have never smoked, for whom 
smoking status should be recorded once 13 points]) and Dia- 
betes Mellitus Indicator 4 (the proportion of patients with di- 
abetes who smoke and whose notes contain a record that 
smoking cessation advice has been offered in the last 
15 months [5 points]). 
Wandsworth Primary Care Trust, located in southwest Lon- 
don, England, has established comprehensive primary care- 
based diabetes registers. Data for the Wandsworth Prospective 
Diabetes Study were collected before Gune-October2OO3) and 
after (November2005-january 2oo6) the introduction of the 
new general practitioner contract in April 2004. Ethical ap- 
proval for the study was granted by the Wandsworth Local Re- 
search Ethics Committee. 
The study area contains 36 primary care practices and has 
a total registered population Of243 5ig. The population of 
the Wandsworth borough is younger than the average popu- 
lation of England; 74% of people in Wandsworth are under 
45 years of age (compared with 6o% nationally). About i in 5 
Wandsworth residents (22%) belongs to a nonwhite ethnic 
group, and this borough has higher levels of socioeconomic 
deprivation relative to elsewhere in England. 21 
The methods used to develop our register of patients with 
diabetes in Wandsworth have been described previously. 22 In 
brief, we asked all practices in the study area to participate. 
We identified all patients with type i or type 2 diabetes by 
searching computerized general practice records for "read 
codes" for diagnoses of diabetes (Cio) or diabetes care (66A). 
[Read codes are the clinical classification system used in pri- 
mary care in the United 1ringdom. "I Patients who received re- 
peat prescriptions for diabetic medications or whose glycosy- 
fated hemoglobin level was greater than 7.5% were also 
included in our study. Patients under 18 years of age and 
women with gestational diabetes or who received treatment 
for polycystic ovarian syndrome rather than diabetes were ex- 
cluded. A unique patient identifier (National Health Service 
number) was used to link the patient records collected in 
both of the study periods. 
We examined smoking status and cessation advice based 
on information recorded on practice computers during the 
2003 and 2005 study periods. Patients self-identified their 
ethnic background (at registration or during a consultation) 
from closed categories based on the classifications used in 
the 2001 UK cenSUS. 24 Socioeconomic status was assigned to 
individual patients based on their postal code using the 2004 
Index of Multiple Deprivation. " This index is the most com- 
monly used method to determine neighbourhood socioeco- 
nomic status in the United Kingdom and is compiled from a 
variety of sources, including the 2001 UK census, and unem- 
ployment and social security benefit records. Patients were 
grouped into deprivation fifths; patients in group i resided in 
the least deprived areas, and those in group 5 resided in the 
most deprived areas. 
Our statistical analyses were influenced by the study de- 
sign, which included repeated measurements and practice- 
level clustering of participants. Therefore, we used the McNe- 
mar test to examine differences in the frequency distributions 
of indicators between 2003 and 2005. Intrapractice correla 
tions for different variables were: recording of smoking sta- 
tus (2003,0-10,95% confidence intervals ICII 0-05-0. A; 
2005,0.03,95% CI 0-01 smoking cessation advice -0-04), 
(2003,0.05,95% CI 0.02-O. o8; 2005,0-01,95% CI 
-0.02) and actual smoking status (2003, o. 16,95% CI, 0.00 
o. o5-o. 26; 2005,0.14,95% CI 0.05-0.23). 
We used conditional logistic regression with practice as 
the clustering variable to determine the association of the in- 
dicator variables with age, sex, ethnic background and depri- 
vation group. Changes in achievement between the 2 study 
periods were assessed by conditioning 2005 achievements on 
2003 achievements. All standard errors were robust to ac- 
count for the clustering of patients within general practices. " 
An adjusted odds ratio of >i indicates that recording of smok- 
ing status, provision of cessation advice or prevalence of 
smoking was greater than in the reference group after adjust- 
ing for age, sex, ethnic background, deprivation group and 
practice level clustering. 
Results 
The European age-standardized prevalence of diabetes in- 
creased ftOm 36.3 to 42.2 per iooo population in all age groups 26 
between 2003 and 2005 . 
Of the 36 practices in the study area, 
32 agreed to participate in the study. We identified 4.284 adults 
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(ý! 18 years) with diabetes who were registered with the 32 prac- 
fices in both the 2003 and 2005 study periods (2227 men, 2057 
women). The percentage of missing data in patient records was 
low (2.90/0). We therefore restricted our analyses to records with 
complete information; thus, missing data had little effect on our 
conclusions. The 4 practices that did not participate in our study 
accounted for less than 6% of the registered population in the 
study area. The practices that did not participate were smaller (3 
had fewer than 3000 patients) and were located in more de- 
prived areas than the participating practices. 
Smoking status was significantly more likely to be ever 
recorded in 2005 than in 2003 (98.8% v. go. o%, p<o. ooi). 
The proportion of patients whose smoking status was 
recorded in the 15 months before the study period was also 
greater in 2005 than in 2003 (86.7% v. 67.6%, p<o. ooi, 
Table i). The greatest improvements in the recording of 
smoking status were observed among women and nonwhite 
ethnic groups (except Bangladeshi) after adjustment for age, 
sex, ethnic background, deprivation status and practice-level 
clustering. The lower recording of smoking status in 2003 
among men and among the white British, white Irish and 
Bangladeshi groups was not attenuated in 2005. However, 
lower recording of smoking status in 2oo3 among younger 
adult patients (18-44 years) was attenuated in 2005. 
The proportion of patients with documented smoking ces- 
sation advice increased from 48. o% in 2-003 to 83.5% in 2005 
(p < o. ooi, Table 2). This increase was not influenced by age, 
sex, ethnic background or deprivation status. The variation in 
the provision of smoking cessation advice evident between 
age and ethnic groups in 2003 was attenuated in 2005. 
The prevalence of smoking among patients with diabetes 
decreased significantly from 20.0% in 2003 and to A. 2% in 
Table 1: Patients with diabetes whose smoking status was recorded in the 15 months before the 2003 and 2005 study periods 
Characteristic No. (%) of patients 
Smoking status recorded, 
% of patients 
2003 2005 % change Adjusted OR (95% CI)* 
Age, yr (n = 4284) 
18-44 557 (13.0) 59.3 84.6 25.3 1.00S 
45-54 676 (15.8) 66.7$ 87.9 21.2 0.92 (0.59-1.44) 
55-64 1165 (27.2) 67.0$ 86.4 19.5 0.80 (0.54-1.17) 
65-74 1212 (28.3) 68.8$ 86.6 17.8 0.78 (0.54-1.14) 
ýý 75 674 (15.7) 74.2$ 88.0 13.8 1.00 (0.65-1.54) 
Sex (n = 4284) 
Mate 2227 (52.0) 63.1 82.7 19.6 1.005 
Female 2057 (48.0) 72.4$ 91A 18.7 2.01 (1.59-2.54) 
Ethnic background (n 4074)t 
White British 1360 (33.4) 68.3 83.8 15.4 1.005 
Black Caribbean 813 (20.0) 73.1$ 90.5$ 17.5 1.53 (1.13-2.07) 
Black African 365 (9.0) 73.7$ 95.1$ 21.4 3.28 (1.92-5.62) 
Indian 464 (11.4) 69.0$ 93.8$ 24.8 2.32 (1.47-3.66) 
Pakistani 296 (7.3) 63.9$ 93.6$ 29.7 2.76 (1.58-4.80) 
Bangladeshi 60 (1.5) 63.3 86.7 23.3 1.67 (0.71-3.94) 
White Irish 166 (4.1) 70.5 84.3 13.9 0.95 (0.59-1.53) 
Other 550 (13.5) 
Deprivation group (n 4150)t 
1 829 (20.0) 67.7 83.6 15.9 1.00S 
2 830 (20.0) 69.0 86.8 17.7 1.20 (0.84-1.72) 
3 B30 (20.0) 65.5 88.3 22.8 1.34 (0.93-1.93) 
4 830 (20.0) 67.2 87.5 20.2 1.31 (0.91-1-90) 
5 831 (20.0) 69.8 86.9 17.1 1.18 (0,80-1.73) 
Total 67.6 86.7 19.1 ** 
Note: OR = odds ratio, CI = confidence interval. 
'Adjusted for age, sex, ethnic background, deprivation group and practice-level clustering. 
TEthnic background was not available for 210 patients. 
flndex of Multiple Deprivation" was used to assign neighbourhood socioeconomic status; patients in group 1 lived in the least deprived areas, and those 
in group 5 
lived in the most deprived areas. A deprivation group could not be assigned for 134 patients. 
SReference group. 
ISignificantly different from reference group after adjustment for age, sex, ethnic background, deprivation group and practice-level clustering. 
"Change in percentage significant (p < 0.001) using McNemar test. 
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2005 (p < o. ooi, Table 3). Reductions in smoking prevalence provision of support for smokers with diabetes in primary 
were lower among women than among men (adjusted odds care settings. Both the recording of smoking status and the 
ratio 0-71,95% C1 0.53-0-95) and lower in the black African documented delivery of smoking cessation advice increased 
and Bangladeshi groups than in the white British group. In significantly between 2003 and 2-oo5. The prevalence 
2005, the smoking rates differed significantly with age of smoking decreased significantly over this period, al- 
6%-2-5-I%), sex (women, 11.5%; men, 2o. 6%) and ethnic (io though these reductions were lower among women than . 
background (4-9%-24.9%). The higher smoking rates ob- among men. 
served in 2003 among younger adults (18-44 years), men and The effectiveness of smoking cessation interventions in 
in both the white British and white Irish groups were not at- primary care has been demonstrated through randomized 
tenuated in 2005. controlled trials in both the general population and among 
people with diabetes . 
1111,2' However, few studies have exam- 
Interpretation ined whether such interventions have a differential impact 
across socioeconomic and ethnic groups and whether such 
our study showed that the implementation of a pay-for- an effect contributes to health inequalities. " We found no evi- 
performance initiative in the United Kingdom increased the dence to suggest that pay-for-performance incentives in- 
creased variation in support for smokers and smoking rates 
Table 2: Proportion of patients with diabetes who were given 
smoking cessation advice in the 15 months before the 2003 and Table 3: Prevalence of smoking among patients with diabetes 
2005 study periods during the 2003 and 2005 study periods 
% of patients % of patients 
% Adjusted OR % Adjusted OR 
Characteristic 2003 2005 change (95% CI)* Characteristics 2003 2005 change (95% Cl)* 
Age, yr Age, yr 
18-44 42.3 80.7 38.5 1.00t 18-44 29.7 25.1 -4.6 1.00t 
45-54 50.7 79.6 28.9 1 ý54 
(0.51-4.59) 45-54 25.4 20.3 -5.1 1.32 (0.79-2.20) 
55-64 47.9 87.3 39.5 1.74 (0.60-5.03) 22.45 18.8S -3.6 1.01 (0.64-1.59) 55-64 
65-74 52.0§ 86.1 34.1 2.97 (0.88-9.99) 65-74 17.1§ 13. OS -4.1 0.74 (0.47-1.18) 
>- 75 43.4 80.3 36.9 0.92 (0.26-3.31) 2t 75 13.5S 10.65 -2.9 0.65 (0.38-1.12) 
Sex Sex 
Mate 51.8 83.2 31.4 1.00t Mate 24.8 20.6 -4.2 1.00t 
Female 41.3 84.2 42.9 1.76 (0.79-3.92) Female 15. OS 11.5S -3.5 0.71 (0.53-0.95) 
Ethnic background Ethnic background 
White British 47.0 87.9 40.9 1.00T White British 27.9 23.1 -4.8 1.00T 
Black Black 
Caribbean 48.4 88.1 39.7 2.78 (0.84-9.17) -3.2 Caribbean 16.6S 13.45 0.69 (0.47-1.01) 
Black African 56.5 83.3 26.8 0.40 (0.08-1.95) Black African 6.9S 4.95 -1.9 0.33 (0.17-0.67) 
Indian 48.1 94.0 45.9 1.15 (0.23-5.85) Indian 12.55 10-85 -1.7 0.87 (0.50-1.52) 
Pakistani 62.1S 74.1 12.0 0.51 (0.10-2.48) Pakistani 12.1S 9.1s -3.0 0.76 (0.38-1.53) 
Bangladeshi 83.3 75.0 -8.3 - Bangladeshi 12.25 6.75 -5.6 
0.12 (0.02-0.72) 
White Irish 46.7 87.8 41.1 8.51 (0.93-77.96) White Irish 28.1 24.9 -3.3 1.55 (0.85-2.80) 
Deprivation group Deprivation groupt 
1 48.3 80.2 31.9 1.00t 1 15.8 12.3 -3.5 1.00t 
2 52.5 81.8 29.4 0.61 (0.14- Z. 69) 21.3 14.8 -6.5 0.84 (0.50-1.42) 2 
3 42.6 82.9 40.3 0.72 (0.16-3.12) 3 20.8 17.1 -3.7 1.47 (0.89-2.44) 
4 48.4 84.8 36.4 0.50 (0.12-2.12) 4 21.3 17.8 -3.5 1.46 (0.87-2.45) 
5 47.4 88.2 40.8 0.62 (0.13-3.02) 5 22.2 19.5 -2.7 1.39 (0.81-2.38) 
Total 48.0 83.5 35.5$ Total 20.0 16.2 -3.8$ 
Note: OR odds ratio, C1 = confidence interval. Note: OR odds ratio, Cl = confidence interval. 
'Adjusted for age, sex, ethnic background, deprivation group and practice- *Adjusted for age, sex, ethnic background, deprivation group and practice- 
level clustering. level clustering. 
tPatients in group 1 lived in the least deprived areas, and those in group 5 tPatients in group I lived in the least deprived areas, and those in gFoup 5 
lived in the most deprived areas. lived in the most deprived areas. 
tReference group. tReference group. 
§Significantly different frorn reference group after adjustment for age, sex, SSignificantty different from reference group after adjustment 
for age, sex, 
ethnic background, deprivation group and practice-(eve[ clustering. ethnic background, deprivation group and practice-level clustering. 
Khange in percentage significant (p , 0.001) using McNemar test. $Change in percentage significant (P < 0.001) using McNemar test. 
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across key demographic variables such as age, sex, ethnic 
background and deprivation status. 
Evaluating the effectiveness of pay-for-performance pro- 
grams is important given that previous studies have sug- 
gested that the rate of smoking among patients with dia- 
betes is similar to the rate in the general population and 
may not have declined in recent years. For example, the 
prevalence of smoking in the United States among adults 
with diabetes remained virtually static between 1988-1994 
(16.3%) and i999-2ooo (15.9%). " Similarly, in Sweden the 
prevalence of smoking among patients with diabetes who 
were less than 6o years of age increased slightly, from 
21.5% in 1996 to 23.8% in 2003. " A recent British study 
found that the prevalence of smoking among white Euro- 
peans with diabetes (men, 22.2%; women, 20.0%) was 
similar to the prevalence in the general population. ' our 
findings indicate that smoking rates are comparable 
among people with and without diabetes within many eth- 
nic minority communities in Britain. " 
Most previous studies that compared smoking prevalence 
over time used data from 2 or more cross-sectional surveys 
of groups of patients that may systematically differ . 
28,29 We 
are cautious in attributing the changes observed in our study 
to pay-for-performance incentives given the limitations of 
our study design. Some of the reduction in smoking preva- 
lence may have been attributable to other cessation interven- 
tions, to improved recording of smoking status or to a secu- 
lar trend of reduced tobacco use. The new contract for 
general practitioners in the United Kingdom was introduced 
nationally; thus, evaluation of its impact by more rigorously 
designed studies, such as randomized controlled trials, was 
not feasible. We were unable to confirm smoking status us- 
ing objective methods such as salivary cotinine measure- 
ment, because these methods are not in routine use in clini- 
cal practice in the United Kingdom. We were also unable to 
assess the quality of cessation advice that was offered. All but 
4 practices in the study area participated in our survey. 
Hence, our findings are representative of the care provided in 
this diverse, inner-city location. 
Pay-for-performance incentives appear to be effective in 
increasing the delivery of cessation advice given by primary 
care physicians and in reducing the prevalence of smoking 
among patients with diabetes. However, financial incentives 
are likely to be most effective in reducing the prevalence of 
smoking when combined with other quality improvement 
initiatives within a comprehensive tobacco control strategy. 
These other initiatives include active dissemination of clinical 
guidelines on smoking cessation, such as those recently pub- 
lished in the United Kingdom, " and ongoing training and 
support for front-line staff. Health care planners in other 
countries may wish to consider the introduction of similar 
pay-for-performance incentives for primary care physicians. 
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BACKGROUND: The UK has a universal health care 
system that is free at the point of access. Over the past 
decade, the UK government has implemented an ambi- 
tious agenda of quality improvement initiatives in 
chronic disease management. 
may have led to more systematic and equitable pro- 
cesses of care for diabetes but have not addressed 
ethnic disparities in intermediate clinical outcomes. 
KEY WORDS: diabetes; primary care: quality, ethnicity. 
DOI: 10.1007/sll6O6-007-0267-4 
OBJECTIVE: To assess the quality of diabetes care and 
intermediate clinical outcomes within a multiethnic 
population after a sustained period of investment in 
quality improvement. 
DESIGN: Population based cross-sectional survey, us- 
ing electronic general practice records, carried out 
between November 2005 and January 2006. 
PATIENTS: Seven thousand six hundred five adults 
(ý! 18 years) with diabetes registered with 32 primary 
care practices. 
MEASUREMENTS: Percentage achievement by ethnic 
group (black, south Asian, or white) of the quality 
indicators for diabetes in a new pay-for performance 
contract. 
RESULTS: There were only modest variations in record- 
ing of process measures of care between ethnic groups, 
with no significant differences in recent measurement of 
blood pressure, HbAlc, cholesterol, micro-albuminuria, 
creatinine, or retinopathy screening attendance. Blacks 
and south Asians were significantly less likely to meet all 
three national treatment targets for diabetes (HbAlc< 
7.4%, blood pressure:! ý145/85 mmHg, total cholester- 
ol: 5 5 mmol/L [ 193 mg/dL]) than whites (25.3%, 24.8%, 
and 32.0%, respectively). 
CONCLUSIONS: Our findings suggest that substantial 
investment in quality improvement initiatives in the UK 
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INTRODUCTION 
Diabetes is a growing public health concern worldwide. The 
prevalence of diabetes is increasing rapidly, and diabetes 
contributes significantly to overall health disparities in many 
countries. ' South Asians (people with ancestry in countries 
from the Indian subcontinent) comprise more than one-fifth of 
the global population and have a particularly high prevalence 
of diabetes-related morbidity and mortality. 2 Minority ethnic 
groups living in developed countries such as the UK and 
United States generally have a higher prevalence of diabetes 
and higher mortality rates than the general population. 
3 
Disparities in access to high quality diabetes care may be an 
important deterininant of variations in health outcomes . 
4-6 To 
help reduce such disparities. the UK government has targeted 
all sectors of the population when implementing new health 
7 policies. Furthermore, considerable investment has been 
made in the UK since 1997 to improve the quality of clinical 
services for diabetes and to reduce variations in care. 
9 This 
investment includes the National Service Framework for Dia- 
betes in 20019 and the implementation of the new family 
practitioner contract in 2004.10 Through this contract. the UK 
government has linked a significant proportion of family practi- 
tioners'income to performance against key quality targets. 
The structure of primary care in the UK offers some unique 
opportunities for examining the utilization and quality of 
primary health care services. 
" Through its National Health 
Service (NHS), the UK government provides universal health 
coverage, and most health services, including consultations 
with primary care physicians and specialist physicians, and 
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laboratory investigations, are free at the point of care. In 
addition to this, people with diabetes also receive free pre- 
scription drugs for diabetes and any other medical condition 
they have, and this entitlement is not linked to income or 
eniployment. Hence, there are no financial barriers to access 
for care for people with diabetes In the UK. 
In this paper, we present findings from a population-based 
study that examines diabetes care in an urban multiethnic 
population. Our primary hypothesis is that the recent investment 
in quality improvement initiatives in the UK has addressed 
known disparities In diabetes care between ethnic groups. 
PATIENTS AND METHODS 
The Wandsworth Prospective Diabetes Study aims to examine 
the quality and outcomes of care in a diverse ethnic popula- 
tion. Through the study, primary care practices in Wandsworth 
have established comprehensive primary care-based diabetes 
registers. 12 Data for the present study were collected from 
primary care practices between November 2005 and January 
2006. The study was approved by Wandsworth Research 
Ethics Committee. 
Setting and Participants 
The area covered by the study contained 36 primary care 
practices with a total registered population of 243,519 
patients. Thirty-two of these practices took part in the study, 
providing 94.3% coverage of the registered population of the 
study area. The population of Wandsworth is younger than 
that of England, with 74% being under 45 years (compared 
with 60% nationally). Around one in five residents (22%) belong 
to a nonwhite ethnic group, and Wandsworth has higher levels 
of economic deprivation relative to elsewhere in England. 
Identification of Diabetes Patients 
The methods used to develop our disease register for diabetes 
have been described previously. 12 In brief, all practices in the 
study area were invited to participate. All people with Type 1 
and 1ýrpe 2 diabetes were identified from computerized family 
practice records by searching for diagnoses of diabetes or 
diabetes care. Records were also searched to identify patients 
receiving medications for diabetes or patients with a HbAlc 
greater than 7.4%. A total of 389 patients, who were either 
under 18 years, women with gestational diabetes, or women 
receiving treatment for polycystic ovarian syndrome rather 
than diabetes, were excluded. 
Study Variables 
We examined quality indicators for diabetes from the new UK 
family practitioner contractlo in our population between 
November 2005 and January 2006. Each indicator is based 
on clinical information recorded on the practice computer 
within the previous 15 months. Patients self-identified their 
ethnic group to the primary care practices based on classift- 
cations that map to the 2001 UK census, ' 3 either at 
registration or during a consultation at the practice. We 
categorized ethnicity into three groups (white British, black, 
or South Asian) for our analyses. Neighborhood socioeconomic 
JGIM 
status was assigned to Individual patients based on their 
postcode (equivalent to ZIP code) using the Index of Multiple 
Deprivation 2004.14 The Index of Multiple Deprivation is the 
most commonly used method of measuring neighborhood 
socioeconomic status in the UK and is compiled from a variety 
of sources, including the 2001 UK census and unemployment 
and social security benefits records. 
Statistical Analyses 
Odds ratios with 95% confidence intervals for quality indica- 
tors were determined for each ethnic category (with whites 
acting as reference group), adjusted for age, gender, and 
neighborhood socioeconomic status. Clustering of patients 
within general practices was taken into account by estimating 
robust standard errors. ' 5 as patients from the same practice 
are assumed to share some things in common violating the 
assumption of independence. Statistical analyses were per- 
formed using Stata 8.2. 
RESULTS 
We Identified 7,605 adults (ýý! 18 years) with diabetes in the 32 
participating primary care practices-, 3,945 (51.9%) patients 
were men. and 3,660 (48.1 %) were women. The European age 
standardized prevalence of diabetes was 42.2 per 1,000 
population. Ethnicity was recorded in 93.1% of the sample 
(34.9% were white British, 25.7% black, and 19.8% south Asian). 
Processes of Care Recorded 
Recording of process measures for diabetes care varied only 
minimally between ethnic groups. There were no significant 
differences in recorded measurement of blood pressure, 
HbAlc, cholesterol, micro-albuminuria, creatinine, or retinop- 
athy screening attendance between the white, black and south 
Asian groups. Blacks were significantly more likely to be asked 
about their smoking status and to have their body mass index 
and peripheral pulses measured than whites, but less likely to 
be offered smoking cessation advice if they were smokers 
(Table 1). South Asians were more likely to be asked about 
their smoking status and to have their peripheral pulses 
measured than whites. 
Achievement of Intermediate Clinical Outcome 
Indicators 
The black and south Asian groups were significantly less likely 
to meet all three treatment targets (for blood pressure, HbAlc, 
and cholesterol control) than the white group (Table 2). The 
black group had significantly poorer blood pressure and 
HbAlc control than the white group. The south Asian group 
had significantly poorer HbAlc control, but better cholesterol 
control, than the white group. 
DISCUSSION 
We found onýy modest variations in recording of process 
measures of care between blacks, whites, and south Asians, 
with no significant differences in recent measurement of blood 
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pressure, HbAlc, cholesterol, micro-albuminuria, creatinine, 
or retinopathy screening attendance. However, we identified 
considerable ethnic disparities in intermediate clinical out- 
comes. with blacks and south Asians significantly less likely to 
meet all three treatment targets for diabetes than whites. 
These disparities were present-after controlling for age, 
gender, and neighborhood socioeconomic status-in a health 
care system that provides universal health coverage and has 
been subject to an ambitious program of quality improvement 
over the past decade. 
Ethnic dispailties in diabetes care and intermediate out- 
comes have been well documented in U. S. health care 
settings. 6.16 our findings are also in keeping with other UK 
studies 17,18 that have found poorer glycemic control among 
south Asians attending primary and secondary care settings in 
other areas of the UK. This may be because of differential 
management of byperglycemia across ethnic groups, as there 
is evidence of lower insulin presciibing in minority ethnic 
patients when compared to whites. ' q- In addition, our finding of 
poorer blood pressure control among black patients is consis- 
tent with previous UK and U. S. studies. 20.2 1 However, most 
previous UK studies have had relatively small samples, only 
included people of European or south Asian origin, or were 
conducted before the implementation of the new pay for 
performance primary care contract, which incentivized family 
practitioners to provide higher quality care. 
Table 1. Ethnicity and Recording of Processes of Care (% and 
AORs) 
White 
% AORG % 
Black 
AOR 
South Asian 
% AORc' 
BMI 85.7 1.00 89.9 1.48 87.4 1.21 
measured (1.19- (0.92- 
1.86) 1.59) 
Smoking 85.7 1.00 89.9 1.88 87.4 2.24 
status (1.45- (1.74- 
determined 2.42) 2,88) 
Smoking 87.8 1.00 83.4 0.65 84.5 0.73 
advice (0,42- (0.41- 
provided 0,99) 1.30) 
HbAlc 84.7 1.00 86.1 1.14 82.5 0.90 
measured (0.89- (0.70- 
1.47) 1.16) 
Blood 96.1 1.00 96.0 0.93 94.0 0.71 
pressure (0.66- (0.49- 
measured 1.31) 1.01) 
Retinal 65.6 1.00 62.0 0.91 62.3 0.92 
screening (0.77- (0.75- 
undertaken 1.07) 1.11) 
Cholesterol 83.5 1.00 85.6 1.12 81.1 0.89 
measured (0.88- (0.65- 
1.43) 1.22) 
Micro- 39.7 1.00 40.2 1.07 35.6 0.86 
alburninuria (0.94- (0.68- 
measured 1.22) 1.08) 
Peripheral 35.1 1.00 47.0 1.59 43.1 1.41 
pulses (1.24- (1.04- 
measured 2.05) 1.92) 
Creatinine 62.8 1.00 64.6 1.11 60.3 0.95 
measured (0.98- (0.70- 
1.26) 1.28) 
"Odds ratios (95% conficletice intervals) have beent adjusted for age, 
gender, socioeconomic deprivation, and practice level clustering; refer- 
ence group=white 
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Table 2. Ethnicity and Achievement of Intermediate Outcome 
Indicators M and AORs) 
White 
% AORa % 
Black 
AORc' 
South Asian 
% AORO 
Cholesterol: 5 69.3 1.00 70.2 1.17 71.6 1.24 
5 mmol/L (0.97- (1.02- 
1.42) 1.50) 
Blood 72.7 1.00 64.3 0.68 71.5 0.94 
pressure< (0.59- (0.74- 
145/85 0.78) 1.21) 
HbAlc:! ý7.40/b 48.0 1.00 42.8 0.77 35.5 0.66 
(0.67- (0.54- 
0.87) 0.80) 
All three 32.0 1.00 25.3 0.76 24.8 0.76 
targets met (0.67- (0.59- 
0.87) 0.98) 
"Odds ratios (95% confidence intervals) have been acyusted for age, 
gender, socioeconomic deprivation, and practice level clustering; refer- 
ence group=white 
This is one of the few population-based studies to examine 
ethnic variations In diabetes management in a multiethnic 
population using individual patient level data. Some of the 
variation in care we identified may be because of differences in 
recording practice, which may underestimate the actual 
quality of care received. However, data for some intermediate 
outcome measures (HBAIc and cholesterol) are electronically 
downloaded from the laboratory into patient records. People 
with diabetes were identified from computerized records using 
algorithms based upon diagnostic and diabetes care codes. We 
have previously shown that computer searches based on 
diagnostic codes for diabetes alone have a low sensitivity, as 
they may miss up to a third of cases. 12 We used a more 
comprehensive search strategy to compensate for this under- 
recording of diabetes. All but four primary care practices 
within the study area participated in our survey. Hence, our 
findings provide a comprehensive and typical picture of the 
care provided in this ethnically diverse, urban location. 
Whereas our study provides an informative snapshot of 
cur-rent levels of care, use of cross-sectional data do not permit 
us to determine whether there is a causal link between quality 
initiatives and diabetes care. More robust studies using 
longitudinal data with multiple measurement points and 
longer term follow-up of patients are required to better 
evaluate the impact of these initiatives. 
In conclusion, our findings suggest that substantial invest- 
ment in quality improvement initiatives In the UK may have led 
to more systematic and equitable processes of care for 
diabetes. However, disparities in intermediate clinical out- 
comes have persisted, suggesting that access to high quality 
health care, although important, remains only one facet of an 
effective strategy to tackle health disparities. Additional strat- 
egies targeting ethnic minority groups are therefore required to 
reduce disparities in chronic disease outcomes. 
Acknowledgements: We thank the primary care practices that 
participated in the study. Ethical approval was granted by Wands- 
worth Local Research Ethics Committee. 
Funding1support: The Wandsworth Pr&nary Care Research Centre 
and the Wandsworth Prospective Diabetes Study arefunded by the 
Department of Heatth. The Wandsworth Prospective Dtabetes Study 
1320 Gray et at.: Ethnicity and Quality of Diabetes Care 
has also received support from the MRC through the Virtual 
Organisation of 11-iaLs and Epidemiological Studies project. SS holds 
a National Postdoctoral Award from the UK Department of Health 
Research Capacity Development Program. Imperial College receives 
a contribution toward AM's salary from the English Diabetes 
Research Network. The sponsor was not involved in the design 
and conduct of the study; collection, management, analysis, and 
interpretation qf the data; and preparation, review, or approval of the 
manuscript. 
Conflict of interest: None disdosed. 
Corresponding Author: Christopher Miffett, AfSc MFPH, Specialist 
Rainee in Public Health; Department of Prirncu-y Care & Social 
Medicine, Imperial College Faculty of Medicine, Reynolds Building, 
St Dunstan's Road, London W6 81ZP LTK (e-mad: c. milletWimperial. 
ac. u1c). 
REFERENCES 
1. World Health Organization. Preventing chronic diseases: A vital 
Investment: WHO global report. October 2005 http: //xvw%v. xvlio. tnt/ 
clip/ chronic-di sea sereport / en / Accessed 17th April 2007 
2. Mather H, Chaturvedi N, Fuller J. Mortalityand morbidity from diabetes 
in South Asians and Europeans: 11-year follow-up of the Southall 
Diabetes Survey, London, UK. Diabctic Medicine 1998; 15 (1): 53-9, 
3. Lanting L. Joung 1. Mackenbach J, Larnberts S, Bootsma A. Ethnic 
differences in mortality, end-stage complications, and quality of care 
among diabetic patients. Diabetes Care 2005; 28(9): 2280-8. 
4. Saaddine JB, CadweH B, Gregg EW, et al. Improvements in diabetes 
processes of care and intermediate outcomes: United States, 1988-2002. 
Ann Intern Med 2006: 144: 465-74. 
5. Szczepura A. Systematic review of ethnicity and health service access for 
London. NHS London Regional Offices: The Research lZindtngs Register; 
2002 Jan. Report No.: Summary Number 666. 
6. Trivedl AN, Zaslavsky AM, Schneider EC, Ayanian JZ. Trends in the 
quality of care and racial disparities In Medicare managed care. N Engl J 
Med. 2005; 353(7): 692-700 (Aug 18). 
7. Department of Health. Tlackling Health Inequalities. A Programme for 
Action. London. Department of Health. 2003. http: //%xr%vxv. dh. gov. uk/ 
PolicyAndGuidance/fs/en Accessed 17th April 2007 
JGIM 
Leatherman S, Sutherland K. The Quest for Quality in the NHS. A 
Mid-term Evaluation of the Ten-Year Quality Agenda. The Nuffield 
Trust 2003 
9. Department of Health. National Service Framework for Diabetes. 
Department of Health 2001 http: //iv%v%v. dli. go, ýý. Lik/PolicvAndGuidance/ 
fs/en Accessed 17th April 2007 
10. Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs 
in family practices in the United Kingdom. N Engl J Med. 2006: 355 
(4): 375-84 (Jul 27). 
11, Gnant S, Majeed A. A user's guide to data collected in primary care in 
England. Eastern Public Health Observatory, Cambridge. UK, 2006. 
12. Gray J, Orr D. Majeed A. Use of Read codes in diabetes management in 
a south London primary care group: implications for establishing disease 
registers. BMJ 2003: 326: 1130-3 
13. Office for National Statistics. UK 2001 Census http: //w-%kw. statisUcs. 
gov. uk/census/ Accessed 17th April 2007 
14. Department of Communities and Local Government. Index of 
Multiple Deprivation 2004. Department of Communities and Local 
Government http: //wiv%v. cominunities. gov. uk/index. asp? id=1128444 
Accessed 17th April 2007 
15. Huber, P. J. The behavior of maximum likelihood estimates under 
nonstandard conditions. In: Proceedings of the Fifth Berkeley Sympo- 
sium on Mathematical Statistics and Probability. Berkeley, CA: Univer- 
sity of California Press: 1967: (1)221-3. 
16. Halanych JH, Wang F. Miller DR, et al. Racial/ethnic differences in 
diabetes care for older veterans: accounting for dual health system use 
changes conclusions. Med Care. 2006.44(5): 439-45 (May). 
17. McElduff P, Edwards R. Burns J, et al. Comparison of processes and 
intermediate outcomes between South Asian and European patients 
with diabetes in Blackburn, north-west England. Diabetic Medicine 
2005: 22(9): 1226-33. 
18. Mukhopadhyay B, Forouhl N, Fisher B. Kesson C, Sattar N. A 
comparison of glycaemic and metabolic control over time among south 
Asian and European patients withType 2 diabetes: results from follow- 
up in a routine diabetes clinic. Diabetic Medicine 2006: 23(l): 94-8. 
19. Millett C, Gray J, Saxena S. Netuvell G. Khuntl K. Majeed A. Ethnic 
disparities in diabetes management before and after the introduction of 
pay for performance in the UK. PLoS Medicine 2007; 4(6): eI91 
20. Wolfe C, Smeeton N, Coshall C, THUng K, Rudd A. Survival differences 
after stroke in a multiethnic population: follow-up study with the south 
London stroke register. BMJ. 2005: 331(7514): 431 (Aug 20). 
21. Chaturvedt N, McKeigue P, Marmot M. Resting and ambulatory blood 
pressure differences in Afro-Caribbeans and Europeans. Hypertension 
1993,22: 90-96. 
journal of Public Health I Vol. 29, No. 4, pp. 413-419 1 d(. )i: l0. l093/pubmed/fclmO58 ! Advance Access Publication 24 September 2007 
Socio-economic status, ethnicity and diabetes management: 
an analysis of time trends using the health survey 
for England 
Christopher Millett', Sonia Saxenal, Anthea Ng', Arch Mainous, 1112, Azeern Majeed' 
'Department of Primary Care and Social Medicine, Imperial College, London W6 8RP, UK 
'Department of Family Nledicine, INfedical University of South Carolina, Charleston, SC 29425, USA 
Addrcss correspondence to Christophcr Nfillett, E-mail: c-millettevimperial. acuk 
ABSTRACT 
Background The National Health Service (NHS) has invested substantially in recent years to reduce variations in health care for chronic conditions 
such as diabetes. We examined trends in the management of diabetes in England between socio-economic and ethnic groups from 1998 to 2004. 
Methods Secondary analyses of Health Survey for England data comparing achievement of national treatment target for blood glucose, blood 
pressure and cholesterol and use of medications in survey respondents with diabetes. 
Results The proportion of respondents with diabetes achieving national treatment targets increased significantly between 1998 and 2004. There 
was a significantly lower increase in blood pressure control in the black group [13.9% (95% confidence interval (CI) 13.0-14.8%)] but higher 
increase in south Asian and white Irish groups when compared to the white British group [15.7% (95% Cl 15.4-16.0%)]. Manual workers 
experienced lower improvements in blood pressure control [15.3% (95% Cl 14.9-15.7%) versus 16.7% (95% Cl 16.2-17.2%)] but higher 
improvements in cholesterol control [10.3% (95% Cl 9.7-10.9%) versus 7.4% (95% Cl 6.8-8.0%)] when compared to non-manual workers. 
Conclusion There were considerable improvements in the management of diabetes in England during a period of sustained investment in health 
care quality but these were not distributed uniformly across ethnic and socio-economic groups. 
Keywords diabetes management, ethnicity, Health Survey for England, socio-economic status, time trends 
Background 
Diabetes is an escalating global epidemic with considerable 
variations in health outcomes between ethnic and socio- 
economic groups. 1,2 Ethr& minority groups within devel- 
oped countries, such as England and the United States (US) 
generally have a higher prevalence of diabetes and higher 
mortality rates than the general population. 3,4 Diabetes- 
related morbidity and mortalitý? are inversely related to 
income and socio-economic status, with higher complication 
rates found in manual, compared with non-manual occu- 
pational groups. 5,6 These inequalities may partly be expl', Uned 
by variable access to high quality diabetes care. 11,8 
Improving the quality of chronic disease management is a 
key component of health policy in many countries. 9,10 
The National Flealth Service (NHS) in England has invested 
substantially in recent years to improve standards and reduce 
variations in health care for individuals widi chronic con- 
ditions such as diabetes. ' 1,12 A key driver for these initiatives 
has been the belief that improved secondary prevention will 
reduce complication rates, demand for hospital services and 
thus overall healthcare spending. 9,13 
For diabetes, this investment includes the National Service 
Framework in 2001,14 National Institute for Clinical 
Excellence ý\IICE) guidelines in 2002 15 and the nm, general 
practitioner contract that introduced pay for performance for 
primary care physicians in 2004.16 The Diabetes National 
Service Framevv'ork sets out a comprehensive national strat- 
egy for the prevention and management of diabetes, includ- 
ing a key target to improve the quality of disease registers 
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in primary care. The fiew general practitioner contract sets 
out national standards for the management of a range of 
chronic diseases and general practitioners receive financial 
incentives for providing high quality care. 
There has been little assessment of the impact of these 
quality initiatives on known variations in access to health 
care and health outcomes, which is a key requirement of all 
new government policies in the UK. 
17 Statistics from the 
first 2 years of the general practitioner contract suggest that 
most practices reached many of the Iiigher Quality and 
outcome Frame-work (QOF) targets for diabetes. 18 Ho-wever, 
these data are aggregated to practice level and do not permit 
examination of variations in care by age, gender, ethnicity or 
income. Moreover, no historical data are available to enable 
comparisons with performance before the implementation 
of the new contract. 
The Bealth Survey for England is an annual survey of 
people living in private households and a primary mech- 
anism for monitoring population health in England. 
The survey is conducted by the National Centre for Social 
Surveys and Research and University College London on 
behalf of the Department of Health. The 1998,1999,2003 
and 2004 surveys examined cardiovascular disease and beha- 
vioural risk factors such as drinking, smoking and eating 
habits; within this, the 1999 and 2004 surveys focused 
on the main ethnic minority communities in England. 
We undertook a secondary analysis of data from these four 
surveys to examine trends in diabetes management within 
ethnic and socio-economic groups. 
Methods 
Sampling and data collection 
Methods for the Health Survey for England are described in 
detail elsewhere. 19 In brief, interviewers obtained household, 
socio-economic and personal details, information on health 
arid illness and health service use from respondents. 
A trained nurse took anthropometric measurements includ- 
ing height and weight and asked respondents about pre- 
scribed medications at a follow-up visit soon after the 
interview according to survey protocols. Blood pressure, 
HbAlc arid total cholesterol were measured in respondents 
aged 16 years and older. No HbAlc measurements were 
Lindertaken in 1998. 
The 1998 and 2003 surveys were conducted with a repre- 
setitatiN. -e sample of the general population, whfflst the 1999 
and 2004 surveys focused on ethnic minority communities 
in%roh, ing a three-stage samphng process; a general popu- n lation sample (approximately half the size of that in the 
previous year), an 'ethnic boost' sample involving stratified 
multistage probabifitý, sampling and a follow up survey of 
569 Chinese households who took part in a Health 
Education Authority survey in 1998. 
We selected respondents aged 40 years and above from 
the 1998,1999,2003 and 2004 surveys who answered yes 
to the question: 'Were you told by a doctor d-lat you had dia- 
betesý'. Interviews with adults in the general population 
sample in 1999 and 2004 did not include cardiovascular 
disease module questions. Wle used wl-Lite British respon- 
dents to the 1998 and 2003 surveys with diabetes as a com- 
parison group. 
Study variables 
We examined control of HbAlc, blood pressure and choles- 
terol against national treatment targets (HbAlc <7.0%, BP 
140/80 mm. Hg and total cholesterol <5.0 m MOI/L) and 
use of medications as they applied to our population in each 
of the 4 years. Independent study variables included social 
class, household income and ethnicity. We collapsed ethrý- 
city into four categories (white British, black, south Asian, 
white Irish) and social class into two categories (manual, 
non-manual) for the analyses due to small numbers. White 
Irish people were considered as a separate ethnic group as 
they have been shown to experience significantly higher all- 
cause mortality than the national average in England and 
20 NVales. Respondents were grouped into approximate 
income quartiles, with those in quartile 1 having the lowest 
incomes and those in quartile 4 having the highest incomes. 
Data analysis 
For each indicator, we describe percentage achievement and 
change in achievement within each ethnic, social class and 
income group standardized by age and gender, with 95% CL 
All analyses were weighted to the general population in 
England, where indicated. We performed statistical analyses 
using Stata 9.1 (TeNas, USA: Stata Corporation). 
Results 
The number of respondents with diabetes aged 40 years and 
over in 1998,1999, '1003 and 2004 surveys were 401,357, 
557 and 372 respecti-vely. 
Use of medications 
Uses of oral hýjDoglycaernic agents (01-LAs), insulin, lipid- 
lowering and antihypertensive medications have all increased 
signýificantly since 1998. The extent of these increases 
differed between ethnic groups. Increases in the use of 
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Table 1 Ethnicity and use of medications 
Lipid-lowering Antihypertensives OHAs Insulin 
1999 2004 Change 95% C/ 1999 2004 Change 95% 0 1999 2004 Change 95% 0 1999 2004 Change 95% 0 
White British 14.1 44.1 30.0 29.6-30.4 38.2 51.3 13.1 12.8-13.4 57.1 63.6 6.5 6.2-6.8 18.8 23.7 4.9 4.6-5.2 
South Asian 13.1 51.6 38.5 37.9-39.1 26.7 55,9 29.2 28.6-29.8 73.5a 79.5" 6ýO 5.5-6.5 17.5 17.8 0.3 -0.2-0.8 
Black 6.7 37.7 31.0 29.9-32ý 1 47.2 54.9 7.7 7.0-8.4 75.1 a 82.5a 7.4 6.7-8.1 30,1 22.9 -7.2 -6.6-7.8 
White Irish 14.4 55,0 40.6 39.3-41 ý9 38.0 55.4 17.4 16.3-18.5 5&6 78.8 20.2 19.2-21.2 27.9 25.8 -2.1 -1.2-3.0 
All groups 13.2 45.4 32.2 31.9-32,5 35.9 52.7 16.8 16.6-17.0 64.7 70.8 6.1 5.9-6.3 20.3 22.4 2.1 1.9-2 3 
OHAs, oral hypoglycaernic agents. 
'Significantly different to the reference group after adjusting for age and gender. 
Table 2 Social class and use of medications 
Lipid-lowering Antihypertensives OHAs Insulin 
1998 2003 Change 95% Cl 1998 2003 Change 95% 0 1998 2003 Change 95% 0 1998 2003 Change 95% 0 
Non-manual 11.8 40.1 28.3 273-28.9 35.1 51.5 16.4 15.9-16.9 57.9 64,2 6.3 5.9-6.7 17.5 18.8 1.3 0.8-1.8 
Manual 14.1 46.1 32,0 31.5-32ý5 41.7 49.9 8.2 7.8-8.6 59.6 65.8 6.2 5.8-6.6 17.7 23.3 5.6 5.2-6.0 
Total 13.0 43.4 30.4 30.0-30.8 38.9 50.6 11.7 11.4-12.0 58.9 65.1 6.2 5.9-6.5 17.6 21.2 3.6 3.3-3.9 
OHAs, oral hypoglycaernic agents. 
Table 3 Income (quartiles) and use of medications 
Lipid-lowering Antihypertensives OHAs Insulin 
1998 2003 Change 95% C l 1998 2003 Change 95% 0 1998 2003 Change 95% 0 1998 2003 Change 95% Cl 
1 16.2 45.1 28,9 27.9-29.9 46.3 61.0 14.7 13.9-15.5 69.1 663 -2.8 -2.1 -3.5 8.2 21.4 13.2 12.1-14.3 
2 12.4 45.1 32.7 31.7-33.7 36.0 45.0 9ýO 8.2-9.8 58.3 61,5 3.2 2.5- 3,9 25.4 27.3 1,9 1,1-2.7 
3 9.9 42.1 32.2 31.4-33.0 49.9 50.8 0.9 0.4-1.4 53.8 65.5 113 11.2 -12.2 1M 19.8 0.0 -M-0.6 
4 13.1 40.6 27.5 26.6-28.4 23.0 41 ý2 
18.2 17A-19.0 55.9 64.9 9.0 8.4- 9.6 16.0 24.5 8.5 7.7-9.3 
Tota 1 12.0 42.9 30.9 30.3-31.5 40.5 49.8 9.3 9.0-9,6 58.3 64.9 6.6 6.3 -6.9 17.5 22.5 5.0 4.6-5.4 
I= lowest income, 4= highest income. 
OHAs, oral hypoglycaernic agents. 
lipid-loNvering and antihypertensive medications were signifi- 
candy higher and insulin significantly lower in the south 
Asian and Irish groups when compared to the white British. 
Increases in prescribing of antih), pertensive medications 
Nvere significantly lower in the black group. South Asian and 
Black respondents were significandy more likely to be taking 
OHAs than white British respondents in both jTears 
(Table 1). 
Increases in the use of lipid-lowering medications and 
insulin were significantly higher and antihypertensive medi- 
cations significantly lower in the manual when compared to 
d-ie non-manual occupational group (Table 2). Increases in 
the use of insulin were significantly higher and the use of 
antihypertensive medications and OHAs significantly lower 
in the lowest income group when compared to the highest 
income group (Table 3). 
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Table 4 EthniCi'Ly and intermediate clinical outcomes 
Cholesterol <5m mollL BP < 140180 mm Hg HbAlc <7.0% 
1999 2004 Change 95% Cl 1999 2004 Change 95%0 1999 2004 Change 95% C/ 
White British 28.3 36.4 8.1 7.6-8.6 32.7 48.4 15.7 15.4-16.0 47.5 
South Asian 37.9 40.6 2.7 1.9-3.5 30.6 49.2 18.6 18.0-19.2 26,5 55.4 28.9 28.3- 29.5 
Black 40.1 65.1 25.0 23.9-26.1 23.8 37.7 13.9 13,0-14.8 15.5 41.9 26.4 25.3- 27,5 
White Irish 42.7 68.2 25.5 23.8-27.2 30.3 55.1 24.8 23.5-26.1 28.4 39.3 10.9 9.6- 12.2 
All groups 32.8 41 ý4 
8.6 8.3-8.9 31.4 48.2 16.8 16.5-17.1 24.4 48.0 23.6 212- 24.0 
Table 5 Social class and intermediate clinical outcomes 
Cholesterol <5m mol/L BP < 140180 rom Hg HbAlc < 7.0% 
1998 2003 Change 95%0 1998 2003 Change 95%0 1998 2003 Change 95%0 
Non-manual 29,0 36.4 7.4 6,8-8.0 30.3 47ýO 16.7 16.2-17.2 - 53.5 -- 
Manual 28.5 38.8 10.3 9.7-10.9 31.6 46.9 15.3 14.9-15.7 - 45.7 - 
Total 28.8 37.4 8.6 8.2-9.0 31.0 47.0 16,0 15.7-16.3 - 49.3 - 
Table 6 Income (quartiles) and intermediate clinical outcomes 
Cholesterol <5m molk BP < 140180 mm Hg HbAlc < 7.0% 
1998 2003 Change 95%0 1998 2003 Change 95% C/ 1998 2003 Change 95%0 
1 30.5 39.5 9.0 8.2-9.8 26.0 48.7 22.7 21.7-23.7 54.8 
2 22.7 39.2 16.5 15,7-173 29.7 47.4 17,7 16.7-18.7 - 39.2 
3 27.7 35.0 7.3 6.7-7.9 30.2 47.0 16,8 16.1-17.5 - 46.0 
4 25.0 473 22.3 21.6-23.0 35.3 49.3 14.0 13.1-14.9 - 45.2 
Total 26.9 40.1 13.2 12.9-13.5 30.5 47.9 17.4 17.0-17.8 - 46.9 
1= lowest income, 4= highest income 
Intermediate clinical outcomes 
The proportion of respondents with diabetes meeting 
national treatment targets for blood glucose, blood pressure 
and total cholesterol increased significantly between 1998 
and 2004. The extent of these increases differed between 
ethnic groups. Improvements in cholesterol control were sig- 
nificantly greater in the black and Irish groups and signifi- 
cantly lo\ý, er in south Asian group when compared to white 
British. Improvements in blood pressure control were sig- 
ilificantly greater in the south Asian and Irish groups but 
significantly lower in the black group when compared to 
white British (fable 4). 
Improvements in blood pressure control were significantly 
lower and improvements in cholesterol control significantlý 
greater in the manual occupation group compared to non- 
manual group ("fable 5). Respondents in the lowest income 
group had a significantly lower improvement in cholesterol 
control but a significantly higher improvement in blood 
pressure control when compared to those in the highest 
income group (fable 6). 
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Discussion 
Main findings of the study 
There has been considerable improvement in the manage- 
ment of diabetes in England during a period of sustained 
investi-nent in health care quality. Despite this improvement, 
fe, xer tlian half of individuals with diabetes met national 
treatment targets for blood pressure, blood glucose and 
cholesterol in '22004. Moreover, improvements in the quality 
of diabetes care have not been uniform across ethnic and 
socio-economic groups. For example, there was a signifi- 
candy lower increase in blood pressure control in the black 
group but higher increase in south Asian and white Irish 
groups when compared to the white British group. 
What is already known on this topic 
Our findings are consistent with previous UK and inter- 
national studies, have found improvements in process 
of care, prescribing of medications and intermediate cl_inical. 
outcomes in diabetes. 21,22,23,24 These improvements prob- 
ably reflect the considerable investment in chronic disease 
management programmes in these countries over the past 
decade. However, available evidence from the United States 
and England indicate that whflst these improvements may 
have been accompanied by an attenuation of variations in 
processes of care, 25 variations in clinical outcomes within dia- 
betes populations frequently persiSt. 26'27 For example, find- 
ings from the National Health and Nutrition Examination 
Survey (NFIANES) Suggest that poorer glycaemic control 
evident in black and Mexican American participants relative 
to whites in the 1988-94 survey had not been attenuated in 
1999-2002, despite publication of national clinical guidance 
218,21) and other quality initiatives in the interim period .A sepa- 
rate Study using data from NHANES and the Behavioural 
Risk Factor Surveillance System found persistently lower 
recording of process measures and worse intermediate out- 
comes between 1988 and 2002 in persons with lower edu- 
cational attainment. 22 In north-west England, McElduff and 
colleagues 30 identified higher Hbalc levels amongst south 
Asians compared to Europeans attending primary and second- 
arly care settings from 1995 to 2001. 
suggesting that universal access to health care by itself wifl 
not address health Inequalities. \X, 'e did though find consider- 
able improvements in the quaht), of diabetes care suggesting 
that national quality initiatives can achieve significant 
improvements in quality of care in a health systern, offering 
universal coverage. 
Limitations of this study 
The Health Survey for England is a national, population- 
based survey and a primary mechanism for monitoring 
population health in England. Comparing outcomes across 
time using cross-sectional surveys may introduce bias, given 
that there may be systematic differences in the participants 
sampled in the different survey years. We combined Indians, 
Pakistanis and Bang-ladeshis into a single ethnic category of 
'south Asians' and black African and Caribbeans as 'blacks', 
due to insufficient numbers. This may have masked differ- 
ences in diabetes management and outcomes in what are 
known to be culturally and epidemiologically heterogeneous 
groups. 31,32,33 Some of the comparisons made may not have 
reached statistical significance due to the small size of our 
sample. \Yle were unable to adjust for certain patient factors, 
such as duration of diabetes and the presence or severity of 
complications, which may have been confounders in the 
relationship between our independent variables and diabetes 
management. 
Our data predate the implementation of a new General 
Practitioner contract in England, a major pay for perform- 
ance initiative, introduced in April 2004. Our findings sug- 
gest that considerable improvements in the management of 
chronic diseases such as diabetes are possible with national 
quality improvement initiatives but without the potential 
benefits of pay for performance. Preliminary findings 
suggest that pay for performance incentives in the new con- 
tract have not addressed ethnic group variations in prescrib- 
ing or intermediate clinical outcomes in diabetes. 34 
However, these findings need to be confirmed with further 
prospective longitudinal studies with longer term follow up. 
What this study adds 
Implications for practice 
The NHS in England offers universal coverage with no 
charges for consultations with primary care physicians or 
specialists. Furthermore, patients with diabetes are exempt 
from prescription co-payments and do not pay towards the 
cost of any of their prescribed medications. Hence, there 
are no financial barriers to access to care for people with 
diabetes. Despite thýis, variations in diabetes care remain, 
There has been considerable improvement in the manage- 
ment of diabetes in England since 1998. However, our find- 
ings suggest that existing quality improvement initiatives in 
England may have had a differential impact across socio- 
economic and ethruc groups. Improved monitoring of the 
impact of universally applied quality initiatives, such as the 
National Service Frarnexworks and General Practitioner con- 
tract, is essential to determine their impact on variations in 
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chronic disease management and health inequalities. Ethical 
approval is not required for this study. 
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SUMMARY 
Objective To examine the association between practice list 
size, deprivation and the quality of care of patients with diabetes. 
Design Population -based cross-sectional study using Quality 
and Outcomes Framework data. 
Setting England and Scotland. 
Participants 55 522 778 patients and 8970 general practices 
with 1852 762 people with diabetes. 
Interventions None. 
Main outcome measures Seventeen process and surrogate 
outcome measures of diabetes care. 
Results The prevalence of diabetes was 3.3%. Prevalence 
differed with practice list size and deprivation: smaller and more 
deprived practices had a higher mean prevalence than larger and 
more affluent practices (3.8% versus 2.8%). Practices with large 
patient list sizes had the highest quality of care scores, even after 
stratifying for deprivation. However, with the exception of retinal 
screening, peripheral pulses and neuropathy testing, differences 
in achievement between small and large practices were modest 
(< 5%). Small practices performed nearly as well as the largest 
practices in achievement of intermediate outcome targets for 
HbAlc, blood pressure and cholesterol (smallest versus largest 
practices: 57.4% versus 58.7%; 70.7% versus 70.7%; and 
69.5% versus 72.7%, respectively). Deprivation had a negative 
effect on the achieved scores and this was more pronounced for 
smaller practices. 
Conclusion Our study provides some evidence of a volume- 
outcome association in the management of diabetes in primary 
care; this appears most pronounced in deprived areas. 
INTRODUCTION 
An association between higher volume and better outcome 
in hospital care is now supported by evidence from more 
than 300 studies, following the seminal report by Luft et 
al. 1,2 Patients with a range of medical conditions receiving 
various treatments or surgical procedures have lower 
mortality rates and otherwise better outcomes if care is 
provided by high caseload providers, whether assessed by 
hospital or by physician. 1,3,4 Most previous studies on the 
volume-outcome relationship have been hospital-based. Yet 
most patients with long-term diseases, including diabetes, 
are managed in primary care. S-7 Volume-outcome relations 
have even greater public health significance in primary care, 
because of the greater numbers of patients with these 
conditions in primary care populations. If larger practices or 
practices with a greater number of patients with chronic 
diseases provided better quality of diabetes care, this would 
have important implications for the future organization of 
primary care services worldwide. 8 
In April 2004, a new contract for General Practitioners 
(GPs) was introduced in the UK, in which a significant 
proportion of practice income is derived from performance 
against targets in a new Quality and Outcomes Framework 
(QOF). 9 The new contract represents a major innovation in 
the organization of primary care services and the first time 
that pay for performance has been used on this scale in any 
health care system. It provides comparative information on 
the quality of care in general practices nationally and unique 
data to measure the quality of primary care experienced by 
the entire national population. These data allow examina- 
tion of factors associated with higher quality of care and 
thus offer lessons about the organization of health services 
to primary health care systems in the UK and abroad. 
We examined the association between general practice 
size and caseload, and outcomes for people with diabetes, in 
English and Scottish general practices using data from the 
new GP contract. Specifically, we considered whether 
prevalence and quality of care scores for diabetes were 
associated with practice size. Second, we examined the 
extent to which the association varied as a function of 
practice diabetes caseload. Finally, we determined whether 
the association between volume/size and outcome was 
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influenced by deprivation. It is well known that deprivation 
influences health outcomes. 10 
METHODS 
Data sources 
The study was carried out using QOF data for England and 
Scotland from the new General Medical Services contract 
for general practices in the UK, introduced from I April 
2004.11 The data comprise 9411 general practices with a 
population of 57 787 662 patients in England and Scotland. 
Practices score points based on their achievement against a 
range of evidence-based clinical indicators and a range of 
indicators covering practice organization and management; 
practice payments are calculated from points achieved. 
The source of QOF data is a national IT system called 
the Quality Management and Analysis System (QMAS). 12 
This single national system ensures consistency in the 
calculation of prevalence and quality achievement. Clinical 
QOF data is extracted from individual practice clinical 
computer systems and sent automatically to QMAS; 
organizational, access, patient experience and additional 
service indicators are entered by the practice directly into 
QMAS via a web-browser. Data from practices without 
QMAS-compliant computer systems are entered manually 
into QMAS. QOF information is collected at an aggregate 
level for each general practice and there is currently no 
patient-specific data within QMAS. 
Selection of processes of care and outcomes 
measured 
There are two types of data: disease prevalence information 
for each disease within the clinical domain of the QOF, and 
data relating to QOF indicator or domain scores. For 
diabetes, 18 process of care measures and outcomes have 
been assessed, based on whether they were performed 
within the last 15 months. Indicators are measured as the 
percentage of people with diabetes who had a recording of a 
process of care or measurement, or achieved the desired 
outcome (e. g. DM 9 is the percentage of patients with 
diabetes with a record of presence or absence of peripheral 
pulses). The indicators for diabetes are based on available 
evidence on the optimal management of diabetes (Box 1). 
The indicators relate to children and adults with both type I 
and type 2 diabetes. Although the care of patients with type 
I diabetes may be shared with specialists, the GP would still 
be expected to ensure that appropriate annual checks had 
been carried out and recorded in the patient's primary care 
medical record. 
Reaching optimal levels of control in people with 
diabetes is often difficult. For this reason two HbAlc 
outcome indicators have been introduced to encourage 
those working with patients with high HbAlc to bring the 
level to <, 10 and <, 7.4. The most commonly identified 
target level for blood pressure in diabetes is 140/80. This is 
the level for which GPs should aim. A slightly higher level 
(145/85) was used in the QOF as the audit standard. We 
excluded the first indicator-that the practice can produce a 
register of all patients with diabetes-as all practices have 
produced a register. Without a register, the denominator 
would be unknown for the practice and it would not be 
possible to calculate prevalence or quafity of care scores. 
Linking of practices to a measure of socio- 
economic status 
Practices were assigned a measure of socio-economic status 
based on their geographical location. We used the 'Index of 
Multiple Deprivation' (IMD, the standard measure of socio- 
economic status in the UK). Practices were linked to 
postcodes using reference tables provided by the National 
Health Service Information Centre for Englandl I and by the 
Information and Statistics Division for Scotland. 13 Both data 
sets employed the same practice identifying codes used in 
the QOF and thus enabled linking of data. Practices were 
mapped to postcode locations using GIS software Map1nfo 
Professional 7.814 and linked to IMI)s for England and 
Scotland. 15,16 Differences between IMI)s for England" and 
Scotland16 are small (English geographic areas, called Lower 
Super Output Areas, are about twice the size of Scottish, 
with a mean population of around 1500)1' and thus 
combined analysis of data was possible. We grouped 
practices into socio-economic tertiles based on the national 
rank of the geographic area in which the practice is located 
(i. e. practices in deprivation group one are located in the 
most deprived 33% of administrative regions nationally). 
Practices were excluded from our analysis if they could 
not be matched to an IMD score via their postcode. 
Practices in Scotland that were not fully part of the contract 
were also excluded from the study. In total, we excluded 
441 (4.1%) practices with 2264884 (3.5%) patients, 
leaving 8970 general practices with a total fist size of 
55522S78, for analysis. We used Stata version 9 for 
analysis. 18 
Exception reporting 
The QOF allows for exception reporting, which has been 
introduced to allow practices not be penalized, NN, here, for 
example, patients do not attend for review, or where a 
medication cannot be prescribed due to a contraindication 
or side-effect. The criteria for exception reporting include: 
patients who are on maximum tolerated doses of 
medication whose levels remain sub-optimal; where a 
patient does not agree to investigation or treatment 
(informed dissent), and this has been recorded in their 
medical records; and where an investigative service or 
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Box 1 Quality and Outcomes Framework (QOF) Indicators for diabetes care 
DM 1A complete register of patients with diabetes for individual practices 
DM 2 The percentage of patients with diabetes whose notes record BMI in the previous 15 months 
DM 3 The percentage of patients with diabetes in whom there is a record of smoking status in the previous 15 months except those 
who have never smoked where smoking status should be recorded once 
DM 4 The percentage of patients with diabetes who smoke and whose notes contain a record that smoking cessation advice has 
been offered in the last 15 months 
DM 5 The percentage of diabetic patients who have a record of HbAlc or equivalent in the previous 15 months 
DM 6 The percentage of patients with diabetes in whom the last HbAl C is 7.4 or less (or equivalent test / reference range depending 
on local laboratory) in last 15 months 
DM 7 The percentage of patients with diabetes in whom the last HbAl C is 10 or less (or equivalent test / reference range depending 
on local laboratory) in last 15 months 
DM 8 The percentage of patients with diabetes who have a record of retinal screening in the previous 15 months 
DM 9 The percentage of patients with diabetes with a record of presence or absence of peripheral pulses in the previous 15 months 
DM 10 The percentage of patients with diabetes with a record of neuropathy testing in the previous 15 months 
DM 11 The percentage of patients with diabetes who have a record of the blood pressure in the past 15 months 
DM 12 The percentage of patients with diabetes in whom the last blood pressure is 145/85 or less 
DM 13 The percentage of patients with diabetes who have a record of micro-albuminuria testing in the previous 15 months (exception 
reporting for patients with proteinuria) 
DM 14 The percentage of patients with diabetes who have a record of serum creatinine testing in the previous 15 months 
DM 15 The percentage of patients with diabetes with proteinuria or micro-alburninuria who are treated with ACE inhibitors (or A2 
antagonists) 
DM 16 The percentage of patients with diabetes who have a record of total cholesterol in the previous 15 months 
DM 17 The percentage of patients with diabetes whose last measured total cholesterol within previous 15 months is 5 or less 
DM 18 The percentage of patients with diabetes who have had influenza immunization in the preceding 1 September to 31 March 
period 
secondary care service is unavailable. National data on 
exception reporting is limited, which meant that we were 
unable to adjust for this in our analyses. 
Analyses 
We studied the volume-outcome effect in two different 
ways. First, we compared practices using the number of 
patients registered with a practice as a measure of practice 
size. We grouped the practices into quintiles according to 
number of patients registered with the practice. Secondly, 
we grouped the practices into quintiles according to the 
number of cases (i. e. patients with diabetes registered with 
the practice). Finally, we studied the effect of deprivation 
on achievement scores. We present percentage achievement 
of quality indicators in each group. Detailed statistical 
analysis was not undertaken as our very large sample size 
compromises meaningful interpretation of results as even 
very minor differences will be statistically significant. 
RESULTS 
In total, there were 1852 762 people with diabetes melhtus 
in the 8970 general practices in this study. Prevalence of 
diabetes mellitus Nvas 3.3%. Practice size varied from 52 to 
36 130 patients (mean 6189). The number of cases of 
diabetes in individual practices varied from 0 to 1142 (mean 
207). The prevalence of diabetes differed according to the 
patient list size of the practice, with smaller practices having 
a higher mean prevalence than larger practices (Table 1). 
However, these differences were reduced when prevalence 
was stratified by practice deprivation scores. Practices in 
deprived areas had the highest prevalence of diabetes. 
Association between practice size, number 
of diabetes cases and quality of care 
Larger practices achieved the highest quality of care scores, 
particularly for process of care measures (Tables 2a and 3a). 
However, with the exception of retinal screening, 
peripheral pulses and neuropathy testing, absolute differ- 
ences in achievement between small and large practices was 
modest (<5%). The performance of small practices was 
broadly similar to larger practices in achievement of 
intermediate outcome targets for HbA I c, blood pressure 
and cholesterol. For example, the same proportion of 
patients achieved the treatment target for blood pressure 
(70.7%) in the smallest and largest practices. There was 
only a 1.3% difference in the proportion of patients 
reaching the treatment target for HbAlc (S7.4 versus 
58.7%). Similar trends were evident between achievement 
of quality indicators and diabetes caseload (i. e. number of 
diabetes cases per practice). 
Association between deprivation and quality 
of care 
Tables 2b and A show the association between practice 
deprivation scores, patient list size and quality of care. 
Practices located in deprived areas performed less well on 2T 
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Table 1 Prevalence of diabetes according to the practice patient list size, deprivation and by the list size and deprivation 
Practices Practices Patients Average Diabetes 
(n) MM list size prevalence 
278 
List size group (n patients) 
0-2999 2058 22.9% 8.1% 2192 3.6% 
3000-4999 2081 23.2% 14.7% 3924 3.5% 
5000-7999 2305 25.7% 26.6% 6402 3.4% 
8000-9999 1101 12.3% 17.8% 8954 3.3% 
>, 10 000 1425 15.9% 32.8% 12 793 3.2% 
Deprivation group* 
1 (Deprived) 3635 40.5% 37.2% 5676 3.6% 
2 (Intermediate) 3275 36.5% 37.0% 6271 3.3% 
3 (Affluent) 2059 23.0% 25.8% 6968 2.9% 
Deprivation group*: List size group 
Deprived: 0-2999 1012 11.3% 4.1% 2240 3.8% 
Deprived: 3000-4999 887 9.9% 6.2% 3889 3.9% 
Deprived: 5000-7999 887 9.9% 10.2% 6365 3.6% 
Deprived: 8000-9999 387 4.3% 6.3% 8976 3.5% 
Deprived: > 10 000 462 5.2% 10.4% 12 545 3.5% 
Intermediate: 0-2999 736 8.2% 2.8% 2120 3.5% 
Intermediate: 3000-4999 745 8.3% 5.3% 3941 3.5% 
Intermediate: 5000-7999 843 9.4% 9.7% 6415 3.3% 
Intermediate: 8000-9999 413 4.6% 6.6% 8917 3.4% 
Intermediate: > 10 000 538 6.0% 12.5% 12922 3.2% 
Affluent: 0-2999 310 3.5% 1.2% 2204 3.1% 
Affluent: 3000-4999 448 5.0% 3.2% 3964 3.0% 
Affluent: 5000-7999 575 6.4% 6.7% 6442 3.0% 
Affluent: 8000-9999 301 3.4% 4.9% 8976 2.9% 
Affluent: >, 10 000 425 4.7% 9.9% 12 900 2.8% 
Tractices are grouped into three bands according to their deprivation scores. 
quality measures than those based in affluent areas. 
Differences in achievement between small practices in 
deprived areas and large practices in affluent areas were 
considerable on some indicators. For example, the 
percentage of patients with a record of neuropathy testing 
differed by 15%. The general trend of higher achievement 
with increasing practice size was less marked in affluent 
areas. For example, smaller practices were more likely to 
achieve the lower treatment target for HbAlc (, <, 7.4%) 
than larger practices in affluent areas. 
DISCUSSION 
Larger general practices achieved the highest quality of care 
scores for diabetes management, even after stratifying for 
deprivation. However, with the exception of retinal 
screening, peripheral pulses and neuropathy testing, 
absolute differences in achievement between small and 
large practices was modest (< 5%). The performance of 
small practices was broadly similar to larger practices in 
achievement of intermediate outcome targets for HbAIc, 
blood pressure and cholesterol. For example, the same 
proportion of patients achieved the treatment target for 
blood pressure (70.7%) in the smallest and largest 
practices. Deprivation had a negative effect on achieved 
scores and this appeared more marked in smaller practices. 
Principal findings 
Findings from this large population-based study provide 
some evidence of an association between volume and 
outcomes in the management of diabetes in primary care. 
Strengths and weaknesses of the study 
This is the largest study to examine the relationship 
between volume and outcomes in primary care. The 
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Table 2a Inter-practice variation in the management of diabetes expressed as percentage of patients achieving targets for key diabetes care 
indicators according to practice list size and number of cases 
Quality indicators* HbA IC<7.4% (DM6) BP 4 145185 mmHg (DM12) Cholesterol 45 mmollL (DM17) 
List size group (n patients) 
0-2999 
3000-4999 
5000-7999 
8000-9999 
>, 10 000 
Diabetes case group 
1: <93 
2: 93-146 
3: 147-214 
4: 215-306 
5: >, 307 
*See Box 1 for details 
57.4% 70.7% 69.5% 
58.4% 71.1% 71.5% 
59.3% 71.1% 72.8% 
59.4% 71.0% 72.8% 
58.7% 70.7% 72.7% 
57.8% 71.4% 70.2% 
58.8% 71.1% 71.2% 
58.5% 71.0% 72.2% 
58.8% 70.9% 72.5% 
59.0% 70.3% 72.4% 
Table 2b inter-practice variation In management of diabetes expressed as percentage of patients achieving targets for key diabetes care indicators 
according to deprivation and by the list size and deprivation 
Quality Indicators* HbA IC<7.4 % (DM6) BP < 145185 mmHg (DM12) Cholesterol<5 mmollL (DM17) 
Deprivation group 
1 (Deprived) 57.3% 69.5% 69.9% 
2 (Intermediate) 59.1% 72.2% 72.7% 
3 (Affluent) 60.1% 71.4% 73.3% 
Deprivation group: List size group* 
Deprived: 0-2999 55.8% 69.0% 67.7% 
Deprived: 3000-4999 56.7% 69.3% 69.6% 
Deprived: 5000-7999 58.4% 69.9% 70.9% 
Deprived: 8000-9999 58.7% 69.5% 71.8% 
Deprived: >, 10 000 58.3% 70.1% 72.0% 
Intermediate: 0-2999 58.2% 72.3% 70.9% 
Intermediate: 3000-4999 59.6% 73.1% 72.8% 
intermediate: 5000-7999 59.5% 72.0% 73.6% 
intermediate: 8000-9999 59.7% 72.1% 73.2% 
intermediate: >- 10 000 58.5% 71.2% 
73.2% 
Affluent: 0-2999 60.9% 72.1% 
71.8% 
Affluent: 3000-4999 59.9% 71.6% 
73.1% 
Affluent: 5000-7999 60.5% 71.6% 
74.3% 
Affluent: 8000-9999 59.9% 71.4% 
73.5% 
Affluent: >, 10 000 59.5% 70.8% 
72.9% 
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structure of primary care in the UK offers some unique 
opportunities to examine this association. Unlike in many 
other countries, almost the entire population is registered 
with a GP, who is responsible for providing primary care 
services and arrang ing referrals for specialist care. In 
addition, individuals can only be registered with one general 
practice at any one time. This means that general practice 
has well-defined denominator populations, which in turn 
allows the calculation of accurate disease prevalence and 
treatment rates. 
Our study has a number of limitations. First, the QMAS 
database contains no patient level data and thus it was not 
possible to adjust practice performance by the age, gender 
or ethnic profile of patients. Second, patients known to 
have diabetes but not coded on the computer record would 
not have been included. However, payments to general 
practices under the new contract are weighted by practice 
prevalence; hence, there is a direct financial incentive to 
identify and report on all cases. Third, at present there is 
limited national data about how many patients were 
'exception coded'. This may be a source of bias in this 
study if rates of exception reporting varied by practice size 
and deprivation. However, analysis of available data 
suggests that exception reporting by practices was not 
extensive and that this is unlikely to have a major bearing on 
our findings. 19 Fourth, there is a risk of manipulation or 
gaming (e. g. recording a patient's blood pressure as being 
lower than it actually is), which will be difficult to detect. 
Although this may occur, practices are subject to an annual 
inspection and the penalties for making fraudulent claims 
are severe. 9 Finally, defining and measuring quality care is 
not a simple process and the indicators examined in this 
study are proxies for total quality. The clinical significance 
of some of the quality measures used is uncertain. Within 
the clinical domain, the current QOF only covers 
conditions affecting a minority of patients and only some 
aspects of the care for these patients. However, it does 
provide valuable information (e. g. on prevalence, HbAlc 
levels and blood pressure) on a scale previously unavailable, 
and will provide a baseline against which to measure future 
levels of improvement in the delivery of care. 12 
Comparison with previous research 
Although numerous studies have examined the volume- 
outcome relationship in secondary care, very few previous 
studies have examined this relationship in primary care. 
Hippisley-Cox and colleagues compared a number of areas 
of practice activity in single-handed and group practices in 
the Trent region of England. 20 They found no evidence that 
single-handed practices offered poorer quality of care than 
group practices. Another smaller study in the Wandsworth 
area of London also found no associations between practice 
size and quality of care for patients with coronary heart 
disease. 21 Our findings confirm previous research, which 
indicate that smaller practices are more commonly located 
in deprived areaS. 22 
Policy implications 
Elucidation of the reasons behind a volume-outcome 
association in the management of diabetes in primary care 
is beyond the scope of this study. However, differences in 
the organization of diabetes care (for example, the presence 
of a diabetes nurse or special clinics for people with 
diabetes) within small and large practices appear the most 
plausible explanation for the quality of care variations 
found. 23 This would explain why variations in diabetes 
management by practice size were more apparent for process 
measures of care (such as the measurement of pulses), which 
may be more responsive to highly structured care, 24 than for 
intermediate outcomes. In contrast, volume-outcome associa- 
tions in secondary care, while complex, are often at least in 
part ascribed to clinicians' expertise. 2S, 26 Our finding that 
patients living in deprived areas are receiving poorer quality 
of diabetes management compared with those living in areas 
that are more affluent is worrying and deserves closer study. 
It is another example of the inverse care law. ' 0 
Our findings suggest it may be worth rethinking the 
remuneration of different aspects of diabetes care. 
Motivation for achieving high scores for diverse indicators 
may have differed in practices of varying size depending on 
'who does what' in the practice team. Some scores are 
easier to achieve with the help of auxiliary staff; for 
example, annual recording of presence or absence of 
peripheral pulses and of neuropathy testing. It may be more 
difficult for smaller practices to employ such staff to support 
GPs' work. Furthermore, it is common in larger practices 
for one of the physicians to develop a special interest in 
diabetes and for such practices to run dedicated diabetes 
clinics. At present, however, no national level data is 
available to support any of these hypotheses. 
Our conclusions are limited to the management of 
diabetes and we cannot say whether similar volume- 
outcome relationships would occur in the management of 
other diseases in primary care. Our findings do not provide 
support for the amalgamation of practices into larger units 
because primary care manages a wide variety of disorders in 
which the volume-outcome association may not be present 
(or may even be reversed) for other conditions. " 
Nevertheless, the findings warrant attention and considera- 
tion of how to best organize diabetes care in smaller 
practices. Initiatives that could accrue benefit comparable to 
volume-outcome effect, such as disease facilitators, nurse 
practitioners, 28 diabetes clinics in primary care offering 
structured care, or GPs with a special interest in diabetes, 
need to be closely evaluated. 
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Abstract 
Aims To conduct a systematic review of published observational studies of quality of diabetes care in primary care in 
the UK and to compare the results with the quality of care data from the Quality and Outcomes Framework (QOF) of the 
new General Practice Contract in the UK. 
Methods MEDLINE and EMBASE were searched for articles published from 1999 to June 2006. We also searched for reference 
lists of studies that fitted our inclusion criteria. All members of the Primary Care Diabetes Europe were contacted and asked 
to send lists of any relevant published articles. Abstracts were reviewed and data were collected independently by two authors. 
Results Abstracts of 742 papers were identified, of which six papers fulfilled the final selection criteria. The total number 
of people included in the six published studies was 83 098 (a range of 504 to 54 180 people) compared with the UK QOF 
data of 1.8 million people with diabetes. The quality indicators for assessment of care varied between different published studies, 
making comparisons more difficult. Overall, there was a trend towards improvement in both process and outcome of care 
in the published studies. The quality of care achieved as a result of QOF was greater than that found in published studies. 
Conclusions There have been improvements in both process and outcome measures recorded in publications of quality 
of diabetes care in the UK between 2000 and 2004. Modest financial incentives in primary care are a successful method 
of improving care for people with diabetes. 
Diabet. Med. 24,1436-1441 (2007) 
Keywords diabetes mellitus, primary care, quality of care, systematic review 
Abbreviations GP, general practitioner; HbA, c, glycated 
haemoglobin; QOF, Quality and Outcomes Framework; 
UKPDS, UK Prospective Diabetes Study 
Introduction 
Diabetes is one of the commonest chronic diseases managed in 
primary care. The prevalence of diabetes in Europe is currently 
3-4% and is predicted to increase substantially in the future 
[1]. Diabetes leads to significant morbidity and mortality, 
which can be reduced by effective treatment and preventive 
measures. Recognizing the wealth of evidence supporting 
prevention and treatment in diabetes, professional and patient 
Correspondence to: Professor Kamlesh Khunti, Professor of Primary Care 
Diabetes and Vascular Medicine, Department of Health Sciences, University of 
Leicester, Leicester General Hospital, Gwendolen Road, Leicester LES 4PW, UK. 
E-mail: kk22@le. ac. uk 
organizations, and governments, have developed guidelines 
and documents on standards of care [1-31. 
How diabetes care is delivered varies, with different 
models of care being implemented across both primary and 
secondary care in different countries. A recent Cochrane 
Review of interventions to improve the management of 
diabetes mellitus in primary care, outpatient and community 
settings concluded that multifaceted interventions can improve 
the management of people with diabetes, as can organiza- 
tional interventions that improve the recall and tracking of 
patients [4]. Despite there being international consensus 
and evidence about the management of people with diabetes, 
there are still large variations in care. Comparisons of process 
and outcomes of care is one method of reducing variations in 
care [5]. 
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Although quality of care is important to health-care pro- 
fessionals, policy makers and patients, there are very few 
systematic reviews of studies of the level of quality provided by 
health-care services [6]. Moreover, only a few studies have reported 
international differences in care. For example, a European study 
of five countries found that there were large variations in the 
proportions of patients treated with diet, oral glucose-lowering 
medication and insulin [7]. It is feasible to collate multipractice 
audit data to describe the prevalence and patterns of care and 
highlight deficiencies in care [8,9]. To help improve quality, it 
would be useful to monitor trends in quality of care [10]. 
In recent years, there has been substantial financial investment 
in the UK, with the aim of improving the quality of care of people 
with chronic diseases such as diabetes and in reducing variations 
in care. The Diabetes National Service Framework was published 
in 2001 with the aim of improving quality of care and reducing 
variations in care [11 ]. In 2004, the UK government introduced 
a new contract for general practitioners (GPs) that gave financial 
incentives for the achievement of standards of process and 
quality in diabetes care across 18 clinical indicator domains in 
the diabetes Quality and Outcomes Framework (QOF) [12]. 
The QOF has been supported by a L1.8bn additional investment, 
and around a quarter of primary care income is now derived 
through achievements of quality targets for management of 
11 disease areas such as diabetes, cardiovascular disease and 
cerebrovascular disease. This is the first pay-for-performance 
incentive scheme used to improve the quality of care delivered 
to all patients in an entire country. The results from the first 
year of this contract were released in September 2005 [131. 
Our aim was to conduct a systematic review of published 
studies of quality of care in primary care in the UK. A further 
aim was to compare the results of the systematic review with 
the diabetes data from the Quality and Outcomes Framework 
of the new General Practice Contract in England [13]. 
Methods 
Search strategy 
To identify the relevant articles for this systematic review, a 
search Of MEDLINE and EMBASE of English language articles from 
1999 to June 2006 was undertaken. Management of people 
with Type 2 diabetes changed significantly after the publication 
of the UK Prospective Diabetes Study (UKPDS) [14,1S]. There- 
fore, articles published from 1999, after the publication of the 
UKPDS, were reviewed. The search terms included Mesh terms 
and keywords: Quality Assurance, Health Care or Quality of 
Health Care, Nursing Audit or Medical Audit, Outcome and Process 
Assessment, Diabetes or Diabetes Mellitus, General Practice or 
Family Practice, Primary Care or Primary Health Care, or com- 
binations of these terms. We also searched reference lists of studies 
that fitted our inclusion criteria. All members of Primary Care 
Diabetes Europe were also contacted by email and asked to send 
details of any relevant published articles. Results from the first year 
of the Quality and Outcomes Framework dataset were obtained 
from the Health and Social Care website for England [13]. 
0 2007 The Authors. 
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Selection strategy and data extraction 
Articles were selected on studies conducted after 1999. Abstracts 
were reviewed and data were collated independently by two 
authors (KK and RG). We defined indicators as those related 
to process or outcome of care [16]. We extracted data for 
commonly measured process indicators and outcome indicators 
associated with improving morbidity and mortality and those 
included in the QOF [13]. Articles that met the inclusion 
criteria of diabetes, primary care, from the UK, containing 
diabetes process and outcome data, multipractice and reference 
to datasets of over 150 patients routinely managed in primary 
care were selected for data extraction. We excluded studies that 
reported data from studies where only a proportion of patients 
had consented to data extraction [171. We also excluded studies 
that reported quality of care of only selected people with diabetes. 
When studies reported data for 2 years as a quality improvement 
report, we selected the latest data for the review. Studies varied 
in reporting of data, with some reporting data as ý! or > or < for 
some outcome measures. For ease of comparison, we have 
reported data as those achieving the quality indicator (! ý or <). 
Results 
The search strategy identified S32 articles in EMBASE and 412 
articles in MEDLINE. After removal of duplicates, we identified 
a total of 742 articles. The full text of articles that fulfilled the 
initial selection criteria were considered further. Six articles 
that fulfilled the final selection criteria were selected for data 
extraction. Table 1 shows the studies describing the quality of 
care that were included in the review [18-231. Five studies 
reported the number of practices in the studies, which varied 
from two to 237 [19-231. Three studies reported data from a 
centralized district register [18 -20,241. The majority of studies 
reported quality of care for people with Type 2 diabetes [19 - 221. 
Studies reporting data on large samples conducted the data 
extraction using computerized records [19-23]. 
There were large variations in the total numbers of people 
with diabetes included in the published papers. The smallest 
study reported data on S04 people, the largest study reported 
on S4 180 participants. The total number of people included in 
the six studies was 83 098, compared with the QOF database 
which reported data on 1.8 million people with diabetes. 
Table 2 presents the results of the recording of process of 
diabetes care. Overall, there were large variations in process 
measures assessed and the standards achieved for the process 
measures. Standards for assessment for neuropathy (S% and 
27%) and microalbuminuria (15%, 39% and 75%) were 
lower than for other process measures. Standards of care for 
process measures achieved in the QOF were much higher than 
those published in previous studies. Most standards were 
achieved at 90%, except for retinal screening (83%), foot 
examination (79%) and assessment for microalburninuria 
(71%). 
Table 3 shows the results of the quality indicators and the 
intermediate outcomes of care. One study reported data 
separately for people with Type 2 diabetes who were 
diet 
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Table 1 Studies describing quality of care of people with Type 2 diabetes in Europe 
Bibliographic Type of 
information diabetes Study type 
Edwards et al. [ 181 Types 1 Cross-sectional survey 
and 2 of district diabetes registry 
Whitford et al. [ 191 Type 2 Comparison of care in a 
comprehensive district 
diabetes system with 
32 general practices 
Guthrie et al. [201 Type 2 Assessment of care in 
Tayside using the DARTS 
clinical information 
system in 67 practices 
Hippisley-Cox and Type 2 Comparison between 
Pringle [21] people on diet and those on 
medication from 42 practices 
Campbell et al. [221 Type 2 Cross-sectional survey 
of 42 practices 
Hippisley- Types 1 Cross-sectional study 
Cox et al. [231 and 2 of 237 practices 
Year of study 
Method of 
data extraction 
No. of 
patients 
Average 
age of 
patients 
Duration 
of diabetes 
(years) 
1993 compared Computerized 5671 64 8. S 
with 2000 register 
1991 compared 2S% random 5809 60 8 
with 2001 sample from 
computerized 
records 
2001 Computerized 9064 66 7.6 
database 
2003 Computerized 7870 62.4 NR 
database 
2003 Manual and 504 NR NR 
computer 
data extraction 
2004 Computerized 54180 NR NR 
data extraction 
DARTS, Diabetes Audit and Research in Tayside Scotland; NR, not recorded. 
Table 2 Studies reporting process of diabetes care in the previous 12-15 months (all results are percentage compliance) 
Parameters 
Edwards 
et al. 
[181 
Whitford 
et al. 
[19] 
Guthrie 
et al. 
[20] 
Hippisley-Cox 
and Pringle 
[211** 
Campbell 
et al. 
[2211 
Hippisley-Cox 
et al. 
[23]1 
QOF 
[12]1 
BMI recorded 60 71 92 87* 86 91 
Smoking recorded 82 95 89 65 96 
Advice to smokers 6 77 90 93 
HbA, recorded 71 86 88 76 93 92 94 c Retinal screening 91 9 72f 60 83 
Foot examination/exan-ýination 44 63 53 79 
of peripheral pulses 
Neuropathy 5 27 97 
Blood pressure recorded 64 87 97 95 95 97 
Microalburninuria recorded 15 75t 39 
71 
Serum creatinine recorded 70 86 90 90 
93 
Cholesterol recorded 61 83 78 81 98S 87 
93 
*Weight recorded; turine proteinuria; texamination of fundi or visual acuity; Smeasurement within the last 5 years; Imeasurement within the 
last 15 months; "measurement ever recorded. 
BMI, body mass index; HbA, c, glycated 
haernoglobin; QOF, Quality and Outcomes Framework. 
treated and those managed with oral glucose-lowering agents 
[21]. However, we were able to calculate total compliance 
from the data in the paper. Three studies assessed compliance 
measures over the previous 12 months [18-20], one assessed 
as'ever'having the process or outcome indicator assessed [211. 
Two studies [22,231 and the QOF assessed compliance within 
the previous 15 months. The quality indicators used for 
assessment of care varied between different published studies. 
Three studies [19,21,23] based the recommendations on the 
QOF indicators. In another study [181, local quality indicators 
were used which were altered in 1998 following the publication 
of the UKPDS papers. The QOF achieved higher standards 
for 
blood pressure, cholesterol and glycated haernoglobin (HbAlc) 
measures compared with previously published studies. 
0 2007 The Authors. 
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Table 3 Studies reporting intermediate outcomes of care of people with diabetes in the past 12-15 months (all results are percentage compliance) 
Edwards 
et al. 
[181* 
Whitford Guthrie 
et al. et al. 
[19] [201 
Hippisley-Cox 
and Pringle 
[211t 
Campbell 
et al. 
[221t 
Hippisley-Cox 
et al. 
[231t 
QOF 
[121t 
HbA, c 
(%) 
7.4% 55 40S S8 
!57.5% 46 43 481 
< 10.0% 85 
Blood pressure (mmHg) 
< 140/80 51 
< 140/85 36 36 59 
!ý 145/85 70 
Cholesterol (mmoIA) 
55.0 62** 42 41** 52** 60** 72 
*Data only for people with diabetes managed in primary care; toutcome measured in last 15 months; f outcome measure ever recorded; 
S< 7.4%; j< 7.5%; * *< 5.0 mmol/l. 
HbA, c, glycated 
haernoglobin. 
Discussion 
The search strategy identified only six articles that fulfilled the 
inclusion criteria, indicating that publication of quality and 
process outcomes data in diabetes care is not well established 
in the UK. This is an unexpected finding given that quality 
improvement of medical care is a major issue for all health-care 
systems [25]. Five studies came from large datasets which used 
electronic data extraction methods. This may reflect the 
greater level of computerization of diabetes recording in 
primary care in the UK. All studies were cross-sectional surveys 
of people with diabetes. The papers show an overall improve- 
ment in the recording of diabetes processes of care from 2000, 
which in itself is a measure of quality. The findings reflect 
other studies of quality of care conducted in Europe and North 
America [24,261. This systematic review shows that process of 
care recording showed the largest improvement as a result of 
QOF. However, we are unable to ascertain whether this is a 
result of better monitoring or recording. Nevertheless, system- 
atic review evidence shows that documentation improves 
significantly with financial incentives [27]. It is also apparent 
that the new GP contract in the UK stimulated two of the UK 
publications. Pay-for-performance incentive schemes aim to 
improve quality of care for all patients to agreed standards. 
There have been limited assessments of the impact of pay for 
performance being delivered in other health-care settings [271. 
Our findings also indicate the QOF incentives have led to 
substantial improvements in standards of many process 
indicators and in all major intermediate outcome measures of 
blood pressure, HbAlc and lipid targets. Improvement in the 
intermediate outcomes are related to improved morbidity and 
mortality [14,15]. Whether this results in actual improved 
outcomes for people with diabetes remains to be seen. 
Variations in quality of chronic disease management in 
primary care have been documented in many countries [6]. 
There have also been calls for comparative European studies as 
Europe moves towards a situation characterized by provision 
that does not recognize national borders [281. Furthermore, 
there are demographic, socio-economic and health-care similar- 
ities between many European countries. We therefore used the 
same search strategy to identify published studies on quality of 
care in other European countries. However, we only identified 
a further three studies [29-311, which all reported data on 
different process and outcome indicators. The limitations of 
this study are that we did not include any studies that were not 
published in the EMBASE or MEDLINE databases. However, we 
used a broad search strategy and we also contacted members 
of the Primary Care Diabetes Europe who are key opinion 
leaders for diabetes. 
This systematic review has also demonstrated a wide variation 
in the process and outcomes indicators used for assessment of 
quality of care in the UK. If more comparisons between 
countries are to be made, there will need to be a greater stand- 
ardization in the way that quality in diabetes biomedical 
factors are recorded to enable meaningful comparisons to be 
made. Quality indicators should be based solely on scientific 
evidence if they are to improve patient care [2S]. Overall, the 
quality indicators were similar on the most important process 
and outcomes of diabetes care, although there were variations 
in the detailed recommendations. This reflects previous 
research on guidelines, which showed that there is a high 
degree of international consensus on the clinical care of people 
with diabetes despite differences in detailed recommendations 
[32]. The dataset from the new UK contract Quality and 
Outcomes Framework is vastly larger than any of the datasets 
from the papers discussed in this review. In most countries 
there is no mandatory national system to monitor quality of 
care delivered to patients [331, although QOF allows monitoring 
of the care delivered to the entire nation. It 
is a dataset 
collected to enable payments to be made and its use to collect 
0 2007 The Authors. 1439 
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diabetes quality information is subject to some limitations. 
The most significant of these is that individual doctors are 
allowed to remove certain individuals from the data recording 
by'exception reporting' them. Exception reporting allows the 
practice to exclude individual patients from the disease indicators 
in particular circumstances, including patients who decline 
care, and people in whom assessment is inappropriate, such as 
patients with terminal illness or severe dementia. Exception 
reporting rates in the QOF data are around 4.7% for most of 
the diabetes clinical indicators [13,341, suggesting a low level 
of potential 'gaming' by doctors seeking to earn maximum 
points. Furthermore, exception reporting only explained 20% 
of variations between practices in achievement of targets [34]. 
Details on exception reporting were not possible for the 2004/ 
2005 data [3S]. However, exception reporting for 2005/2006 
data f or England is robust [361, and the overall exception 
reporting rate for diabetes for 2005/2006 is 6%, with variation 
in exception rates across indicators. In general, lowest 
exception rates are for process indicators and highest for 
intermediate outcome indicators. At practice level, 94.6% of 
practices had overall exception rates lower than 10%. Hence, 
the effect of exception reporting on the reported quality of care 
is likely to be small. There is a wide variation in reported 
exclusion rates, but the huge size of the diabetes database will 
tend to level out any discrepancies arising from variable 
exception reporting rates. 
Both the process and outcome measures recorded in these 
publications have improved over time. The levels of process 
and quality recorded in the QOF are greater than those found 
in published studies from the UK and Europe included in this 
systematic literature review, despite the QOF data including 
people with both Type 1 and Type 2 diabetes. Diabetes made 
up 99 out of the IOSO quality points available in the contract, 
and income from the QOF amounted to around 20% of the 
practice income [12]. The maximum income from diabetes 
indicator points amounted to less than 2% of the total practice 
income from QOF. However, practices achieved 96.7% of the 
available points for the QOF indicators, which exceeded the 
7S% predicted when the scheme was negotiated [34]. Hence, 
modest financial incentives to primary care physicians may 
be a successful strategy for improving care for people with 
diabetes. The results of this study will be useful for health- 
care providers in comparing performance and for standard 
setting. 
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Association of age, sex and deprivation with quality 
indicators for diabetes: population- based cross sectional 
survey in primary care 
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SUMMARY 
Objectives To determine the quality of diabetes management 
in primary care after the publication of the National Service 
Framework and examine the impact of age, gender and 
deprivation on the achievement of established quality indicators. 
Design Population -based cross sectional survey using 
electronic general practice records carried out between June- 
October 2003. 
Setting Thirty-four practices in Wandsworth, South-West 
London, UK. 
Participants 6035 adult patients (>, 18 years) with diabetes 
from a total registered population of 201572 patients. 
Interventions None. 
Main outcome measures Success rates for the diabetes 
quality indicators within the General Medical Services contract for 
general practitioners. 
Results We identified large variations in diabetes management 
between general practitioner practices with poorer recording of 
quality care in younger patients (18-44 years). In addition, 
younger patients had a worse cholesterol and glycaemia profile, 
although hypertension was more common in older patients. 
Gender and deprivation did not appear to be important 
determinants of the quality of care received. 
Conclusions There are large variations in diabetes manage- 
ment between general practitioner practices, with care seemingly 
worse for younger adults. Longitudinal studies are required to 
determine whether current UK quality improvement initiatives 
have been successful in attenuating existing variations in care 
and treatment outcomes. 
' Director ,2 Specialist Trainee in Public Health, Wandsworth Primary Care 
Research Centre, London SW1 1 6HN ; 3S pecialist Trainee in Public Health, 
4 Professor of Primary Care, Department of Primary Care & Social Medicine, 
Imperial College Faculty of Medicine, London W6 8RP; 'Medical Statistician, 
'Senior Lecturer In Medical Statistics, Medical Statistics Unit, Research & 
Development Directorate, University College London Hospitals, London 
WC1 E 5DB; 7 Medical Statistician, aSenior Lecturer In Medical Statistics, 
Department of Statistical Science, University College London, London 
WC1 E 6BT, UK 
INTRODUCTION 
Diabetes has been identified as a national priority condition 
in the UK. Considerable investment has been made to 
improve the quality of clinical services for individuals with 
diabetes since 1997.1 The National Service Framework for 
diabetes set out key quality standards to both improve the 
overall quality of services and address known variations in 
care. 2 Financial incentives to improve the management of 
chronic diseases such as diabetes in primary care were 
introduced in 2004 as part of the General Medical Services 
contract. 
Early evidence indicates that these initiatives may have 
led to better management of diabetes in primary care; 
although the extent of improvement may have been more 
modest than that achieved for coronary heart disease. 3 In 
addition, recent studies highlight persisting variations in the 
quality of diabetes care being delivered. The General 
Medical Services quality indicators for diabetes have been 
shown to be less likely to be achieved for certain sectors of 
the population, for example in areas of high deprivation and 
high ethnic Mix. 4 Gender differences have also been 
identified, with women less likely to have quality care 
4 indicators recorded for their diabetes than men. 
Reducing differential access to services and treatments 
across age-groups is clearly important in improving the 
management of diabetes in primary care. 5 Age inequalities 
have been identified in the secondary prevention of 
coronary heart disease, with older patients less likely to 
6,7 
receive effective treatments than younger age-groups. 
However, few recent studies have examined the relation- 
ship between age and the quality of care received for 
diabetes. We therefore examined associations between age, 
gender, deprivation and achievement of the General 
Medical Services quality indicators in adult diabetes patients 
in one primary care trust in South-West London. 
METHODS 
CONDUIT project 
Correspondence to: Christopher Millett, Specialist Trainee in Public Health, 
Department of Primary Care & Social Medicine, Imperial College Faculty of 
Medicine, 3rd Floor, Reynolds Building, St Dunstan's Road, London W6 8RP, 
UK 
E-mail: c. milleft@imperial. ac. uk 
The CONDUIT (Cutting Out Needless Deaths Using 
information Technology) programme began in 1998, and 
was initially piloted in the Battersea Primary Care Group in 
South-West London. 
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Since then the programme has established comprehen- 
sive diabetes and coronary heart disease registers within two 
localities in Wandsworth Primary Care Trust. The data 
collection period for the present study was June-October 
2003. Ethical approval for the study was granted by 
Wandsworth Local Research Ethics Committee. 
Setting and participants 
The two localities contained 40 practices with a total 
registered population of 245 872. Thirty-four practices 
participated in the 2003 collection round, providing 82% 
coverage of the registered population. The population of 
Wandsworth is younger than that of England and Wales, 
with 74% under 45 years. One in five Wandsworth 
residents (22%) belongs to a non-white minority ethnic 
group and the borough has high levels of deprivation 
relative to elsewhere in England (index of multiple 
deprivation 20048 rankings: overall 128/354, income scale 
51/3S4, employment scale 60/3S4). 
Identification of diabetes patients 
The methodology used to develop our disease register for 
diabetes in Wandsworth has been described previously. 9 In 
brief, all patients with type I and type 2 diabetes were 
identified from computerized records by searching diagnosis 
of diabetes (CIO) or diabetes care (66A) Read codes. 
Patients with repeat prescribing for diabetic medications or 
with an HbA Ic greater than 7.5% were also included in our 
sample. Patients under 18 years and women with 
gestational diabetes were then excluded. Female patients 
who had no other data relating to diabetes apart from 
metformin prescribing were excluded on the grounds that 
they were likely to be receiving treatment for polycystic 
ovarian syndrome rather than diabetes. Additional verifica- 
tion of the diagnosis of diabetes through hand searching of 
patient records was not feasible due to the large numbers 
involved. 
Study variables 
We examined quality indicators for diabetes from the 
General Medical Services contract as they applied to our 
population between June and October 2003. Each indicator 
is based on clinical information recorded on the practice 
computer within the previous 15 months. 
Socio-economic status was assigned to individual 
patients based on their postcode using the Index of Multiple 
Deprivation 2004.8 Patients were then grouped into 
quintiles, with those in quintile one residing in the most 
deprived areas and five in the least deprived areas. 
Statistical analyses 
We examined variation between general practitioner 
practices in acl-ýievement of each of the quality indicators 
for diabetes by calculating median values and 1 Oth and 90th 
centiles. Logistic regression was undertaken to determine 
odds ratios, with 95% confidence intervals, for each quality 
indicator with age, gender and deprivation as the 
independent variables. We used robust standard errors to 
take account of the clustering of patients within general 
practices. 10 Statistical analyses were performed using 
STATA 9.1. 
RESULTS 
In 2003,603S adults (>, 18 years) were identified as having 
diabetes in the 34 participating practices: 3118 were men 
and 2917 were women. The European age -standardized 
prevalence of diabetes per 1000 population in all age-groups 
was 34.5 for females and 38.1 for males. Nearly 70% of 
patients were aged 55 years or older (18-44 years [ 16.6%], 
4S-S4 years [15.2%], 55-64 years [24.7%], 6S-74 years 
[26.6%1,75+ years [16.9%1). 
The median practice achievement for blood pressure and 
haemoglobin Alc (HBAIc) recording were 83.6% and 
73.0%, respectively. However, practice achievement of 
treatment targets was much lower, at 46.2% for HbAlc 
<7. S and 58.3% for blood pressure K, 14S/8S. Consider- 
able between practice variation was evident in the 
achievement of quality indicators (Table 1). 
Age 
Process measures of quality care (Tables 2 and 3) were 
significantly less likely to be recorded in young adult 
patients (18-44 years) than in older age-groups. Patients 
aged 18-44 years were significantly less likely to meet the 
General Medical Services treatment targets for cholesterol 
and HbAlc but had better blood pressure control than older 
patients (Tables 4 and 5). 
Gender 
Recording of quality care indicators was broadly similar in 
men and women. However, women were significantly 
more likely to be asked about their smoking status than 
men, but less likely to receive cessation advice if they were 
smokers. 
Women were significantly more likely to have 
cholesterol levels above 5 mmol/L but there was no 
significant difference between women and men in terms of 
meeting General Medical Services targets for HBAIc 
control and blood pressure. 57 
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Table 1 Interpractice variation on diabetes quality Indicators (%) 
Diabetes care measures 
Body mass index measured 
Smoking status determined 
Smoking advice provided 
HblAc measured 
Blood pressure measured 
Retinal screening undertaken 
Pulses measured 
Cholesterol measured 
Micro-albuminuria measured 
Creatinine measured 
Flu jab administered 
Outcome measures 
HbAll c<7.4 
HbAlc <, 10 
Cholesterol <5 
Blood pressure -< 145/85 
Deprivation 
10th 90th 
Median centile centile 
71.9 23.4 85.5 
64.3 37.8 81.9 
50.5 11.8 76.2 
73.0 30.8 82.9 
83.6 50.0 94.0 
36.8 6.3 62.2 
43.8 4.5 68.5 
69.4 20.4 82.8 
1.0 0.0 32.6 
72.5 26.9 88.3 
56.0 37.3 69.1 
46.2 31.3 58.0 
89.2 84.4 93.5 
56.3 48.1 68.8 
58.3 46.5 68.9 
Recording of quality care indicators was similar-in patients 
within the most and least deprived groups in our sample. 
Patients in the most deprived group were less likely to meet 
the General Medical Services target for blood pressure 
Table 2 Processes of care recorded in all practices 
control and more likely to have HbA Ic> 10% than those 
in the least deprived groups. However, these differences did 
not attain statistical significance. 
DISCUSSION 
Principal findings 
We identified large variations in diabetes management 
between general practitioner practices with poorer 
recording of quality care in younger patients (18-44 years). 
In addition, younger patients have a worse cholesterol and 
HBA 1c profile, although blood pressure control was better 
than in older patients. Gender and deprivation did not 
appear to be important determinants of the quality of care 
received for most of the indicators. However, control of 
cholesterol was found to be significantly worse in women. 
Strengths and weaknesses of this study 
We identified considerable patient group and practice level 
variation in the achievement of the General Medical 
Services quality indicators. Some of this variation may be 
due to differences in recording practice, rather than the 
actual differences in the quality of care received. Variations 
in recording practice in primary care should be gradually 
eliminated now that the General Medical Services contract 
has been implemented and general practices are being paid 
based on the information they are recording. 
Body 
mass 
index 
measured 
Smoking 
status 
determined 
Smoking 
advice 
provided 
HbA Ic 
measured 
Blood 
pressure 
measured 
Retinal 
screening Pulses 
undertaken measured 
Micro- 
Cholesterol alburninuria 
measured measured 
Creatinine 
measured 
Age 
18-44 50.7 52.2 28.7 44.5 65.1 23.9 25.3 39.2 7.2 40.9 
45-54 64.5 62.1 46.4 62.0 76.3 34.4 42.0 57.8 10.0 60.7 
55-64 69.5 64.0 46.9 69.1 83.6 40.1 47.8 67.3 9.9 68.3 
65-74 70.5 64.7 48.9 67.8 84.0 40.3 47.7 67.3 9.7 70.1 
75+ 66,7 67.8 38.5 66.0 82.5 36.4 46.4 66.0 11.1 74.0 
Gender 
Male 65.8 58.5 46.1 63.5 78.5 35.4 42.7 61.5 9.4 63.2 
Female 65.0 66.9 35.2 62.6 80.3 36.6 43.2 60.4 9.8 
64.9 
Deprivation* 
1 71.3 66.4 47.2 68.4 83.8 38.0 44.6 64.9 12.1 
69.0 
2 60.9 60.1 39.8 57.9 75.2 34.5 40.2 56.0 10.7 
59.7 
3 65.4 62.2 40.0 62.7 81.0 35.7 43.9 59.3 
10.0 62.5 
4 64.7 62.6 42.4 64.0 78.8 37.1 42.6 61.5 
7.5 62.4 
5 64.7 61.6 39.4 62.3 78.0 34.6 43.4 63.0 
7.6 66.6 
578 1 '1=most deprived, 5=least deprived 
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Table 4 Achievement of intermediate outcome indicators (%) 
Serum Blood 
cholesterol pressure HbAlc HbA 1c 
<5 mmollL <, 145185 < 7.4 % < 10% 
Age 
18-44 54.2 75.2 39.0 86.6 
45-54 53.7 57.9 46.1 85ý6 
55-64 56.0 55.1 43.0 87.1 
65-74 59.6 57.6 49.8 89.7 
75+ 59. B 54.2 5B. 6 93.5 
Gender 
Male 62.1 59.7 47.3 88.6 
Female 51.9 57.8 48.2 88.7 
Deprivation* 
1 57.3 55.9 45.3 86.4 
2 55.8 59.9 48.1 88.8 
3 61.2 59.2 48.4 88.6 
4 53.6 59.7 48.7 90.4 
5 58.2 59.4 48.3 89.2 
*1=most deprived, 5=1east deprived 
Patients with diabetes were identified from computer- 
ized records using algorithms based upon diagnostic and 
diabetes care codes. We have previously shown that 
computer searches based on diagnostic Read codes for 
diabetes alone have a low sensitivity, as they may miss up to 
a third of cases. 9 We used a more comprehensive search 
Table 5 Achievement of Intermediate outcome indicators (odds ratios 
strategy to compensate for this under-recording of diabetes. 
All but six general practitioner practices within the study 
area participated in our survey. Hence our findings provide 
a comprehensive and typical picture of the care provided in 
this diverse, inner city location. 
Comparison with previous studies 
Few recent studies have examined the relationship between 
age and the quality of overall diabetes care received. Our 
findings confirm previous research which has shown that 
ageing is associated with improved glycaernic control, 11-13 
but an increased likelihood of hypertension. 14,15 Our 
findings are also consistent with the recent National 
Diabetes Audit in England, 16 which suggested that older 
patients may be more likely to achieve cholesterol 
treatment targets. These differences may reflect tighter 
management policies for older patients within practices and 
better treatment compliance amongst this patient group. 
Patients aged 75+ years did not appear to receive poorer 
quality care when compared to younger patients. This 
finding contrasts with recent evidence of persistent age 
inequalities in the secondary prevention of coronary heart 
6,7 disease. 
Our findings confirm recent research which suggests that 
glycaernic control may be similar in women and men, 4,11 
but that women with diabetes are more likely to have 
poorly controlled cholesterol. 4 Intermediate treatment 
outcomes were not significantly different amongst partici- 
pants living in deprived areas compared with those living in 
and 95% confidence intervals for logistic regression models) 
Serum cholesterol Blood pressure HbAIc HbAIc 
<5 mmollL < 145185 < 7.4% < 10% 
Age 
18-44 1.00 1.00 1.00 1.00 
45-54 0.99 [0.76,1.28] 0.45 [0.36,0.57) 1.34 [1.05,1.701 0.92 [0.62,1.36] 
55-64 1.10 [0.88,1.36] 0.40 [0.33,0.49) 1.18 [0.93,1.491 1.05 [0.76,1.431 
65-74 1.27 [1.04,1.551 0.44 [0,36,0.55] 1.55 11.23,1.961 1.36 [0.99,1.871 
75+ 1.32 [1.04,1.69] 0.39 [0.30,0,511 2.21 [1.68,2.90) 2.22 [1.37,3.61] 
Gender 
Male 1.00 1.00 1.00 1.00 
Female 0.65 [0.56,0.75) 0.93 [0.83,1,04] 1.00 [0.89,1.13] 0.97 [0.78,1.21] 
Deprivation* 
1 1.00 1.00 1.00 1.00 
2 0.93 [0.76,1.14) 1.21 [1.03,1.421 1.08 [0.88,1.321 1.21 10.93,1.571 
3 1.16 [0.99,1.37) 1.16 [0.98,1.371 1.11 [0.93,1.33] 1.20 [0.90,1.601 
4 0.86 [0.71,1.04] 1.16 [0.96,1.41] 1.15 [0.94,1.40] 1.49 [1.09,2.03] 
5 1.02 [0.81,1,28) 1.18 [0.92,1.52] 1.10 [0.87,1.38] 1.27 
10.97,1.651 
=most deprived, 5=least deprived 
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more affluent areas. Existing evidence on the association 
between socio-economic status glycaemic control is 
mixed4,1 1,17 but may be influenced by definitions used as 
well as the choice of measurement tool. 18 Our findings 
differ from that of Hippisley-Cox et al., 4 who found that 
women and patients living in deprived areas may receive 
less comprehensive care for their diabetes. The compre- 
hensive diabetes disease management programme being 
implemented in Wandsworth and the regular monitoring of 
practice performance may have helped to attenuate gender 
and socio-economic differences in the quality of care for 
diabetes in this locality. 
The European age- standardized prevalence of diabetes 
per 1000 population in all age-groups was 34.5 for females 
and 38.1 for males, which is higher than that reported in 
previous population based surveys. 16,19 This is not 
unexpected given that our study population was character- 
ized by a relatively high proportion of individuals from 
minority ethnic and deprived groups, who are known to 
experience elevated rates of diabetes. 2 
CONCLUSIONS AND FUTURE RESEARCH 
There is scope to improve the management of diabetes in all 
age-groups, particularly in younger patients, and address 
between practice variations in care. Failure to improve 
diabetes care in younger patients, many of whom will be 
from ethnic minorities, may lead to an increase in the major 
complications of diabetes, such as renal failure and 
peripheral vascular disease, in future years. 20 Finally, 
longitudinal studies are required to determine whether 
current UK quality improvement initiatives are successful in 
attenuating existing variations in care and treatment 
outcomes. 
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